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Abstract 
 
Basal cell carcinoma (BCC) of the skin is predominantly associated with mutational inactivation 
of the PTCH1 tumour suppressor gene resulting in constitutive activation of the Hedgehog (HH) 
developmental pathway. Tumour formation is linked to induction of the GLI (GLI1 and GLI2) 
transcription factors via a pathway that is thought to require the transmembrane protein 
SMOOTHENED (SMO) and accordingly, SMO is attracting much interest as a drug target in 
cancer therapy. However, although there has been a high degree of success in treating some 
BCCs with anti-SMO compounds, many tumours are only partially or unresponsive which 
indicates that SMO-independent mechanisms may contribute to tumour formation and/or 
viability. 
 
To further understand how loss of (or reduced) PTCH1 function contributes to BCC, RNAi 
(retroviral shRNA) was employed to suppress PTCH1 in NEB1 and N/Tert immortalised human 
keratinocyte cells. Compared to control (shCON) cells, PTCH1 knockdown (shPTCH1) cells 
displayed more compact colony formation as well as increased GLI1 (but not GLI2) expression 
however, whereas the increase of GLI1 was suppressed upon transfection with SMO siRNA in 
shPTCH1 cells, it was insensitive to the presence of the SMO antagonists Cyclopamine-KAAD 
and SANT1 in shCON cells. The reason for this is unclear but SMO levels were increased and 
more nuclear in shPTCH1 cells indicating that SMO may have nuclear signalling capability that 
is unresponsive to certain SMO antagonists. Indeed, cDNA microarray profiling revealed that 
80% of the genes that were differentially expressed in NEB1-shPTCH1 cells (>2-fold, p<0.01) 
remained differentially expressed in the presence of Cyclopamine-KAAD; this includes the 
chemokines CXCL10 and CXCL11 which were recently shown to be over-expressed in BCC thus 
helping validate the efficacy of NEB1-shPTCH1 cells as an in vitro tumour model. In addition, 
functional gene grouping has predicted novel biological processes downstream of PTCH1 that 
may be important in BCC biology including NF-κB signalling. In summary, the data presented in 
this thesis suggests that the mechanism(s) through which the loss of PTCH1 leads to BCC 
formation may be more complex than has been inferred from previous studies. 
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Chapter 1 Introduction 
 
1.1 Structure of the skin 
 
The skin encapsulates the whole surface of the body and provides a number of vital functions 
including barrier formation, synthesis of vitamin D, thermoregulation and protection from 
ultraviolet (UV) irradiation. The skin is composed of three layers which are the epidermis, 
dermis and subcutaneous layer (Figure 1.1). The epidermis is the outermost layer of the skin 
which interacts with the external environment and is mainly consistent of keratinocytes with 
differing levels of differentiation. The stratum corneum contains the most differentiated cells, 
the stratum granulosum is followed by the stratum spinosum which contains desmosomes that 
provide structure and strength and the stratum basale layer which contains undifferentiated 
keratinocytes that can proliferate and migrate. Differentiation of keratinocytes occurs from the 
basal layer towards the superficial layer of the epidermis where the terminally differentiated 
keratinocytes or corneocytes, will shed from the surface.  
 
Melanocytes that are found in the stratum basale contain membrane bound organelles called 
melanosomes that produce the pigment melanin which is involved in human skin 
pigmentation. Melanocytes are bound to keratinocytes by E-cadherin which is a cell to cell 
adhesion protein, allowing the transfer of melanin to the keratinocytes (Freedberg et al., 
2003). Melanin pigmentation increases upon UV irradiation as a defence mechanism to 
prevent DNA damage as the excess melanin is able to absorb UV light (Agar et al., 2005). The 
stratum basale also contains Merkel cells which are part of the somatosensory system that 
plays a role in touch response (Maricich et al., 2009). These cells are larger than keratinocytes 
(to which they are attached) and are present in hair follicles. Langerhans’ cells are present in 
the stratum spinosum and are part of the immune system presenting antigens to T 
lymphocytes. 
 
The basement membrane divides the epidermis from the dermis and acts as a matrix by which 
cells may attach for the purpose of differentiation or apoptosis. Also, it can provide a scaffold 
to allow for tissue repair. The adjacent dermis is rich in collagen to provide stability as well as 
fibroblasts which play an important role in wound healing. The dermis gives the skin its 
strength as well as its flexibility which is provided by collagen, elastin and fibrillin proteins. The 
hypoderm or subcutaneous tissue contains fat that serves to insulate the body and can be 
utilised for energy storage. The dermis also accommodates hair follicles. 
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Figure 1.1: Structure of the skin (Wong and Chang, 2009) 
SC: stratum corneum, SG: stratum granulosum, SS: stratum spinosum, SB: stratum basale. 
  
 
 
 
 
 
 
  Chapter 1 
20 
 
1.1.1 Epidermal layers 
 
The epidermal layers are distinguishable based on various levels of keratinisation (Figure 1.2). 
Keratins are structural proteins which form heteropolymers that give rise to intermediate 
filaments. In combination with actin microfilaments and microtubules, a cytoskeletal structure 
is formed. Type I keratins (KRT10 to KRT20) have acidic properties while Type II keratins (KRT1 
to KRT9) are basic or neutral. In order to form a heteropolymer filament structure, both Type I 
and II keratins must be expressed.  
 
The stratum corneum is the most differentiated layer of keratinocytes and is the layer which 
interacts with the external environment. The thickness of this layer varies depending on age, 
sex and area of the body i.e. palms of the hand and soles of the feet have a thicker cornified 
layer. Cells of the stratum corneum are referred to as corneocytes and are the largest form of 
keratinocyte with a flattened morphology lacking nuclei and cellular organelles (McGrath et al., 
2004). Corneocytes contain the filament aggregating protein filaggrin (FLG) which causes the 
cell to become flattened (Fuchs, 1990; McGrath et al., 2004). These cells that mainly consist of 
keratins and lipids create a water resistant barrier. The cornified layer has a certain level of 
elasticity as the plasma membrane surrounding the stratum corneum is stabilised by involucrin 
cross-linked to keratins and membrane proteins by transglutaminase (TGM) (Eckert et al., 
1997). Corneocytes become less compact as desmosomes that keep the cells bound together 
are degraded leading to shedding of the skin.  
 
Below the stratum corneum is the stratum granulosum layer that contains 3 to 5 layers of 
granular cells. Granular cells contain enzymes that degrade organelles such as the nuclei, 
ribosomes and mitochondria as part of keratinisation (Freedberg et al., 2003). Loss of these 
organelles leads to an accumulation of keratohyalin granules that contain FLG as well as 
profilaggrin which is a precursor to FLG. During the differentiation of granular cells, profilaggrin 
is cleaved into smaller FLG units that aggregate the keratin cytoskeleton. TGMs cross-link the 
cytoskeleton structures to create the stratum corneum. FLG is therefore very important and 
loss of function mutations to the protein is known to cause Ichthyosis vulgaris which is 
characterised by dry, scaly skin (Smith et al., 2006).  
 
In areas of thicker skin such as palms of the hand or soles of the feet, a stratum lucidum layer 
can be found between the stratum granulosum and stratum corneum to reduce friction 
between the two layers. Keratinocytes of the stratum lucidum contain eleidin which is a 
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transformation product of keratohyalin and this makes the stratum lucidum hydrophobic 
(McGrath et al. 2004).   
 
The stratum spinosum that consists of rows of keratinocytes is the next layer of the epidermis. 
Keratinocytes of this layer are enlarged and cuboidal in appearance forming 4 to 8 layers. Cells 
from the stratum basale migrate to the stratum spinosum and this is the first point at which 
keratinocyte differentiation occurs (Fuchs, 1990). Proteins, lipids and keratins are synthesised 
here. The stratum spinosum consists of lipid containing lamellar granules that make the 
external epidermis hydrophobic. The stratum spinosum contains KRT1 and KRT10 that form 
cytoskeletal filaments that are anchored to adhesion complexes called desmosomes; this 
provides structural support to the skin (Blanpain and Fuchs, 2006).   
 
The stratum basale is a layer of single cells that separates the epidermis from the dermis and is 
responsible for the constant renewal of epidermal cells. This layer is generally one cell thick 
consisting of small cuboidal cells (McGrath et al., 2004). Keratinocytes begin proliferation in 
the basal layer and will differentiate towards the stratum corneum where the cells will 
eventually be shed. Due to this, it is important to maintain a sustainable rate of cell 
proliferation in relation to cell death to avoid hyperproliferation or insufficient epidermis 
development. Melanocytes are also present within the basal layer responsible for the 
pigmentation of the skin and nails. Markers of the basal layer include KRT5 and KRT14. 
 
Approximately 10% of the basal layer consists of stem cells that have a high reproductive 
potential and greater life span (Li and Neaves, 2006). As these cells divide, one of the cells will 
remain in the basal layer as a stem cell while another daughter cell or transit amplifying cell 
(TA) is committed to differentiate (McGrath et al., 2004). The TA cells maintain the population 
or differentiate via three lineages to either the interfollicular epidermis, sebaceous gland or 
the hair follicle (Watt et al., 2006). Epidermal stem cells strongly adhere to the basement 
membrane and maintain the interfollicular epidermis by replacing differentiating cells 
(Blanpain and Fuchs, 2006). In contrast, TA cells are limited in their potential to divide and will 
become less adhesive so that they can ascend through the epidermis, gradually differentiating 
as they approach the stratum corneum (Fuchs, 2008; Owens and Watt, 2003). 
 
Keratinocytes attach to each other via desmosomes and in the basal layer keratinocytes are 
secured to the basement membrane by hemidesmosomes. Integrins within the basement 
membrane bind to laminins that attach the basement membrane to the dermis (Figure 1.3). 
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Figure 1.2: Layers of the epidermis (adapted from Shier et al., 1999) 
 
 
 
 
 
 
 
 
 
Stratum corneum 
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Figure 1.3: Basement membrane (Ross and Christiano, 2006) 
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1.1.2 Dermis 
 
The dermis provides the skin with its strength as well as its flexibility which is provided by 
collagen, elastin and fibrillin proteins. The dermis protects the body from injury and helps with 
thermoregulation via the hypoderm. The dermis also supports hair follicles, nails and both 
excretory and secretory glands. 75% of the dermis is made up of collagen with the majority 
being type I and to a lesser extent, types III, IV and V (Frinkel and Woodley, 2001; Goldsmith, 
2005). Fibroblasts are the principal cell type of the dermis and are required to synthesise 
collagen, fibronectin, elastin and laminin; all of which are necessary for the basement 
membrane and extracellular matrix (ECM) structure. Fibroblasts are mesenchymal cells and 
form connective tissue and play a role in structure and support of organs such as the skin, 
lungs and eyes. The dermis also contains a hypoderm layer of fatty tissue and sweat glands 
both of which are important for thermoregulation. Apocrine and endocrine glands can also be 
found within the dermis. 
 
1.1.3 Hair follicle  
 
Hair follicles are appendages of the skin that produce hairs which are important for 
thermoregulation and collecting sensory information from the surrounding environment. The 
structure of the hair and its three dimensional morphology dictates the shape of the hair 
produced which characterises different racial hair types. Asians have straight hair follicles that 
are round in cross section while Caucasian follicles are angled slightly and elliptical in cross 
section, producing hair with a slight curl. Afro Caribbean follicles are kinked and flat in cross 
section which produces curly hairs (Montagna and Ellis, 1958). The hair follicle originates in the 
subcutaneous fat layer that is situated below the dermis intersecting the dermis and epidermis 
from where the hair shaft extends out. The follicle has a sebaceous gland located within the 
dermis which secretes the oily substance sebum that gives the skin its water resistant 
characteristic.  
 
The hair fibre that is made of keratin forms the main body of the follicle. It is surrounded by 
the inner root sheath (IRS) then the outer root sheath (ORS) (Figure 1.4). The IRS protects and 
directs the growth of the hair shaft. The IRS itself consists of three concentric layers: a cuticle 
layer surrounding the hair fibre, Huxley’s layer and Henle’s layer all characterised by 
expression of specific keratins. All three layers contain straight protein filaments aligned along 
the axis of the follicle. The IRS is the first component of the hair follicle to be keratinised which 
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acts as a template or mould for the emerging hair fibre as the IRS compresses the cortex cells 
and helps shape the emerging fibre. 
 
The outer root sheath (ORS) surrounds the layers of the IRS and accommodates the bulge 
region which sits slightly below the sebaceous gland. The bulge contains a niche for epithelial 
stem cells and attached to the bulge is the arrector pili muscle (Cotsarelis et al., 1990). The 
sebaceous gland also extends from the ORS. The sebaceous gland consists of a number of 
sebocyte containing lobes. Sebocytes situated around the periphery of the gland are small 
flattened cells which divide producing daughter cells that migrate towards the lumen of the 
gland. Mature sebocytes are large in appearance with large vacuoles that contains sebum 
which is released into the lumen of the sebaceous gland. Sebum is then secreted via the 
sebaceous duct, directly onto the skin surface or into the hair canal (Downing et al., 1982; 
Deplewski and Rosenfield, 2000).  
 
The connective tissue sheath (CTS) or dermal sheath is derived from the dermis and this layer 
contains fibroblasts and collagen fibrils which provides the follicle with structural stability. 
Fibroblasts synthesise collagen and play an important role in follicle regeneration as well as 
renewal of the dermal papilla (DP) after wounding (Jahoda and Reynolds, 2001). 
 
Generation of the hair follicle is directed by the DP. The DP is a collection of mesenchymal 
derived fibroblasts, pear-shaped in its appearance and is located at the base of the hair follicle. 
The DP is highly active and consists of cells that induce hair follicle development from the 
epidermis as well as the root sheaths (Jahoda and Oliver, 1984; Jahoda and Reynolds, 2001).  
 
Surrounding the DP are germinative epithelium (GE) cells and proliferation of these cells affect 
hair growth (Weinstein and Mooney, 1980). GE cells terminally differentiate to hair follicle 
matrix cells that are committed to follow one of several differentiation lineages including the 
IRS and ORS. As cells leave the GE pool, full keratinisation occurs within 2½ days (Weinstein 
and Mooney, 1980). The interaction between the DP and GE cells is an important factor in hair 
growth. The larger the size of DP, the greater the number of cells that it contains which 
correlates with the size of hair follicle therefore the larger the hair follicle, the greater the size 
of hair fibre produced by the follicle. 
 
DP cells are essential for hair growth as the removal of the DP in rats arrests hair growth. 
However, the ORS is able to compensate and helps generate a new DP from which hair follicle 
growth is resumed (Oliver, 1967; Jahoda, 1992). Studies have also shown that the CTS is 
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capable of supplying cells for DP renewal (Oliver, 1966; Oliver, 1967; Jahoda, 1992). DP cells 
retain their embryonic functional ability and are able to induce new hair fibre growth in 
mature adult skin when implanted into previously deactivated hair follicles although the DP 
cells are required to be in close association with epidermal cells (Oliver, 1967; Horne et al., 
1986). DP cells can also interact with the epidermis to induce the development of new hair 
follicles (Jahoda, 1992). 
 
Hair follicles undergo a cycle of activity whereby the follicle will grow to its maximum length 
which is then discarded followed by the generation of a new follicle. There are three distinct 
stages of growth which are anagen, catagen and telogen (Figure 1.5).  
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Figure 1.4: Structure of the hair follicle (adapted from Toll et al., 2004) 
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Figure 1.5: Hair follicle cycle (Fuchs, 2007) 
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Anagen is the initial growth stage of the follicle and hair shaft. The epidermal cells that 
surround the DP form the shaft and are constantly dividing which will push each layer of cells 
towards the epidermis. The hair shaft of the previous cycle will also be completely forced out 
of the follicle and skin which is known as exogen.  
 
The anagen phase can be further separated into six stages. During Anagen I, the DP cell niche 
will increase in its size. In Anagen II, the follicle anchors itself in the dermis and differentiation 
of the cells will give rise to the root sheaths. During Anagen III, Melanocytes develop near the 
DP. At this point, the follicle has grown to its maximum capacity and is attached to a now 
enlarged DP. Anagen IV marks the point where DP cells start producing melanin. The hair shaft 
is still within the IRS and during Anagen V the shaft is able to break out of the IRS and travel 
towards the epidermis. At Anagen VI, the hair shaft is visible at the surface of the skin. The hair 
shaft from the previous hair cycle is either forced out or compressed in a clubbed hair which 
will eventually be removed.  
 
During early anagen, CTS is composed of a thin basal lamina and surrounded by collagen. The 
collagen gradually thickens as the hair follicle grows until late anagen by which time the 
collagen separates into three layers. The inner layer outside of the basal lamina consists of thin 
collagen fibres that run parallel to the follicle. The middle layer is thicker with fibres that run 
transversely against the hair axis. The outer layer contains fibres that run in different 
directions parallel to the outer surface of ORS cells. 
 
Anagen is followed by catagen which marks the start of degradation. Catagen provides a 
mechanism whereby the hair follicle stops production of the hair shaft causing it to move 
towards the epidermis for shedding. The process begins with the DP shrinking and dissociating 
from the dermis with the ORS of the lower follicle ceasing to proliferate. The ORS located at 
the mid section of the follicle begins to harden and forms a bulb at the bottom of the hair 
shaft. The DP shrinks due to the loss of cells allowing the DP to move towards the bulge region 
which also causes the hair shaft to move towards the epidermis. The GE will also stop 
proliferating which causes the follicle epithelium to undergo apoptosis. Production of melanin 
ceases and a number of melanocytes are lost through apoptosis (Slominski et al., 1994; Tobin 
et al., 1998). 
 
The telogen phase follows catagen and this is known as the resting phase of the hair cycle. 
With the hair shaft having been dissociated from the DP, the cells below the hair shaft that 
have now stopped proliferating will form a club shape creating a club hair. This club hair is 
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shed in the final stage which is known as exogen. If the club hair is not removed by physical 
means, the onset of the next anagen phase will force out the club hair. The length of the hair 
cycle varies depending on the location on the body with the duration of anagen determining 
the type of hair produced and its length (Paus and Cotsarelis, 1999).  
 
1.1.4 Signalling pathways involved in hair follicle development 
 
A number of developmental signalling pathways have been implicated in hair follicle formation 
including the Wnt, Hedgehog (HH), fibroblast growth factor (FGF), transforming growth factor 
(TGF) and bone morphogenic protein (BMP) pathways.  
 
The Wnt signalling pathway is involved in the development of embryological systems and is 
controlled by paracrine Wnt signalling molecules that act via frizzled (Fz) receptors (Cadigan 
and Nusse, 1997). Wnt signalling exists in canonical β-catenin dependent and non-canonical β-
catenin independent modes (Chien et al. 2009) (Figure 1.6). The Wnt ligand binds to a co-
receptor complex consisting of Fz and low density lipoprotein receptor 5 and 6 (LRP5/6) to 
activate Dvl which acts upon the β-catenin complex. This complex consists of β-catenin, APC 
tumour suppressor, CK1α kinase and GSK3β kinase, all of which are attached to the tumour 
suppressor protein Axin. As the pathway is inactive, β-catenin is phosphorylated then 
ubiquitinated leading to its degradation by CK1α (Gao et al., 2002). As Wnt activates the 
pathway, Dvl blocks the activity of GSK3β which allows dephosphorylated β-catenin to enter 
the nucleus and activate the transcription of certain target genes by binding with the T-cell 
factor (dTCF) and lymphoid enhancing factor (LEF-1) transcription factors (van de Wetering et 
al., 1997; Behrens et al., 1996). Downstream targets of LEF-1 include c-Myc which is a 
transcription factor as well as the cell cycle regulator Cyclin D1 (Wodarz and Nusse, 1998). 
Non-canonical Wnt signalling can occur via calcium flux or JNK (Veeman et al., 2003) with 
functions being described such as planar cell polarity (PCP) in D. melanogaster embryos 
(Seifert and Mlodzik., 2007). Deregulated signalling of canonical WNT signalling leads to the 
over expression of β-catenin either by stabilising β-catenin or inhibiting the GSK3β complex 
(Morin et al., 1997; Rubinfeld et al., 1997). 
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Figure 1.6: Wnt signalling (Chien et al., 2009) 
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The importance of Wnt signalling in hair follicle has been highlighted in LEF-1(-/-) mice that do 
not develop hair follicles as seen from histological sections (van Genderen et al., 1994) while 
over expression of LEF-1 in the epithelium of transgenic mice leads to the aberrant patterning 
of hairs and the growth of hairs in the oral cavity (Zhou et al., 1995). Suppression of Wnt 
signalling either by ablation of β-catenin or expression of a truncated form of LEF-1, results in 
inhibition of hair follicle formation (Huelsken et al., 2001, Merrill et al., 2001). 
 
The Wnt pathway can be activated independently of β-catenin involvement by alternative 
signalling mechanisms including JNK and calcium flux (Veeman et al., 2003). Wnt-4 is 
expressed in both embryonic and adult mouse skin while Wnts 5a and 11 are expressed in the 
dermis of embryonic mouse skin. Although the function is unknown, studies suggest that Wnt-
5a may be a downstream target of the HH pathway and plays a role in hair follicle 
morphogenesis (Reddy et al., 2001). 
 
The HH signalling pathway which will be discussed in more detail later (section 1.3) plays an 
important role in regulating the development of embryonic structures including limbs 
(Goodrich et al., 1996). HH signalling also plays a role in hair follicle formation in mammals. 
The Sonic HH (SHH) ligand is shown to be expressed in the developing whisker of mice (Iseki et 
al., 1996). It was also reported that Patched (PTCH) which represses HH signalling, is also 
present in cells surrounding SHH positive cells of mouse whisker follicles implying that HH 
levels may need controlling to limit hair follicle development (Goodrich et al., 1996). Further 
studies in chicks where SHH was over expressed through retroviral transduction resulted in the 
development of abnormally large feather buds (Ting-Berreth and Chuong, 1996; Morgan et al. 
1998). These studies suggest that the HH pathway is involved in the development and the size 
of hair follicles.  
 
The BMP signalling pathway is involved in embryonic development and has been linked with 
HH and Wnt pathways in hair follicle morphogenesis. BMP factors work in concurrence with 
the Wnt and SHH signalling to stimulate the induction of hair follicles during embryogenesis 
(Botchkarev and Sharov, 2004). SHH expressed in the epithelium has also been shown to 
induce condensation of the dermis as a precursor to DP formation via TGF-β2 signalling (Ting-
Berreth and Chuong, 1996). TGF-β peptides control differentiation and proliferation among 
other functions (Figure 1.7). TGF-β acts with the TGF-α cytokine to induce cell transformation 
as well as to initiate apoptosis of certain cell types (Schuster and Krieglstein, 2002). As a TGF-β 
ligand binds to TGF-β receptor types I and II, type II receptors phosphorylate the type I 
receptor leading to pathway activation (Massague, 1998). TGF-β signals are mediated via the 
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SMAD and TAK1 pathways which also mediate BMP signals (Miyazono, 1997). Of the three 
TGF-β isoforms, TGF-β1 is required for the homeostasis between cell growth and apoptosis. 
TGF-β1 is expressed and secreted as an inactive complex that consists of latent associated 
protein (LAP) and a TGF-β1 peptide. LAP-TGF-β1 is linked to latent TGF-β binding proteins 
(LTBP) which enhance the stability of the cytokine and helps target the signal to the ECM. 
Latent TGF-β1 is usually stored in the ECM where it can be secreted and activated (Koli et al., 
2005). 
 
Members of the TGF-β family play an important role in DP development. The TGF-β2 isoform is 
required for inducing mouse hair follicle morphogenesis while TGF-β receptors I and II are 
observed during the hair follicle development and cycling. TGF-β2 has also been shown to play 
a role in regulating the down growth of keratinocytes that are committed to becoming hair 
follicles (Paus et al., 1997).  
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Figure 1.7: TGF-β signalling (Pinzani and Marra, 2001) 
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1.1.5 Stem cells 
 
Stem cells are defined by three characteristics: the ability to self renew, the regulation of cell 
number and the ability to differentiate into various cell types that may perform a number of 
functions based on their cell fate (Stecca and Altaba, 2005). The basal layer contains 
approximately 10% of stem cells that give rise to differentiating keratinocytes however the 
main source of stem cells is thought to be the hair follicle (Li and Neaves, 2006; Cotsarelis et 
al., 1990). Stem cells of the hair follicle can give rise to eight different cell types within the hair 
follicle. These include the ORS, companion layer of the ORS, Henle’s layer, Huxley’s layer, IRS 
cuticle, hair fibre cortex, hair fibre cuticle and the germinative epithelium (Liu et al., 2003). 
Hair follicle stem cells may also differentiate into sebocytes or form the interfollicular 
epidermis (IFE) from which sebocyte and hair follicle lineages can be induced depending on the 
type of mesenchymal signal transduction (Owens and Watt, 2003; Youssef et al., 2010). 
 
A number of hair follicle stem cell markers have been identified including β1-integrin, α6-
integrin, CD34, CD71 and p63, however, hair follicle stem cells are difficult to distinguish from 
daughter TA cells (Ma et al., 2004). Hair follicle stem cells are slow cycling and have a high 
proliferative potential and clonogenicity (Liu et al., 2003). A slower rate of growth has the 
advantage of conserving the proliferative potential of the cells as well as reducing the chance 
of errors occurring during DNA replication.  
 
The division of a stem cell will give rise to another stem cell to maintain stem cell numbers as 
well as a TA daughter cell which is limited in its proliferative potential (Ma et al., 2004). It has 
been suggested that the bulge region of the hair follicle is a pool of stem cells (Cotsarelis et al., 
1990). Stem cells of the bulge region have been shown to differentiate into the ORS, IRS, hair 
shaft and sebaceous gland (Oshima et al., 2001). 
 
Keratinocytes and the epidermis act to protect the body from damaging factors such as UV 
irradiation. As the keratinocytes are subjected to such conditions, there is a high potential of 
mutations occurring. As such, TA differentiated keratinocytes are shed so there is a limited 
time in which any mutations can occur. In contrast, stem cells reside in the basal layer for long 
periods of time and can therefore accumulate a number of different mutations or stresses that 
may give rise to tumour formation. 
 
It is believed that in cancers, small stem cell niches are responsible for tumour growth and 
maintenance (Reya et al., 2001). Hair follicle stem cells of the bulge region are pre-
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programmed to invade the dermis which is characteristic of the developing hair follicle 
(Muller-Rover et al., 2001) therefore, a bulge stem cell may be more invasive than other more 
differentiated cells (Perez-Losanda and Balmain, 2003). However, it is unknown whether 
tumours arise from stem cells located within normal tissue or if tumour cells develop stem cell 
characteristics due to genetic changes that may occur (Perez-Losanda and Balmain, 2003). 
 
There are various different tumours that arise from the epidermis such as Basal cell carcinoma 
(BCC) and sebaceous adenoma (Kore-eda et al., 1998; Owens and Watt, 2003). It is also well 
established that BCCs arise from mutations that deregulate the HH pathway and it is believed 
that BCCs may arise from undifferentiated cells of the ORS (Wicking et al., 1999; Owens and 
Watt, 2003). As the HH pathway has been shown to control certain properties of stem cell 
niches within the brain (Palma and Altaba, 2004), it is possible that deregulated HH signalling 
leads to changes in stem cell properties that lead to tumour formation. Other epidermal 
tumours including tricofolliculomas and pilomatricomas may potentially arise from stem cells 
that initially differentiate into the hair shaft or IRS (Owens and Watt, 2003). Studies have also 
shown that blocking of the TGF-β pathway prevents bulge stem cells from forming colonies 
suggesting that the TGF-β pathway maintains bulge stem cells (Lin and Yang, 2013). 
 
1.2 Skin cancer 
 
Cancer describes the uncontrolled growth of cells that can occur in nearly all types of tissue 
resulting in tumour formation. Diseases may be inherited or acquired through mutations 
caused by UV radiation for example. Mutations create an imbalance in the ratio of 
proliferation to cell death leading to tumour formation and possible metastasis. Various 
different mutations can affect certain aspects of cell biology that contribute to cancer 
development for example, mutations of Wnt and HH pathways components may cause 
hyperproliferation while matrix metalloproteases (MMP) mutations may alter cell invasion. 
Skin cancer is the most common malignancy as the purpose of the skin is to protect the body 
from stress such as UV damage therefore the skin is the most susceptible organ to tumour 
formation.  
 
Age is a major risk factor in skin cancer as there is an accumulation of sun exposure over time. 
UVA and UVB radiation penetrate the skin and more specifically UVB has been associated with 
mutations that lead to BCC formation (Kim et al., 2002). Other risk factors include virus 
infections such as HPV 16 virus which is linked to SCC formation (Eliezri et al., 1990). Genetic 
factors that give rise to certain characteristics such as freckles, moles, blue eyes and red hair 
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are known to increase susceptibility to developing skin cancer (Elwood et al., 1985). Skin 
cancer is classified as either melanoma or non-melanoma cancer. 
 
1.2.1 Squamous cell carcinoma (SCC) 
 
SCC is an epithelial malignancy that can occur in the mouth, lung, prostate as well as the skin 
which is the second most prevalent non-melanoma skin cancer after BCC. UV radiation is the 
most common cause of SCCs which produces mutations in DNA, forming thymidine dimers in 
the p53 tumour suppressor gene (Preston and Stern, 1992; Fears and Scotto, 1983). If the DNA 
is not repaired or the cells are not targeted for apoptosis, tumours may form (Grossman and 
Leffell, 1997). As a result, fair skinned people are more susceptible to developing SCCs and 
people who are born in areas where there are large amounts of UV radiation from the sun are 
also more likely to develop these tumours (Johnson et al., 1992). The loss of p53 function is 
also a characteristic of head and neck SCC (HNSCC) (Bonner et al., 2006). Functional 
inactivation of p16 through deletion or methylation is a common occurrence in HNSCCs 
(O’Regan et al., 2008). Metastatic SCC of the skin have been shown to have mutations that 
lead to the over expression of EGFR (Shimizu et al., 2001; Maubec et al., 2005; Krahn et al., 
2001). 90% of HNSCCs also show over expressed EGFR protein levels (Ang et al., 2002). Also, 
mutations of PTCH1 have been identified in cutaneous SCCs of patients who have a history of 
BCC (Ping et al., 2001). 
 
1.2.2 Basal cell carcinoma (BCC) 
 
Basal cell carcinoma (BCC) accounts for 70% of all skin cancers (Mancuso et al., 2004) and is 
the most common cancer to affect Caucasians with increasing incidence (Crowson, 2006). 
Compared to melanomas and SCCs, there are no precursor lesions detected in BCCs (Saldanha 
et al., 2003). BCCs rarely metastasise and are therefore very rarely fatal despite having a high 
frequency. There is a high patient morbidity and if tumours are not removed, they can cause 
extensive scarring and deformity (Elwood et al., 1985). 
 
The prevalence of BCC varies depending on geographical location where the incidence is 
greater in countries with high sunlight exposure (Holmes et al., 2000; Marks et al., 1993). 
Although the cure rate for BCC treatment is close to 100% (Svard et al., 2006) (with an 
extremely rare possibility of metastasis and fatality), the illness can cause substantial 
disfigurement and scarring. The most common areas where BCCs develop are the head and 
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neck where tumours can invade locally and cause tissue damage (Shea et al., 1992). The 
causative factors in BCC development are thought to be both genetic and environmental. 
 
1.2.2.1 Basal cell carcinoma subtypes 
 
Three subtypes of BCCs exist, each identifiable by their histology. These main subtypes are 
superficial, nodular and morpheic BCCs with morpheic the most aggressive and nodular the 
most common (Crowson, 2006) (Figure 1.8). Superficial BCCs appear as ulcers on the surface of 
the skin and histologically, they form a mass of cells below the epidermis. These extend from 
the dermis to the papillary dermis and have an increased risk of reoccurring if they are not fully 
removed (Saldanha et al., 2003). 
 
In contrast, nodular BCCs can be clearly seen as a growth on the surface of the skin and 
through a cross section, tumour islands develop varying in size and number. It is a low risk 
subtype that commonly occurs on the head, neck and other sun exposed areas. Micronodular 
BCCs are a subtype of nodular BCCs that are characterised by smaller tumour island usually 
below 0.15 mm in diameter (Saldanha et al., 2003). 
 
Morpheic BCCs are not particularly visible on the surface of the skin however, these are the 
most aggressive and infiltrative BCCs that develop. They appear as tumour islands that vary in 
shape and size but more often as flattened cell masses. Morpheic BCCs display stromal fibrosis 
which is associated with aggressive local invasion. Other rare forms of BCCs include pigmented 
types where tumours contain brown or black pigments, more common to dark skinned 
individuals. The basisquamous form is more difficult to classify as they have characteristics of 
both BCCs and SCCs (Saldanha et al., 2003). 
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Figure 1.8: BCC histology 
Histological section of [A] superficial, [B] nodular and [C] morpheic BCC (Crowson, 2006). 
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1.2.2.2 Treatment 
 
BCCs very rarely metastasise and are not fatal but they can cause significant scarring and 
disfigurement especially around the eyes and nose. The most common treatment is to 
surgically remove the tumour while other common treatments include cryotherapy or 
radiotherapy while Imiquimod and photodynamic therapy (PDT) are more recent forms. 
Imiquimod based creams are applied to the tumour in order to cause an inflammatory 
response to destroy the lesion. 74% of patients reported complete remission of the tumours 
(Lien and Sondak, 2011); however, this is only used to treat superficial BCCs. PDT involves 
applying a photosensitive drug to the tumour and upon activation of the drug by light, oxygen 
radicals are released that induce cell death with a cure rate reported to be 79% (Lien and 
Sondak, 2011). GDC-0449 (Vismodegib) is a SMO antagonist that has shown a 50% response in 
metastatic tumours and 60% in advanced local tumours (Göppner and Leverkus, 2011); this 
and other SMO inhibitors will be discussed in more detail later (see section 1.3.4.4). Other 
drugs such as Fluorouracil have been used to treat BCCs however it is only effective for 
superficial and non-invasive BCCs and it results in adverse side effects (Love et al., 2009). 
 
1.2.2.3 Genetics and molecular biology 
 
Our current understanding of BCC genetics stems from studies of patients with a hereditary 
predisposition to BCC: Gorlin syndrome also known as Nevoid Basal Cell Carcinoma syndrome 
(NBCCS). NBCCS is a rare autosomal dominant condition where sufferers are predisposed to 
BCC formation and was first described by Professor Robert J Gorlin in 1960 (Gorlin and Goltz, 
1960). Children that suffer from the disease can also develop certain characteristics such as a 
protruding jaw and a wide set of eyes. The nervous system may also be affected that 
culminates in an enlarged head as well as suffering from seizures, deafness, blindness and 
mental retardation (Dicker et al., 2002). The incidence of NBCCS in the UK is 1 in 19,000; 
NBCCS patients usually develop BCCs from a young age and are prone to developing 
other tumors including medulloblastomas (Evans et al., 2010). 
 
Familial linkage studies performed on NBCCS patients revealed a mutation located on 
chromosome 9q22.3, specifically to one allele of the PTCH1 tumour suppressor gene (Johnson 
et al., 1996; D’Errico et al., 1997). The formation of BCCs in NBCCS patients occurs after the 
loss of heterozygosity which is where the remaining, functioning PTCH1 allele acquires a 
mutation (Gailani et al., 1996). PTCH1 is a cell membrane receptor specific to HH ligands that 
suppress the HH pathway therefore, loss of PTCH1 functionality is thought to result in the 
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constitutive activation of the pathway in BCC tumours. From the results of several studies, up 
to 90% of sporadic BCCs (i.e. non-NBCCS tumours) also have PTCH1 mutations predicted to 
reduce protein function while 10-20% have activating mutations of the downstream protein 
Smoothened (SMO) which renders the protein insensitive to inhibition by PTCH1 (Rubin et al., 
2005; Youssef et al., 2010). Mutations of the PTCH1 locus has also been linked to hair follicle 
derived neoplasia (Nilsson et al., 2000). 
  
HH signalling has been shown to be important in maintaining the epidermal stem cell 
populations of the stratum basale and the bulge region of the hair follicle (Blanpain and Fuchs, 
2006). BCCs arise from the basal layer of the epidermis with the tumour mass consisting of 
basaloid cells. BCCs do not become cornified as seen from in vivo studies implying that they 
should not differentiate in vitro (Grando et al., 1996). BCCs express KRT5 and KRT14 however, 
there are no KRT1 and KRT10 differentiation markers suggesting that BCCs arise from basal 
cells (Leigh et al., 1993). Tumours consist of clusters of basal cells surrounded by a thin 
cytoplasmic layer. The surrounding basal cells of the tumour mass are arranged in a palisading 
manner to separate the tumour from the stroma (Vantuchova and Curik, 2006). There is also 
evidence that BCCs can arise from the hair follicle. Although BCCs are usually negative for 
differentiation markers, they express components of the HH pathway such as GLI1 which are 
important for the hair cycle and hair follicle regeneration. Also, Cytokeratin 17 which is a 
differentiation marker of the hair follicle has been detected in BCCs (Alessi et al., 2008) which 
supports the idea that BCCs arise from ORS cells (Crowson, 2006; Owens and Watt, 2003). 
 
Mouse studies where oncogenic SMO-M2 is conditionally over expressed reveals that BCC-like 
tumours form mainly on the ears and tail. These tumours did not originate from the bulge 
region however, there was strong induction of Ptch1, Gli1 and Gli2 (Youssef et al., 2010). Also, 
SMO-M2 expression in hair follicle TA cells did not give rise to tumours. The same study 
showed that the long term expression of SMO-M2 of interfollicular epidermal progenitor cells 
results in the development of more invasive BCC. This suggests that tumours may not arise 
from the bulge region although HH signalling is highly active, but more specifically the IFE. 
 
A role of the skin is to protect the body from UV radiation meaning that keratinocytes have a 
higher risk of acquiring mutations. UV radiation comes in two forms, UVA at 320-400 nm and 
UVB at 290-320 nm. Cellular exposure to UV radiation results in the generation of reactive 
oxygen species (ROS) that damage cells. Types of ROS include hydrogen peroxide, hydrogen 
radical, lipid peroxide and singular oxygen (Farage et al., 2010). Free radicals that are produced 
damage DNA causing mutations in oncogenes, tumour suppressor genes and can activate 
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pathways that regulate differentiation, growth, apoptosis and senescence. The effects of UVB 
damage of skin can accumulate in keratinocytes over a number of years until a certain key 
mutation occurs or a point at which there are enough mutations that make the cells 
carcinogenic (Lewis et al., 2008). Mutations of mitochondrial DNA for example are irreversible 
as the mitochondria have no system to repair the damage making these mutations more 
common. In contrast, nuclear DNA damage can be repaired or the cell can be targeted for 
apoptosis.  
 
67% of sporadic BCCs display C to T and CC to TT transitions of DNA coding for PTCH, caused by 
UVB damage (Rubin et al., 2005). Approximately 40% of BCCs were also shown to carry 
mutations of p53 which is likely to be due to UV exposure as well as mutations to components 
of the HH pathway (Reifenberger et al., 2005). People that have type I skin which is 
characterised by pale, non-tanning and easily burnt skin are at a higher risk of developing 
BCCs. Also, those who have red or blonde hair with blue or green eyes are more susceptible. 
UV radiation from sunlight is the largest source however the increased use of sunbeds for 
cosmetic purposes as well as some dermatological treatments has led to younger females 
developing sporadic BCCs (Rubin et al., 2005). 
 
Other genetic illnesses including Rombo syndrome (Michaelson et al., 1981), Xeroderma 
pigmentosum (Kraemer et al., 2007) and Cartilage-hair hypoplasia (Makite et al., 1999) are all 
associated with a high risk of developing BCC which demonstrates the involvement of other 
pathways linked to DNA damage and repair. Xeroderma pigmentosum is an autosomal 
recessive disorder that results in an inability to repair DNA damage caused by UV radiation. 
Patients were found to have mutations of p16, p53, SHH, PTCH1 and SMO in skin tumours all 
of which are induced by UV radiation (Couve-Privat et al., 2004). As well as UV being a risk 
factor, people that are immunosuppressed have an increased incidence of BCC and more 
specifically, develop infiltrative forms rather than superficial or nodular BCCs (Crowson, 2006). 
 
1.3 The Hedgehog signalling pathway 
 
The hedgehog (HH) signalling pathway plays an essential role in the regulation of proliferation, 
differentiation, patterning and growth of the embryo (Altaba et al., 2002). The pathway is most 
active during embryogenesis and involved in pattern formation of the developing limb bud 
(Towers and Tickle, 2009) as well as the ventral neural tube (Dessaud et al., 2008). The 
pathway is also required for the control of cell growth, proliferation, differentiation (Wicking 
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and McGlinn, 2001), stem/progenitor cell renewal, tissue regeneration and repair (Beachy et 
al., 2004). 
 
1.3.1 Development 
 
HH signalling is important for embryogenesis and tissue patterning. Stem cells can be induced 
by the HH pathway so that they differentiate into precursor cells which will then follow 
different cell fates. HH signalling is involved in the patterning, regulation of cell proliferation 
and differentiation of most tissues during development (Daya-Grosjean and Couve´-Privat, 
2005). During development, the embryo relies on various genetic interactions that will specify 
cell fates within the tissue (Park et al., 2000). HH signalling plays an important role in 
vertebrate skeletal development, digit formation on the hands and feet, teeth, lungs and 
nervous system (Mo et al., 1997; Hardcastle et al., 1998; Grindley et al., 1997). 
 
The zone of polarising activity (ZPA) is an important region involved in limb bud development 
that has strong HH expression (Park et al., 2000). The ZPA is an area of the developing limb bud 
that instructs its growth and polarity. It is controlled by many different genes and signalling 
pathways which determine its development into bones, joints, tendons and muscles. 
Development of embryo cell location, shape, size and differentiation into tissues are managed 
by HH signalling that varies in its strength, timing and location (Altaba et al., 2003). 
 
HH signalling is strongly involved in development of both the peripheral and central nervous 
systems (CNS). This pathway has been shown to act as a morphogen which is a substance that 
forms a gradient by which early neuronal tube development is governed. HH signalling also 
acts as a mitogen to induce mitosis in brain development. SHH ligand null mouse embryos 
display small neural tubes due to the lack of ventral differentiation in the notochord (Altaba et 
al., 2003). The neocortex is part of the cerebral cortex and is responsible for higher functions in 
mammals. Its development is dictated by HH signal regulation of early ventral patterning of the 
dorsal brain, a precursor for the neocortex. HH has also been implicated in midbrain expansion 
and the proliferation of granular precursors in the cerebellum (Palma and Altaba, 2004). HH 
ligands are secreted from the notochord and its floor plate generating a ventral to dorsal HH 
signal gradient. This gradient dictates the progenitor cell identity and the fate of neuronal cells 
within the ventral neural tube (Liem et al., 2000). The HH signal effect on neural development 
is further controlled by the TGF pathway, more specifically BMP4 and BMP7 (Liem et al., 1995). 
HH proteins also interact with the RAB23 GTPase to determine dorsal ventral patterning as 
well as with FGF components (Altaba et al., 2003). RAB23 (small GTP binding protein and part 
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of the Ras protein family) has been shown to be a negative regulator of HH in mice 
(Eggenschwiler et al., 2001). The importance of HH signalling in development is further 
demonstrated by HH null mice that have no CNS cell types present and lack any patterning of 
limbs (Chiang et al., 1996). 
 
1.3.2 Hedgehog signalling in Drosophila melanogaster 
 
Much of our understanding of the HH signalling pathway stems from studies performed on the 
fruit fly, Drosophila melanogaster. The origin of Hedgehog as the name for the pathway 
derives from the phenotypic change in D. melanogaster upon the mutation of the HH gene 
(Nusslein-Volhard and Wieschaus, 1980). A large scale screen was performed on fruit flies to 
identify mutations that may alter the development of the larval body. HH in D. melanogaster 
was identified as one of a number of genes that are important in developing the anterior and 
posterior parts of the individual body segments. The mutation of the D. melanogaster HH gene 
results in a coat of spines to grow on the underside of larvae (Nusslein-Volhard and Wieschaus, 
1980). As well as D. melanogaster, HH genes are also present in a number of invertebrates 
including Hirudo medicinalis (leech) and Diadema antillarum (sea urchin) (Chang et al., 1994; 
Inoue et al., 2002). It is important to note that Caenorhabditis elegans (roundworm) have no 
HH ortholog however there are a number of proteins homologous to PTCH (Kuwabara et al., 
2000). A number of HH orthologs vertebrates have been cloned such as mouse, zebrafish and 
chicken (Echelard et al., 1993; Krauss et al., 1993; Riddle et al., 1993). 
 
HH ligand processing and secretion are very highly conserved between D. melanogaster and 
mammals although there are some differences. D. melanogaster has a single HH gene whereas 
vertebrate signalling involves three HH ligands named after different types of hedgehog; 
Desert (DHH), Indian (IHH) and Sonic hedgehog (SHH); the latter based on the video game 
(McMahon, 2000). Of the three ligands, SHH is most expressed in mammals as it is involved in 
the development of the brain, spinal cord and limbs (Chiang et al., 1996). IHH has been 
reported to regulate bone growth (Lanske et al., 1996) while DHH regulates nerve sheath 
formation (Mirsky et al., 1999).  Zebrafish express a further three types of HH ligand which are 
Tiggywinkle hedgehog (TWHH), Echidna hedgehog (EHH) and Qiqihar hedgehog (QHH) (Ekker 
et al., 1995; Currie and Ingham, 1996; Ingham and McMahon, 2001). In both vertebrates and 
invertebrates, the binding of HH to its specific receptor PTCH starts a signalling cascade that 
results in the activation of zinc finger transcription factors - GLI in mammals and Ci in D. 
melanogaster. This results in the expression of specific target genes (Huangfu and Anderson, 
2006; Varjosalo and Taipale, 2007). 
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1.3.3 The Hedgehog signalling cascade 
 
The HH signalling cascade is initiated by HH ligands and controlled by the tumour suppressor 
protein PTCH1. Upon the binding of HH to PTCH1, SMO that is suppressed by PTCH1 is free to 
translocate to a complex consisting of Fused (FU) and Suppressor of Fused (SUFU). This 
complex releases the GLI transcription factors that translocate to the nucleus where they begin 
transcription (Figure 1.9). 
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Figure 1.9: The Hedgehog signalling pathway (di Magliano and Hebrok, 2003) 
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HH ligands are required to initiate the HH signalling cascade with SHH, IHH and DHH all active 
in mammals. The HH gene encodes a 45 kDa glycoprotein that is cleaved at the C- and N-
terminal regions. The N-terminal fragment is post transcriptionally modified to accommodate a 
hydrophobic cholesterol structure that allows the ligand to bind to the cell membrane (Lodish 
et al., 2000). A further lipid modification may occur where palmitic acid is added to the N-
terminus (Taipale and Beachy, 2001). The difference in modified and non-modified HH ligands 
was highlighted where it has been shown in mice that over expression of lipid modified HH is 
more potent than non-modified HH although the mechanism is unknown (Kohtz et al., 2001; 
Lee et al., 2001). Studies of mice only expressing N-terminal HH fragments that lack lipid 
modification reveal limb and digit developmental defects (Lewis et al., 2001). HH ligand can be 
transported by diffusion through extracellular spaces or a concentration gradient. HH can also 
enter the cell via endocytosis which can be receptor mediated (Ryan and Chiang, 2012). 
Heparin sulphate proteoglycans (HSPG) have been shown to control a number of signalling 
pathways such as HH, Wnt, TGF-β and FGF signalling pathways. HSPGs are capable of retaining 
and stabilising HH ligands by facilitating ligand-receptor interactions (Ryan and Chiang, 2012).  
 
For HH to be released from the cell, a 12-pass transmembrane protein Dispatched (DISP) is 
required. DISP has a significant sequence similarity to PTCH in particular, the sterol sensing 
region that is implicated in lipid transport or secretion of lipid modified proteins (Lum and 
Beachy, 2004). Lipid modified HH is not secreted from cells if there is an absence of DISP. In D. 
melanogaster, DISP releases lipid modified HH from the cell compared to mammalian DISP 
which is thought to be involved in HH multimer formation (Daya-Grosjean and Couve´-Privat, 
2005). 
 
HH signalling is controlled by the tumour suppressor protein PTCH1 and the G-protein coupled 
receptor SMO (Taipale and Beachy, 2001). PTCH1 contains twelve transmembrane domains 
and two extracellular loops that bind to HH ligands (Marigo et al., 1996). Mutations of PTCH1 
are associated with various birth defects as the HH pathway is heavily involved in embryonic 
development (Hahn et al., 1996). PTCH2 that was discovered in vertebrates shares a 54% 
sequence homology to PTCH1 however the amino and carboxylic regions differ which confers a 
different protein function (Carpenter et al., 1998). HH reception by PTCH1 can be enhanced by 
HH binding proteins located at the cell surface; these are IHOG and BOI in D. melanogaster, 
BOC and CDO in vertebrates as well as GAS1 (Allen et al., 2011; Beachy et al., 2010; Izzi et al., 
2011). Loss of IHOG and BOI in D. melanogaster results in a complete loss of signalling and this 
is also observed in mice that lack BOC and GAS1 highlighting the importance of these cofactors 
(Allen et al., 2011; Izzi et al., 2011).  
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Not only does PTCH1 function as the HH receptor, PTCH1 is a negative regulator of the HH 
pathway by inhibiting SMO. In the absence of a HH signal, PTCH1 localises to the primary 
cilium and maintains SMO in an inactive form thus preventing its translocation to the cilia 
(Rohatgi et al., 2007). Early studies of PTCH1 would suggest that it binds directly with SMO 
(Murone et al., 1999) however more recent studies indicate that the two proteins do not 
physically bind to each other (Taipale et al., 2002). 
 
In the presence of HH, PTCH1 relieves its inhibition of SMO. SMO is targeted for 
phosphorylation by CK1α and GRK2 protein kinases at the C-terminal end which induces 
conformational changes allowing SMO to translocate to the primary cilium (Chen et al., 2011). 
This translocation is controlled by β-Arrestins and the kinesin 2 motor protein KIF3A that bind 
to SMO after it has been phosphorylated. Active SMO modifies full length GLI proteins into 
active transcription factors (Kovacs et al., 2009) (Figure 1.10). 
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Figure 1.10: SMO translocation to the primary cilium mediated by β-Arrestins (Kovacs et al., 2009) 
[1] Upon HH binding, SMO is released from PTCH1. [2] SMO is phosphorylated by GRK2 that leads to the 
formation of a complex consisting of SMO, β-Arrestin and KIF3A. [3] This SMO complex is translocated to 
the primary cilium where [4] SMO cleaves GLI1 into an active form. [5] Active GLI translocates into the 
nucleus [6] where transcription of downstream targets occur. 
 
 
 
 
  Chapter 1 
50 
 
Inactive GLI proteins are part of a complex consisting of FU and SUFU where the cytoplasmic 
domain of SMO is able to bind with this GLI/SUFU complex (Beachy et al., 2004). When GLI is 
bound to the complex, GLI is retained in the cytoplasm through phosphorylation of the C-
terminus preventing translocation to the nucleus (Lauth and Toftgard, 2007). There is little 
known about how SMO interacts with the GLI/SUFU complex but it is thought that GLI/SUFU 
that accumulates in the cilium, dissociates as a result of interacting with SMO (Zeng et al., 
2010). It has also been proposed that the kinesin protein KIF7 can promote the disassembly of 
GLI from SUFU (Endoh-Yamagami et al. 2009). Further evidence of this comes from mice that 
are deficient in KIF7 which exhibit decreased HH signalling and reduced PTCH expression in the 
notochord (Liem et al., 2009). It is unknown if KIF7 and SMO interactions are dependent on 
SMO phosphorylation as this has been shown with Costal-2 (Cos2), the D. melanogaster 
equivalent of FU (Shi et al., 2011; Jia et al., 2003). 
 
Once GLI dissociates from the SUFU complex, it is able to enter the nucleus where it is 
converted to its activator form, GLI-A (Tukachinsky et al., 2010). Cytoplasmic microtubules are 
required for this translocation to occur as it has been shown that the addition of Nocodazole 
(destabilising agent of microtubules) prevents GLI entering the nucleus and also reducing its 
activity (Humke et al., 2010). GLI is active when in its full length form and repressed when 
truncated or modified (Bishop et al., 2010). GLI binds to the DNA of HH target genes that 
contain the consensus binding sequence 5’-TGGGTGGTC-3’ (Hooper and Scott, 2005). A 
negative feedback loop exists between PTCH1 and GLI1 which illustrates the importance of HH 
pathway regulation (Rahnama et al., 2006).  
 
There are three members of the GLI family all of which have a highly conserved DNA binding 
domain containing a zinc finger that binds to the consensus sequence (Dennler et al., 2007). 
GLI1 is the most prominent of the three and its over expression has been observed in many 
different types of cancers (Altaba et al., 2002). A positive feedback mechanism has been 
reported between GLI1 and GLI2 (Regl et al., 2002). HH signalling has also been linked to TGF-β 
(Cretnik et al., 2009), Notch and Wnt/β-catenin pathways (Adolphe et al., 2006).  
 
GLI2 and GLI3 have C-terminal activator domains as well as N-terminal repressor domains 
while GLI1 only has a C-terminal activator domain (Hooper and Scott, 2005). This means that 
all three GLI proteins function as activators while GLI2 and GLI3 can act as repressors. PTCH 
can then inhibit the HH pathway at the cell membrane whereas GLI1 will positively feed back 
by inducing GLI1 specific genes (Hooper and Scott, 2005). GLI1 has been reported to target a 
number of genes such as CCND1, FOXM1, PDGFRA and SFRP1 (Katoh and Katoh, 2008). 
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SUFU is able to stabilise full length GLI2 and GLI3, sequestering both proteins in the cytosol 
which prevents nuclear translocation and activation (Tukachinsky et al., 2010; Wang et al., 
2010). SUFU can also promote C-terminal phosphorylation of full length GLI via protein kinase 
A (PKA) followed by further phosphorylation via glycogen synthase kinase 3β (GSK3β) and 
CK1α (Tempe et al., 2006; Kise et al., 2009). Sufu deficient mice perish before embryo day 9.5 
and display reduced levels of full length and repressed GLI (Svard et al., 2006).  
 
1.3.4 Hedgehog signalling in disease 
 
As the HH pathway is involved in a number of developmental processes, it is unsurprising that 
mutations of HH pathway genes give rise to a number of diseases. With the HH pathway 
associated with various major pathways, diseases may arise indirectly. 
 
1.3.4.1 Ciliopathies 
 
Cilia are organelles that can be found on the surface of many cell types, consisting of 
microtubules. Cilia can either be motile or non-motile primary cilia. Motile cilia are able to 
generate movement while primary cilia play a sensory role. Both cilia types consist of nine 
microtubules that run in parallel to each other but with the addition of dyenin arms in motile 
cilia (Figure 1.11). 
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Figure 1.11: Structure of the cilia (Berbari et al., 2009) 
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Cilia contain a core of microtubules known as the axoneme. The axoneme consists of nine 
microtubule doublets and in motile cilia, the doublets surround another pair of microtubules. 
This is referred to as a 9+2 structure as opposed to a 9+0 arrangement in non-motile cilia. Cilia 
extend from the basal body which is associated with transition fibre proteins that regulate 
protein exit and entry from the cilia (Reiter et al., 2012). Cilia with the 9+2 arrangement are 
usually found on the surfaces of epithelial cells in the trachea for example. These cilia move 
together in tandem for the purpose of moving mucus or fluids. 
 
Proteins are transported to the cilia along the axoneme by the intraflagellar transport (IFT) 
system. IFT and motor proteins such as kinesin-2 are involved in the transport of proteins from 
the basal body along the axoneme while dynein is involved in protein transport in the opposite 
direction, towards the basal body (Gerdes et al., 2009). This process is vital for accurate 
localisation of proteins to the cilia as well as ciliogenesis. 
 
Non-motile cilia are found in specialised sensory cells such as in the cochlea and 
photoreceptors where external sensory signals are received. A number of receptors and ion 
channels are expressed in the cilia including HH which have been discussed, Wnt and PDGFα 
(Lee and Gleeson, 2010). Cilia involvement in Wnt occurs via the Wnt ligand, Frizzled receptor 
and Disheveled that regulate migration, proliferation and cell fate determination (Simons et 
al., 2005). PDGFα is located in the primary cilia and is important in cell migration, growth and 
survival (Schneider et al., 2005). 
 
The HH signalling pathway is mediated through cilia as demonstrated in mouse embryonic 
fibroblasts where upon SHH activation, SMO localises at the primary cilium (Corbit et al., 
2005). In the absence of SHH, PTCH1 localises at the cilia which in turn prevents SMO 
accumulating at the cilia. Therefore, the cilia can act as chemosensors that detect extracellular 
SHH (Rohatgi et al., 2007). It has also been shown that mutations of two IFT proteins, IFT88 
and IFT172 gives rise to similar defects of the neural tube as SHH mutant mice. Mice with 
mutations to both PTCH1 and IFT88 or IFT172 were shown to display identical features to mice 
with the single PTCH1 mutation which indicates that IFT proteins act downstream of PTCH1 
(Huangfu et al., 2003). Disruption of the basal body via the OFD1 gene in mice also showed 
similar defects to SHH mutant mice (Ferrante et al., 2006). GLI2, GLI3 and SUFU have also been 
observed at the tip of the cilium (Haycraft et al., 2005). 
 
The Wnt signalling pathway (see section 1.4.3) regulates cell fate, proliferation and migration 
that can signal in canonical and non-canonical modes. Both modes are regulated by cilia due to 
  Chapter 1 
54 
 
PCP proteins that are localised to the basal body such as Inversin, VANGL2 and FAT4 (Morgan 
et al., 2002; Ross et al., 2005; Saburi et al., 2008). The disruption of the cilia and the basal body 
has highlighted the importance of these structures in Wnt signalling. Zebrafish that have 
disrupted basal bodies via RNAi methods reveal impaired gastrulation and convergent 
extension. shRNA knockdown of basal body proteins BBS4 or BBS6 in Human embryonic 
kidney-293 (HEK293) cells also resulted in impaired convergent extension as well as increased 
canonical Wnt activity. Knockdown of KIF3A using shRNA also gave a similar phenotype with 
increased Wnt signalling (Gerdes et al., 2007). Other studies have shown that the ciliary 
protein NPHP3 binds to Inversin to inhibit canonical Wnt signalling which further links cilia to 
the Wnt signalling pathway (Bergmann et al., 2008). 
 
Primary cilia in fibroblasts play an important role in cellular growth via the PDGF signalling 
pathway which is involved in processes such as migration, survival and proliferation. PDGF 
receptors are able to activate MEK and ERK pathways that control gene transcription. PDGF 
receptor α (PDGFRα) has been shown to localise at the primary cilia in NIH3T3 cells during 
growth arrest and in mouse embryonic fibroblasts which results in up-regulated PDGFRα 
phosphorylation and subsequent phosphorylation of MEK and AKT (Schneider et al., 2005; 
Schneider et al., 2010).  
 
Polycystins 1 and 2 (PKD1 and PKD2) are two proteins that regulate cilia length and signalling, 
these proteins are also involved in adhesive protein to protein and carbohydrate interactions. 
Cilia also contain Integrins that work in tandem with PKD1 and PKD2 to allow for cilia to sense 
the microenvironment which has been associated to wound healing (Lu et al., 2008). Primary 
cilia of chondrocytes (cells involved in cartilage growth and maintenance) are in direct contact 
with ECM proteins suggesting that cilia respond to mechanical stimuli (Jensen et al., 2004). 
 
Another pathway that can act via cilia is the Fibroblast growth factor (FGF) pathway that is 
involved in cell survival, proliferation and migration. FGF ligands have also been implicated in 
facial and forebrain development (Creuzet et al., 2004) while others have shown that FGF 
signalling is required for regulating cilia length and function (Neugebauer et al., 2009). The 
disruption of FGF receptor 1 (FGFR1) leads to reduced expression of IFT88 as well as the 
transcription factors FOXJ1 and RFX2 that are involved in the control of cilia gene expression.  
 
Ciliopathies describe a class of genetic disease whereby primary cilia do not function. 
Ciliopathies of motile cilia affect cell motility while non-motile ciliopathies will cause conditions 
that alter the phenotype due to aberrant cilia function and signalling. Bardet-Biedl syndrome 
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(BBS) is characterised by postaxial polydactyly (growth of an extra digit on the hand or foot) 
and approximately 98% of patients are obese (Beales et al., 1999; Tobin and Beales, 2009). 
 
Meckel Gruber syndrome is a lethal autosomal recessive illness that presents in a similar 
fashion to BBS. Like BBS, there are a number of developmental defects which may be linked to 
IFT proteins. IFT proteins are required for ciliogenesis as well as the maintenance of cilia and 
flagella with the HH and Wnt pathways active in this organelle (Pedersen and Rosenbaum, 
2008). Studies where IFT proteins are knocked down in mice reveals that there is no GLI 
activator or repressor activity (Huangfu et al., 2003; Haycraft et al., 2005). IFT proteins are also 
required for GLI1, GL2 and GLI3 transport as well as SUFU where the proteins localise at the tip 
of the cilium (Haycraft et al., 2005). 
 
Other ciliopathies such as Alström syndrome (ALMS) are similar to BBS and further 
characterised by neurosensory hearing loss, cone-rod dystrophy and Type II diabetes. Certain 
features may emerge including dilated cardiomyopathy, hepatic and renal dysfunction (Tobin 
and Beales, 2009). Knockdown of the Alström syndrome 1 (ALMS1) gene using siRNA in mice 
causes defective ciliogenesis where the cilia are stunted in length and are unable to generate a 
calcium influx when cilia are stimulated (Li et al., 2007). 
 
1.3.4.2 Cancer  
 
It has been well documented that the aberrant activation of the HH signalling pathway can 
lead to a number of cancers. There are three models proposed for HH pathway activity in 
cancer (Figure 1.12) (Scales and de Sauvage, 2009). The first classification of cancers that were 
discovered were type I cancers that harbour activating mutations of the HH pathway and are 
HH ligand independent such as medulloblastomas and BCC. Type II cancers are defined as 
autocrine or juxtacrine and ligand dependent. This means that HH ligand that is produced by 
the cell is to stimulate that same cell or a close neighbour which could be a tumour cell. 
Cancers that are type III are paracrine ligand dependent which is defined as when epithelial 
tumour cells release HH ligand and activate the pathway in stromal cells which subsequently 
feed other signals back to the tumour resulting in growth and survival (Rubin and de Sauvage, 
2006; Scales and de Sauvage, 2009). 
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Figure 1.12: Modes of Hedgehog signalling (Scales and de Sauvage, 2009) 
[a] Type I ligand independent cancer where PTCH1 is inactive or SMO is active resulting in constitutive 
activation of the HH pathway even when HH ligands are present. [b] Type II ligand dependent autocrine 
cancer cells produce and respond to HH from the same cell. [c] Type III ligand dependent paracrine 
cancer cells secrete HH into the stroma which can feed back to the cancer cell with signals such as 
Vascular endothelial growth factor (VEGF), Insulin growth factor (IGF) and Wnt. [d] Similarly, type IIIb 
ligand dependent paracrine tumours receive HH from stromal cells resulting in pathway activation in the 
cancer cells. [e] HH signalling in self-renewing cancer stem cells that may come from the cell itself or the 
stroma. These cancer stem cells may give rise to HH dependent cells or even HH negative tumour cells. 
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Type I cancer was initially linked to the HH signalling pathway after the identification of PTCH1 
inactivating mutations in Gorlin’s syndrome that results in the constitutive activation of the 
pathway that does not require HH ligands to stimulate the pathway (Hahn et al., 1996, Johnson 
et al., 1996). Studies have shown that up to 90% of BCCs have inactivating mutations of PTCH1 
and 10% have SMO activating mutations (Xie et al., 1998). Deregulated HH signalling is also a 
feature of medulloblastomas and rhabdomyosarcomas which can be due to PTCH1 inactivating 
mutations and less frequently SUFU mutations (Taylor et al., 2002; Tostar et al., 2006).   
 
Type II autocrine tumours where HH signalling is constantly active affect a wide range organs 
including the liver, pancreas and prostate (Sicklick et al., 2006; Thayer et al., 2003; Karhadkar 
et al., 2004). These tumours have increased levels of HH ligand and PTCH1 and GLI expression. 
HH ligand that is produced by tumour cells will act upon itself or other neighbouring tumour 
cells in order to promote growth and survival of the cells. To suppress such autocrine tumours, 
HH neutralising antibodies or downstream inhibitors targeting SMO for example are most 
effective. 
  
Type III paracrine cancers depend heavily on HH signalling to promote a favourable tumour 
microenvironment in the stroma (Yauch et al., 2008). It has been shown that in mice, prostate 
cancer signals to the stroma via paracrine signalling with an increased level of PTCH and GLI 
detected in mouse stroma in response to human HH production (Fan et al., 2004). It was also 
observed that HH ligands derived from the tumour as a result of HH over expressing xenografts 
are able to stimulate PTCH1, GLI1 and GLI2 expression of infiltrative stroma but not in the 
tumour. Treatment of these tumours with a HH blocking antibody and a SMO inhibitor reduced 
expression of PTCH1, GLI1 and GLI2 in the stroma as well as slowing tumour growth. This 
shows that the stromal cells can send growth and survival signals back to the tumour and not 
just the tumour stimulating the stormal cells (Theunissen and de Sauvage, 2009; Yauch et al., 
2008). In pancreatic adenocarcinoma, deletion of SMO in pancreatic cells does not significantly 
affect PTCH1 and GLI expression in neoplastic pancreatic ductal cells and also do not affect the 
adenocarcinoma itself (Nolan-Stevaux et al., 2009). 
 
These studies show that paracrine HH signalling that originates from tumour cells activate HH 
signalling in the stroma which results in the promotion of tumour growth and survival that 
occur through the stromal expression of certain factors (Theunissen and de Sauvage, 2009). 
The mechanism by which stromal cells feedback to the tumour cells is still unclear however, it 
is believed that a number of signalling pathways including IGF and Wnt may be involved (Scales 
and de Sauvage, 2009, Yauch et al., 2008). 
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Type IV HH signalling describes a reverse paracrine model whereby stromal cells secrete HH 
ligands that are received by tumour cells (Theunissen and de Sauvage, 2009). Type IV cancers 
include haematological malignancies such as B-cell lymphocytic leukemia (B-CLL) where HH 
secreted from stromal cells was shown to be vital for the survival of the cancer B-cells due to 
the up regulation of BCL2 which is an anti-apoptotic factor as well as other HH components 
including  GLI1, GLI2 and SUFU (Hegde et al., 2008). With the reverse paracrine signalling 
model, stromal HH that is believed to be driving tumour growth could be a potential 
therapeutic target.  
 
1.3.4.3 Hedgehog signalling in Basal cell carcinoma 
 
As the HH signalling pathway plays an important role in development, it is not surprising that 
dysregulation of the pathway is associated with disease including cancer (di Magliano and 
Hebrok, 2003; Rubin and de Sauvage, 2006; Altaba et al., 2002; Taipale and Beachy, 2001). HH 
signalling has also been shown to be required for the maintenance of cancers such as lung and 
prostate cancer despite the tumours arising from the dysregulation of other signalling 
pathways (Watkins et al., 2003; Karhadkar et al., 2004).  
 
HH signalling was implicated In BCC biology after the observation that Gorlin’s syndrome 
patients are predisposed to developing BCCs (Johnson et al., 1996). Gorlin’s syndrome patients 
are born with a defective PTCH1 allele and upon the loss of function of the remaining allele 
(loss of heterozygosity, LOH) BCCs develop (Gailani et al., 1996). As a result Gorlin’s patients 
are more likely to acquire the LOH mutation of PTCH1 and develop BCCs at an earlier age than 
non-Gorlin’s patients. Non-Gorlin’s patients develop tumours later in life because loss of 
function mutations to both PTCH1 alleles takes longer to occur for BCCs to form.  
 
PTCH1 LOH mutations have been observed sporadic BCCs ranging between 11-67% in various 
studies (Saran, 2010). It has been reported that approximately 90% of sporadic BCCs harbour 
loss of function mutations of PTCH1 and 10% activating mutations of SMO (Rubin et al., 2005; 
Youssef et al., 2010). 50% of sporadic BCCs have been shown to carry mutations of PTCH1 that 
are caused by UVB radiation (Gailani and Bale, 1997). In contrast one study has shown that out 
of the BCCs examined, PTCH mRNA was over expressed in all samples. PTCH protein expression 
was found in all tumour cells and stronger in palisading cells but not in normal epidermal cells 
(Tojo et al., 1999).  
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Downstream of PTCH1, activating mutations of SMO have been described in sporadic BCCs as 
Arg-562-Gln in SMO-mutant 1 (M1) and Trp-535-Leu in SMO-mutant 2 (M2). Of the two 
identified mutations the SMO-M2 mutation was found in nearly all BCCs where PTCH1 
remained intact. Mice over expressing wild type SMO do not develop any abnormalities 
whereas SMO-M2 over expressing mice display BCC like characteristics. There are areas of 
down growth into the dermis, a non-keratinised epithelium and an absence of hyalin granules 
in the stratum granulosum. There is also a large accumulation of PTCH in basal cells (Xie et al., 
1998). The study strongly implicates HH signalling in BCC and that the increase of PTCH mRNA 
levels is due to do mutant SMO activity.  
 
Non-canonical activation of the HH pathway i.e. the pathway is stimulated by another factor, 
may also contribute to BCC development. Transforming growth factor-β (TGF-β) has been 
reported to induce both GLI1 and GLI2 expression in keratinocytes. Furthermore, increased 
GLI1 and GLI2 expression was maintained in the presence of the SMO inhibitor Cyclopamine 
suggesting that GLI1 and GLI2 can operate independently of SMO (Dennler et al., 2007). Also, 
mRNA analysis of BCC reveals elevated levels of TGF-β and SMAD pathway components 
(Gambichler et al., 2007). The deletion of Notch in mouse skin has been shown to induce GLI2 
expression resulting in BCC formation (Nicolas et al., 2003). 
 
A number of mouse models of BCC have been developed to help understand how BCCs may 
form. As PTCH-/- mice are not viable, PTCH+/- mice were developed with a single allele mutation 
of PTCH as seen in Gorlin’s patients. After the mice were UV irradiated, they develop a large 
number of tumours that resemble BCCs (Donovan, 2009; Daya-Grosjean and Couve´-Privat, 
2005). This is due to UV damage that causes the LOH of the remaining PTCH allele although it is 
not known why actual BCCs do not develop. Other studies have shown that PTCH+/- mice 
develop tumours similar to Trichoblastomas which are rare dermal tumours that develop close 
to the hair follicle and X-ray irradiation of these mice increased the number of tumours and 
altered their appearance to be more similar to nodular BCCs (Mancuso et al., 2004). There is 
evidence suggesting that Trichoblastomas share many similarities to nodular BCCs (Schirren et 
al., 1997). 
 
An in vivo study has shown that loss of PTCH1 function in mouse skin is capable of inducing 
BCC formation (Adolphe et al., 2006). An inducible PTCH1 knockout mouse system has 
demonstrated that the loss of PTCH1 function from the basal cell population is sufficient to 
induce skin tumour formation that resembles BCC. This system differs to PTCH+/- mouse 
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models that are UV irradiated to tumours therefore there may be non-specific effects of the 
UV radiation (Donovan, 2009; Daya-Grosjean and Couve´-Privat, 2005). The Adolphe model 
shows that the targeted deletion of both PTCH1 alleles is sufficient to induce BCC-like tumour 
formation which implies that specifically the loss of PTCH1 function is important for tumour 
formation. 
 
Further downstream of the HH pathway, mice over expressing GLI1 were able to develop 
tumours that share a resemblance to BCCs (Nilsson et al., 2000). Interestingly, mice over 
expressing an activated mutant form of GLI2 which is a positive regulator of GLI1 developed 
multiple BCCs (Sheng et al., 2002; Grachtchouk et al., 2000). GLI2 studies in mice show that 
over expression of the protein in hair follicle stem cells leads to nodular BCC formation 
compared to GLI2 over expression in the IFE which leads to a more superficial BCC phenotype 
(Grachtchouk et al., 2011). 
 
Other components of the HH pathway have been investigated including SUFU. SUFU 
knockdown in mice results in embryonic death but SUFU+/- mice develop characteristics that 
can be found in Gorlin’s patients such as jaw keratocysts. Fibroblasts derived from SUFU-/- mice 
were shown to have elevated levels of GLI1 mediated HH signalling which implies that loss of 
SUFU function leads to ligand independent HH activity (Svard et al., 2006).  
 
Mouse studies where GLI2 is over expressed reveals the development of multiple BCCs which 
suggests that GLI2 is a potent oncogene. These tumours strongly resemble human BCCs in 
their histology and express various BCC markers. HH components such as PTCH1, GLI1 and 
GLI2 were increased at the mRNA level in the tumours but not the epidermis. As HH ligand is 
not detected in human BCCs, this suggests that tumours can arise independently of the HH 
ligand (Grachtchouk et al., 2000).  
 
Some BCC tumours that do not have mutated PTCH, can still have increased HH signalling as a 
result of SMO activating mutation which negates the repressive function of PTCH on the 
pathway (Xie et al., 1998). More recent studies show that mutant SMO-M2 over expressing 
mice do not develop BCCs. The tumours that do emerge are more characteristic of follicular 
hamartomas (benign tumour) with invasive down growth into the dermis and 
hyperproliferation of the epidermis (Grachtchouk et al., 2003).  In another study, expression of 
active mutant SMO-M2 in mice did in fact lead to tumour formation (Youssef et al., 2010). 
Here it was also shown that the tumours originate from undifferentiated basal layer stem cells 
via increased HH signalling and not from the hair follicle bulge region for example. This may be 
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a reason as to why the two models differ as the specific area where the mutations occur could 
determine the type of tumours that form.  
 
Mouse studies regarding Wnt signalling show that the pathway is required for Hamartoma 
development around the hair follicle and this tumour has been associated with dysregulation 
of the HH pathway. Expression of an active mutant of SMO induced tumour development in 
mice via constitutively active HH signalling however, the addition of the Wnt antagonist Dkk1 
resulted in the inhibition of Hamartoma development (Yang et al., 2008). This suggests that 
inhibition of Wnt may serve as a viable therapeutic target and demonstrates a link between 
HH and Wnt signalling pathways. 
 
1.3.4.4 Therapeutic targeting 
 
Aberrant HH signalling can be caused by the dysregulation of a number of components within 
the pathway and through different mechanisms. Specific therapies can be selected for 
autocrine or paracrine ligand dependent cancer which would involve blocking or reducing HH 
activity however, as BCCs are ligand independent which makes the therapy more difficult 
administer. The current strategy for treating BCCs would be to treat the tumour with inhibitors 
that are downstream of the activating mutation such as SMO. 
 
As a potential treatment for BCC there are SMO antagonists currently available, the first being 
Cyclopamine. Cyclopamine was discovered when pregnant sheep that were eating the 
Veratrum californicum species of lily containing Cyclopamine, would carry embryos with 
holoprosencephaly (HPE). HPE is a developmental disorder where the midline of the face does 
not develop resulting in a cyclopic eye which has been linked to HH signalling as Cyclopamine 
was shown to specifically inhibit SMO (Taipale et al., 2000). SHH-/- knockout mice have also 
been reported to develop HPE (Chiang et al., 1996). Cyclopamine has been shown to inhibit 
human medulloblastoma growth (Dahmane et al., 2001) which has led to the proposal for HH 
antagonists as a valid treatment however non-canonical HH signalling and the development of 
BCC through this mode of signalling has important therapeutic implications.  
 
Due to the low affinity of Cyclopamine, synthetic derivatives have been developed such as 
BMS-833923, CUR-61414, HhAntag-691, IPI-926, MK4101, SANT1, SANT4 and Cyclopamine-
KAAD with GDC-0449 having undergone phase I clinical trials to treat BCC (Scales and de 
Sauvage, 2009, Van Hoff et al., 2009) with 50% of metastatic tumours and 60% of advanced 
local tumours responded to the treatment (Göppner et al., 2010).  
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Other potential therapies include HH blocking antibodies which prevent the binding of HH 
ligand to PTCH1 and have shown to be successful (Scales and de Sauvage, 2009). The targeting 
of other HH components such as GLI with GANT58 and GANT61 are undergoing various phases 
of development (Lauth and Toftgard, 2007). 
 
The use of SMO inhibitors is an appealing therapeutic target however there are a number of 
studies that show differing levels of efficacy. NIH-3T3 mouse embryonic fibroblasts that were 
stimulated with a modified version of SHH (ShhNp) show a 150 to 200 fold increase of GLI 
reporter activity. Upon the addition of Cyclopamine, GLI reporter activity fell to near normal 
levels. Also, PTCH-/- mouse embryos that have increased HH expression could be lowered using 
Cyclopamine which shows that the inhibitor works downstream of PTCH. The NIH-3T3 cells 
were then transduced with wild type SMO to increase GLI reporter activity by 10 fold that was 
subsequently reduced to normal levels after Cyclopamine treatment. Interestingly, NIH-3T3 
cells that are transduced with an active SMO mutant to induce HH signalling could not be 
reduced by Cyclopamine. Although mutant SMO NIH-3T3 cells do not respond to the inhibitor, 
HH signalling was repressed upon the introduction of PTCH. This suggests that certain 
activating mutants of SMO can make cells resistant to Cyclopamine but can be regulated by 
PTCH and still respond to SHH (Taipale et al., 2000). 
 
Regarding mouse models of BCC, PTCH+/- mice that develop BCCs after UV irradiation that were 
treated orally with Cyclopamine for 20 weeks show a reduction in approximately 66% of 
tumours (Athar et al., 2004). BCC biopsies taken from UV irradiated PTCH+/- mice that were 
subsequently cultured in vitro, were shown to regress upon treatment with the SMO inhibitor 
CUR61414 (Williams et al., 2003). These studies demonstrate the capabilities of using SMO 
inhibitors to treat BCCs in mice and from this, valid reason to use such inhibitors to treat 
human BCCs. A criticism of these studies is that the BCCs occur after the UV irradiation of the 
mice and not through other mutations such as SMO activation although these are rare.   
 
Studies have shown that not all BCCs respond to SMO inhibitors such as GDC-0449 which is 
undergoing Phase I trials. Of the metastatic BCCs that were treated, only 30% responded to 
treatment. 43% of locally invasive BCCs responded to GDC-0449 and of these, 21% showed a 
total response. Unfortunately, 30% of patients suffered from minor side effects and 25% more 
serious effects resulting in the death of seven people (Sekulic et al., 2012).  
 
Targeting components downstream of SMO such as GLI1 have been tested. GANT58 and 
GANT61 both inhibit GLI1 in HEK293 cells. Treatment with GANT61 resulted in the 
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accumulation of GLI1 in the nucleus but transcriptional activity and DNA binding was 
suppressed. Interestingly, when 22Rv1 prostate carcinoma cell lines were treated with 
Cyclopamine in vitro there was no inhibition of cell growth however, when these cells are used 
in xenografts Cyclopamine was able to stop tumour growth. GANT61 treatment of the 
xenografts shows strong tumour regression (Lauth et al., 2007). The data suggests that tumour 
growth could be controlled by an external factor such as stromal signalling or that both the 
tumour and stroma need to be targeted for inhibition. 
 
1.4 Alternative pathways involved in Basal cell carcinoma 
 
1.4.1 The p53 signalling pathway 
 
The p53 tumour suppressor gene plays an important role in cellular regulation (Figure 1.13). Its 
functions include tumour suppression, metabolic control, stem cell control, DNA damage 
repair and the initiation of apoptosis (Olivier et al., 2010). 
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Figure 1.13: p53 signalling (Sigma-Aldrich, 2012) 
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It is well documented that around half of all BCCs have mutations of the TP53 gene (Mancuso 
et al., 2004; Soleti et al., 2009; Rady et al., 1992). The frequency of BCCs was shown to increase 
with patient age which implies that longer exposure to UV light may cause mutations of p53 
(D'Errico et al., 1997). CC to TT or C to T transitions at dipyrimidine sites of the p53 gene were 
found in UV exposed tumours resulting in protein loss of function (Mancuso et al., 2004; 
D'Errico et al., 1997; Denef et al., 2000; Zhang et al., 2001). Due to this, the cells are unable to 
repair DNA damage caused by UV exposure and may not undergo apoptosis. Indeed, p53 
knockout mice have been shown to develop tumours significantly earlier than wild type mice 
after UV irradiation (Kim et al., 2002).  
 
Studies of PTCH+/- mice reveal that after UV irradiation, the mice are more susceptible to 
developing spontaneous tumours. PTCHNeo67/- (heterozygous knockout mice targeting exons 6 
to 7) develop BCC precursor lesions and upon UV treatment, these lesions develop into 
nodular and infiltrative BCCs. Immunohistochemistry also revealed that p53 expression is 
increased in tumours after UV treatment whereas p53 levels in normal skin were not affected. 
p53 expression was concentrated around tumour islands (Mancuso et al., 2004). The study 
shows that the progression from hyperproliferation to nodular to infiltrative BCC formation is a 
stepwise process which may occur due to an accumulation of sequential genetic alterations. A 
similar study of PTCH+/- mice shows that X-ray treatment of these mice results in BCC 
formation but only from KRT15 expressing cells of the bulge region. PTCH+/- p53-/- mice show 
greater BCC carcinogenesis from the bulge region and develop BCC from the IFE which also has 
increased levels of SMO. In areas such as the ears and tail of PTCH+/- mice, there was no BCC 
formation which may be associated with the lack of SMO expression in these regions (Wang et 
al., 2011).  
 
1.4.2 The EGFR signalling pathway 
 
The epidermal growth factor receptor (EGFR) is a cell membrane receptor that activates a 
number of downstream pathways and targets with various different functions (Figure 1.14). 
EGFR is part of the receptor tyrosine kinase family ErbB and is stimulated by several ligands 
including epidermal growth factor (EGF) and transforming growth factor-α (TGF-α) (Olayioye et 
al., 2000). 
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Figure 1.14: EGFR signalling (Brambilla and Gazdar, 2009) 
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Phosphorylation of EGFR at various residues has been shown to have different effects on 
downstream signalling targets. Phosphorylation of Tyr845 has been implicated in maintaining 
activation of EGFR (Hubbard et al., 1994) while Tyr1173 phosphorylation has been linked to 
ERK activation (Hsu et al., 2011). EGFR can perform auto-phosphorylation to initiate signalling 
pathways including MAPK, JNK and AKT (Oda et al., 2005). 
 
The PI3K/AKT pathway plays an important role in cell survival by inhibiting apoptosis. As AKT is 
activated, a number of apoptosis factors such as Caspase-9 and Forkhead transcription factors 
become inactive (Cardone et al., 1998; Brunet et al., 1999). As well as regulating cell survival, 
the AKT pathway controls proliferation and angiogenesis via the mTOR (Mammalian target of 
Rapamycin) and PTEN (Phosphatase and tensin homolog deleted on chromosome 10) 
signalling pathways (Figure 1.15) (Castellino and Durden, 2007). PTEN is a tumour suppressor 
protein that negatively regulates the PI3K/AKT pathway (Maehama and Dixon, 1998) and loss 
of function of this protein has been linked to a number of skin cancers (Ming and He, 2009). 
There is little known about the role that PTEN may play in BCC biology however as PI3K/AKT 
activation is required for HH signalling, mutations of PTEN may activate PI3K/AKT which could 
potentially initiate BCC formation (Riobo et al., 2006 A).  
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Figure 1.15: PI3K/AKT/PTEN pathway (Castellino and Durden, 2007) 
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AKT that is activated downstream of PI3K was shown to be important for HH signalling in 
chicken neuronal development and the stimulation of the PI3K pathway also activates GLI 
transcription factors. AKT that positively regulates HH signalling suggests that there is a 
synergistic role of these pathways that is required for embryonic development which may 
extend to HH dependent tumours (Riobo et al., 2006 A). PI3K/AKT activation has been 
implicated in BCC development after immunohistochemistry of BCCs were shown to have 
increased levels of pAKT (Hafner et al., 2010). However, another study has shown a lack of 
pAKT activation in BCCs (O’Shaughnessy et al., 2007). 
 
HH signalling has been further associated with EGFR signalling as the over expression of SHH in 
HaCaT immortalised keratinocytes that were grown in organotypic culture, induced a basal 
phenotype and promoted invasion of the cells into the collagen matrix. SHH expression was 
shown to increase the phosphorylation of EGFR, JNK and Raf as well as increase Matrix 
Metalloproteinase-9 (MMP-9) which has been implicated in cell invasion and tumour 
aggression (Rebecca et al., 2005; Tai et al., 2008). Inhibition of EGFR using the antagonist 
AG1478 reduced the invasiveness of the cells while supplementing SHH over expressing cells 
with EGF increased invasiveness. It is not stated whether MMP-9 expression is mediated 
through SHH, EGFR or both but the data implies that both pathways are linked together and 
may contribute to tumour invasion by activating MMP-9 (Rebecca et al., 2005).  
 
Studies have shown that EGFR signalling modulates the expression of GLI target genes in 
N/Tert human immortalised keratinocytes (Kasper et al., 2006). 19 genes were found to be 
induced synergistically by GLI1 and EGF treatment also; GLI1 target genes were shown to be 
modulated by EGFR signalling through MEK/ERK pathways.  
 
Studies have also identified that HH and EGFR synergy can induce oncogenic transformation 
which is mediated through EGFR activation of RAS/RAF/MEK/ERK. EGFR/MEK/ERK pathways 
are able to induce JUN signalling which is essential for oncogenic transformation. 
EGFR/MEK/ERK pathways also increase GLI1 and GLI2 expression. In mouse cells where BCCs 
develop as a result of activated HH signalling, inhibiting both EGFR and GLI signalling shows a 
reduction of BCC growth and therefore presents a potential therapeutic opportunity (Schnidar 
et al., 2009). 
 
In contrast, our research group has previously shown that the over expression of GLI1 in 
N/Tert cells reduces EGFR expression and that compact colony formation (a characteristic of 
BCC tumour formation) is associated with repressed ERK activity (Neill et al., 2008). 
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Furthermore, staining of a panel of BCCs reveals no pERK expression in 13/14 tumours 
whereas pERK was expressed in the epidermis suggesting that its loss is important for tumour 
formation. 
 
1.4.3 The Wnt signalling pathway 
 
The Wnt signalling pathway has been shown to play an important role in cell proliferation, 
differentiation and stem cell fate (Angers and Moon, 2009; Ling et al., 2009). Activation of this 
pathway is frequently observed in human cancers with active Wnt promoting the 
accumulation of β-catenin. β-catenin is a component of adherens junction complexes that are 
required to maintain epithelial cell layers and regulate cell growth. The CTNNB1 gene encodes 
β-catenin and this gene is thought to be an oncogene (Wang et al., 2008). β-catenin is able 
regulate gene expression however, CTNNB1 is not mutated in BCC and it is likely that 
disregulation of Wnt and/or HH signalling pathways leads to nuclear β-catenin accumulation 
(Hino et al., 2005; Liu et al., 2005; Saldanha et al., 2004). 
 
The HH and Wnt pathways have been shown to be linked with each other in normal 
development.  Activation of GLI2 was shown to regulate Wnt8 expression while inhibition of 
Wnt also reduces GLI2 and GLI3 expression (Mullor et al., 2001). The same study also showed 
that GLI1 induces certain Wnt genes in BCC-like skin tumours. 
 
1.5 Aims of the study 
 
Although BCC genetics have been well established and the involvement of the HH signalling 
pathway in BCCs recognised, there is some conflicting data regarding the molecular basis of 
disease. The HH signalling pathway is known to interact with a number of other major 
signalling pathways so it is unclear how important direct HH signalling is regarding BCC 
development. Mouse models where PTCH1, GLI1 and GLI2 have been influenced show that 
BCCs can develop when manipulating this pathway. The over expression of mutant SMO-M2 
specifically in the IFE, also leads to BCC formation (Youssef et al., 2010) although others have 
shown that SMO-M2 over expression in mice does not lead to BCC formation (Grachtchouk et 
al., 2003). These mouse studies show that manipulation of the HH components play a role in 
BCC biology however, there are discrepancies in the exact type of tumours that form from 
each study as not all develop BCCs.  
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Following on from this, it is also a mystery as to why a large percentage of BCC patients do not 
respond to SMO inhibitors regardless of whether SMO mutations can or cannot lead to BCC 
development. This could be because HH is not as important for BCC biology as first thought or 
there are more complex modes of HH signalling that do not depend upon SMO. Furthermore 
as seen in NIH-3T3 cells where mutant SMO has been over expressed, HH signalling could not 
be repressed by Cyclopamine but could be controlled by the reintroduction of PTCH (Taipale et 
al., 2000). 
 
Regarding the use of clinical SMO inhibitor GDC-0449, one study has demonstrated that 2/33 
BCCs show a complete reduction while 16/33 shows partial reduction in tumour growth (74) 
while others have shown that 50% of metastatic tumours and 60% of advanced local tumours 
responded to the treatment (Van Hoff et al., 2009; Göppner et al., 2010). Another study has 
shown that 30% of metastatic BCCs respond to GDC-0449 while 43% of locally invasive BCCs of 
which 21% showed a full response however there were side effects including the deaths of 
seven people (Sekulic et al., 2012). In contrast, an amino acid substitution identified in SMO 
that shows no effect of the HH signalling pathway, has been reported to disrupt the ability of 
GDC-0449 to bind to SMO and repress the HH pathway (Yauch et al., 2009). 
 
At the molecular level and as noted above, BCC is principally associated with mutational 
inactivation of the PTCH1 tumour suppressor gene which is thought to lead to increased 
expression of the proto-oncogenic GLI transcription factors, GLI1 and GLI2 via a mechanism 
that requires the protein SMO. Indeed, anti-SMO compounds are effective at suppressing GLI1 
expression and tumour formation in pre-clinical mouse models however the results of recent 
clinical trials have been mixed with some tumours showing regression or stability whereas 
others demonstrated no response. In addition, the evidence that these SMO inhibitors 
suppress GLI1 in human tumours is weak and recent research in Dr Neill’s group has shown 
that many BCCs do not actually express high levels of GLI1 as determined by 
immunohistochemistry (unpublished data). As such, the aim of the study was to: 
 
1- Create a novel in vitro model of BCC through targeted suppression of PTCH1 in human 
keratinocytes with the aim of identifying novel mechanisms that may contribute to the 
formation and progression of this common skin tumour; these may be SMO-dependent 
and/or SMO independent. 
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2- To utilise this model to investigate and delineate the canonical HH signalling pathway in 
human keratinocytes i.e. does loss of PTCH1 function lead to an increase of GLI1 through 
SMO or are other factors involved? 
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Chapter 2 Materials and methods 
 
2.1 Immortalised keratinocyte cell culture  
 
The three different types of cell line that were used for the study are HaCaT, NEB1 and N/Tert 
immortalised human keratinocytes. NEB1 cells originate from early epidermal keratinocytes 
and were immortalised using HPV16 E6/E7 virus (Morley et al., 2003). N/Tert keratinocytes 
were generated by retroviral transduction of telomerase (Dickson et al., 2000). HaCaT cells are 
spontaneously immortalised keratinocytes (Boukamp et al., 1988) with a mutation of the p53 
pathway later being identified as the likely cause of immortalisation (Lehman et al., 1993). 
 
NEB1, N/Tert and HaCaT cells were cultured in keratinocyte growth medium (KGM) consisting 
of Alpha MEM and 10% (v/v) heat inactivated foetal bovine serum of Brazilian origin (Lonza, 
Slough, UK), 2 mM L-glutamine and 2% o(v/v) penicillin streptomycin (PAA Laboratories, 
Somerset, UK). L-glutamine is an amino acid required for glycolysis while penicillin and 
streptomycin are antibiotics required to prevent bacterial contamination of cell cultures. The 
KGM supplement was made up of 10 ng/ml epidermal growth factor (EGF), 0.5 µg/ml 
hydrocortisone, 5 µg/ml insulin (bovine pancreas), 1.8x10-4 M adenine and 1x10-10 M cholera 
toxin (Sigma, Poole, UK). Cells were incubated at 37°c in 5% (v/v) CO2. EGF is a growth factor 
that stimulates cell growth, differentiation and proliferation while hydrocortisone and insulin 
are steroid hormones. Adenine is an amino acid that forms adenosine which is a component of 
ATP. Cholera toxin increases intracellular cAMP levels in cells which promotes cell growth. 
 
Cells were passaged at 70% confluence. Cells were washed with phosphate buffered saline 
(PBS) (PAA Laboratories, Somerset, UK) once and after aspirating, 1x Trypsin-EDTA (PAA 
Laboratories, Somerset, UK) was added. Cells were incubated at 37°c until they detached from 
the culture flask and an equal amount of serum containing media e.g. KGM media to Trypsin-
EDTA was added to neutralise the enzyme reaction and prevent proteolysis.  
 
Cells were counted using a haemocytometer. A coverslip was placed on the haemocytometer 
and 20 µl of cell suspension placed at the edge of the coverslip. A count was taken for all four 
4x4 outer quadrants on the haemocytometer. An average number of cells of the four 
quadrants was taken and the total number of cells calculated. After centrifugation and 
aspiration of the supernatant, an appropriate amount of KGM media would be added to re-
suspend the pellet before seeding of the cells. 
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2.2 Retroviral particle formation 
 
All retroviral DNA constructs were transfected into amphotropic Phoenix packaging cells 
(developed in the Nolan lab, Stanford University, USA) to produce the retrovirus which was 
cultured in DMEM media (PAA Laboratories, Somerset, UK) supplemented with 10% (v/v) heat 
inactivated foetal bovine serum (FBS), 2 mM L-glutamine and 2% (v/v) penicillin streptomycin.  
 
1.5x106 Phoenix cells were seeded in a 6 cm dish 24 hours before transfection. Fugene6 (Roche 
Applied Science, East Sussex, UK) was added to 100 µl serum and antibiotic free DMEM media 
in polypropylene flow cytometry tubes and incubated for 5 minutes. 8 µg of DNA construct 
was added to the mixture at a ratio of 1:2.5 of construct to Fugene6. After adding a further 100 
µl of serum and antibiotic free DMEM media, the mixture was incubated at room temperature 
for 15 minutes. This was added to the Phoenix cells and incubated at 37°c, 5% (v/v) CO2. The 
media was changed the following day and 1 µg/ml Puromycin (Sigma, Poole, UK) added with 
fresh serum containing DMEM media.  
 
After selection with Puromycin, the cells were left to grow until 100% confluence at which 
point new DMEM media was added and the cells incubated at 32°c, 5% (v/v) CO2. After 24 
hours, the virus containing media was harvested and syringed through a 0.45 µm filter to 
remove virus producing cells (Thermo Fisher Nalgene, Loughborough, UK). The virus was then 
snap frozen in liquid nitrogen and stored at -80°c until required. 
 
2.3 Retroviral transduction  
 
Keratinocyte cell lines were retrovirally transduced with PTCH1 small hairpin RNA (shRNA) 
constructs 29A and 189A that target exons 3 and 24 respectively (a gift from Professor David 
Kelsell, Queen Mary University of London). A scramble control vector was used to generate a 
control cell line (a gift from Monika Cichon, Queen Mary University of London). All sequences 
were previously cloned into the pSUPERIOR.retro.puro vector (Oligoengine, Seattle, USA) 
which contains Puromycin resistance. 
 
Scramble control non-targeting sequence: GCGCGATATATAGAATACG 
29A target sequence exon 3:   AAGGTGCTAATGTCCTGACCA 
189A target sequence exon 24:   AAGGAAGGATGTAAAGTGGTA 
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A short loop sequence is incorporated between the sense and antisense target sequence then 
cloned into the pSUPERIOR.retro.puro vector downstream of the H1 promoter which ensures 
that the shRNA sequence is constitutively expressed. The hairpin structure is cleaved out of the 
vector as a small inhibitory RNA (siRNA) sequence and bound to an Argonaute protein which is 
part of the RNA-induced silencing complex (RISC). This complex will bind to the specific mRNA 
target sequence to degrade it thus silencing the target gene. 
 
Keratinocytes were seeded in a 6 well plate and at 70% confluence they were ready for 
retroviral transduction. The media was aspirated and cells washed with PBS. Serum and 
antibiotic free DMEM media was mixed with 5 µg/ml of Polybrene (Millipore, Watford, UK) and 
added to the keratinocytes for 10 minutes. Polybrene is a positively charged molecule that 
binds to the cell to neutralise its surface allowing for stronger virus binding due to reduced 
charge repulsion (Davis et al., 2002). The retrovirus was then added to the cells and 
centrifuged in their 6 well plates at 3,000xg for 1 hour. Cells were washed once with PBS 
before adding KGM media. The retrovirally transduced cells were then selected with 1 µg/ml 
Puromycin in the following days and cultured normally thereafter. 
 
2.4 Vector construction 
 
2.4.1 EGFP-SMO-WT/M2 
 
For the study an EGFP-SMO fusion protein was generated to be transfected into keratinocyte 
cells to help determine the localisation of SMO protein. Compared to SMO-WT (wild type), 
SMO-M2 contains a point mutation of Trp-535-Leu which is an activating mutation first 
identified in a BCC patient (Xie et al., 1998). The PRK-SMO (M2) vector used in the paper was 
utilised for generating an EGFP-SMO-WT/M2 vector.  
 
SMO-WT/M2 was excised from PRK-SMO (M2) using XhoI and EcoRI restriction enzymes 
simultaneously (New England Biolabs, Hertfordshire, UK). 1 µg of PRK-SMO-WT/M2 was 
incubated with 1 µl of both XhoI and EcoRI (20,000 units/ml), 2 µl of Buffer 4 with H2O to make 
a total reaction volume of 20 µl which was incubated overnight at 37°c. The following day, 
enzymes within the reaction mix were heat inactivated for 20 minutes at 65°c. 
 
A 0.6% (w/v) agarose gel (Fisher Scientific, Leicestershire, UK) was prepared in 1x TAE solution 
(Appendix Table 8.1) and repeatedly boiled until the agarose crystals were fully dissolved. At 
this point, the agarose solution was cooled for 1 minute with cold tap water before GelRed 
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was added at 1 µl/ml (Biotium, CA, USA). The solution was then poured into a gel castor with a 
comb and left to solidify. The reaction mix was then loaded onto the gel (placed in gel tank, 
submerged in 1x TAE) along with DNA Hyperladder I and II (Bioline, London, UK). The gel is run 
at 90 V until the products of the reaction mix were appropriately separated. 
 
2.4.2 Gel extraction of cloning products  
 
Digested cloning products were purified from the 0.6% (w/v) agarose gel in 1x TAE using 
QIAquick Gel Extraction kit (Qiagen, Crawley, UK). The restriction cut product bands that were 
visible under UV light, were cut from the gel and transferred to a 1.5 ml tube. The excised gel 
was weighed and for every 100 mg, 300 µl of QG buffer was added and incubated at 50°c to 
dissolve the gel. Chaotropic salts within the QG buffer disrupt the hydrogen bonds of the 
extracted DNA and also create a hydrophobic environment which makes the silica membrane 
of the QIAquick spin column more suitable for DNA binding. A volume of isopropanol (1 µl/mg 
of gel) is added to the 1.5 ml tube which precipitates the DNA allowing it to better bind to the 
silica. 
 
The samples were then transferred to a QIAquick spin column and centrifuged at 13,000 rpm 
for 1 minute which binds the DNA to the silica membrane of the column. The flow-through 
from the centrifugation process was discarded. The column was washed with 750 µl of Buffer 
PE and centrifuged again. The flow-through was again discarded and the column was dried by 
empty centrifuging for a further minute. The DNA was eluted from the column into a sterile 1.5 
ml tube by loading 50 µl of Buffer EB into the column which was left to stand for 1 minute 
before centrifuging at 13,000 rpm for 1 minute. The DNA was then measured on the NanoDrop 
spectrophotometer and the DNA stored at -20°c.  
 
2.4.3 SMO-WT/M2 ligation with EGFP-C2 
 
Using the same methodology to excise SMO-WT/M2 from PRK-SMO-WT/M2, a small fragment 
from the multiple cloning site (MCS) of pEGFP-C2 (Clontech Laboratories, CA, USA) was 
removed using XhoI and EcoRI enzymes leaving sticky ends available for ligating SMO-WT/M2 
(Figure 2.1). The pEGFP-C2 vector was selected so that SMO-WT/M2 would be inserted in-
frame to ensure that SMO-WT/M2 was correctly expressed upon transfection into cells. Having 
isolated SMO-WT/M2 from the PRK-SMO-WT/M2 vector as well as pEGFP-C2, both were 
ligated together at a ratio calculated using the following equation: 
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The ligation mix was made up of approximately a 3:1 ratio of SMO-WT/M2:pEGFP-C2, 1 µl of 
T4 DNA Ligase enzyme and 2 µl of 10x T4 DNA Ligase Buffer (New England Biolabs, 
Hertfordshire, UK). H2O was added to make a total of 20 µl and the mix incubated at room 
temperature overnight. 
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Figure 2.1: Strategy for cloning SMO-WT/M2 into EGFP-C2 
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2.4.4 Bacterial transformation 
 
After ligation of SMO-WT/M2 into pEGFP-C2, the reaction mix was transformed using One Shot 
TOP10 competent Escherichia coli bacteria (Invitrogen, Paisley, UK). The purpose of this 
procedure is to amplify the DNA plasmid in large quantities. The competent bacteria originally 
stored at -80°c, were thawed on ice prior to transformation. Up to 100 ng of ligation mix was 
added to the bacteria and mixed by gently tapping which was then left on ice for 30 minutes. 
The bacteria mix was then heat shocked at 42°c for 30 seconds and placed back on ice 
immediately for 2 minutes. The heat shock process makes the bacterial lipid membrane 
permeable so that DNA can enter the bacteria. 250 µl of SOC media (Invitrogen, Paisley, UK) is 
added to the bacteria which is nutrient rich and encourages bacterial growth with better 
transformation. The bacteria mix was incubated at 37°c for 1 hour on a fast shaker. 
 
100 µl of the bacteria mix was then streaked out on a Kanamycin resistant Luria-Bertani (LB) 
(Sigma, Poole, UK) agar plate as pEGFP-C2 is resistant to this antibiotic. The bacterial plate was 
inverted and incubated at 37°c overnight. As a negative control competent bacteria that were 
not transformed with any DNA were also plated out with the hope that no colonies appear as 
the bacteria would have not gained resistance to Kanamycin.  
 
2.4.5 Miniprep of EGFP-SMO-WT/M2 plasmid 
 
Successfully transformed bacteria were identifiable as bacterial colonies on the agar plates as 
pEGFP-C2 contains a Kanamycin resistance gene. However, this does not necessarily mean that 
the bacteria contains EGFP-SMO-WT/M2 DNA therefore, a number of colonies were selected 
for analysis. A small amount of the selected colony was isolated and transferred to 5 ml of pre-
autoclaved LB broth (Sigma, Poole, UK) containing 50 µg/ml of Kanamycin (Sigma, Poole, UK) 
and left on a fast shaker at 37°c overnight. 
 
The DNA plasmids were purified from the bacterial LB broth using the QIAprep Miniprep kit 
(Qiagen, Crawly, UK). The bacterial LB broth was centrifuged at 4000 rpm for 10 minutes whilst 
at 4°c. The resultant pellet was re-suspended in 250 µl of Buffer P1 which contains RNase A 
that digests unwanted RNA. 250 µl of Buffer P2 was then added and mixed by inverting five 
times. Buffer P2 contains SDS to lyse the cells and NaOH to create an alkaline condition that 
denatures genomic DNA. 350 µl of Buffer N3 was added immediately and again the solution 
inverted five times before being centrifuged at 4000 rpm for 10 minutes. After this, the 
supernatant was transferred to a QIAprep spin column and centrifuged for 1 minute. Buffer N3 
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is a neutralisation buffer which will cause all protein, debris and genomic DNA to precipitate as 
a salt. Buffer N3 also helps bind DNA to the silica particles within the QIAprep spin column. 
 
The flow through was discarded from the QIAprep spin column as now the DNA was bound to 
the column filter. The spin column was centrifuged again for 30 seconds to remove any 
residual buffer. The top of the spin column was transferred to a clean 1.5 ml tube and the DNA 
eluted by adding 50 µl of Buffer EB onto the silica within the tube. The column was left to 
stand for 1 minute before being centrifuged for a minute. The plasmid was quantified on the 
NanoDrop spectrophotometer (NanoDrop Technologies, DE, USA) and stored at -20°c. Cloning 
products were validated by PCR and protein analysis. 
  
2.4.6 Maxiprep of EGFP-SMO-WT/M2 plasmid 
 
A small amount of the selected colony was isolated and transferred to 20 ml of pre-autoclaved 
LB broth containing 50 µg/ml of Kanamycin and incubated at 37°c for 8 hours whilst shaking. 
The 20 ml of bacterial LB media was then added to 200 ml of LB media containing 50 µg/ml of 
Kanamycin and left on a fast shaker at 37°c overnight. 
 
The DNA plasmids were purified from the bacterial LB broth using the Qiagen Plasmid 
Purification Maxi kit (Qiagen, Crawly, UK). The bacterial LB broth was centrifuged (in 50 ml 
falcon tubes) at 4000 rpm for 10 minutes whilst at 4°c. The resultant pellet was re-suspended 
in 10 ml of Buffer P1. 10 ml of Buffer P2 was then added and incubated for 5 minutes at room 
temperature. 10 ml of Buffer P3 was added and the mix was left to incubate for 20 minutes at 
room temperature. This is a neutralisation buffer similar to Buffer N3 that precipitates 
unwanted debris into a salt. The mix was then centrifuged at 4000 rpm for 10 minutes at 4°c to 
remove the waste materials as the supernatant was collected and centrifuged again for 
increased purity. 
 
The plasmid containing supernatant was then transferred to a pre-equilibrated Qia-Tip 
column. The DNA was retained in the column filter while the flow-through was removed in a 
conical flask. 30 ml of wash Buffer QC was added to the filter, twice. The Qia-Tip was then 
placed in a 50 ml falcon tube and the DNA was eluted using 15ml of Buffer QF which was 
subsequently precipitated with 10.5 ml of Isopropanol. The DNA was then centrifuged at 4000 
rpm for 15 minutes at 4°c and the pellet washed with 5 ml of 70% ethanol before a second 
centrifugation. The pellet was then air dried before being re-suspended in 200 µl of Buffer EB. 
The plasmid was quantified on the NanoDrop and stored at -20°c. 
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2.5 RNA extraction 
 
RNA was extracted from cells at 70% confluence or three days post seeding. The extraction 
was performed using an RNeasy Mini Kit (Qiagen, West Sussex, UK). After aspirating the PBS 
from the cells, 350     f RL   uff    β-Mercaptoethanol added beforehand (10 µl for 1 ml of 
RLT buffer); Sigma, Poole, UK) was added which lyses the cells and also contains Guanidine 
Isothiocyanate, both of which deactivate RNase enzymes. The cell lysate was transferred and 
passed through a QIAshredder Mini Spin column by centrifugation at 13,000 rpm for 2 minutes 
which removes cell debris. The flow through solution was retained and transferred to the 
gDNA eliminator column and centrifuged for 1 minute which retains any genomic DNA in the 
filter. The flow through was then mixed with 600 µl of 70% ethanol and left to stand for 1 
minute allowing the RNA to bind to the silica membrane when transferred into an RNeasy Mini 
Spin column. The RNA within the sample was collected by the column after centrifugation.  
 
350 µl of RW1 wash buffer was added and the column was centrifuged in order to remove any 
remaining genomic DNA. The column was then washed with 700 µl RPE buffer and washed 
again with 500 µl RPE buffer. This removes any salts remaining from previous washes. The 
column was then transferred to a fresh 1.5 ml tube and RNA eluted by adding 25 µl of RNase 
free water and centrifuging. A second elution step with a further 25 µl was performed before 
quantifying the RNA. The RNA concentration was measured using the NanoDrop. A 
measurement of the absorbance values at 260 nm was recorded as this is the wavelength at 
which RNA absorbs light. RNA was stored at -80°c. 
 
2.6 Complementary DNA (cDNA) synthesis 
 
cDNA was synthesised from RNA obtained directly from the cells using the Superscript VILO 
cDNA synthesis kit (Invitrogen, Paisley, UK). Up to 2.5 µg of RNA was used per reaction. 4 µl of 
5x VILO mix was added which contains random primers, MgCl2 and deoxynucleotide 
triphosphates (dNTPs) all of which are optimised for PCR reactions. 2 µl of 10x Superscript mix 
is added and this consists of the reverse transcriptase enzyme to synthesise the cDNA and a 
recombinant ribonuclease inhibitor to prevent RNA degradation. The reaction mix is made up 
to a total of 20 µl with RNase free water and placed in a PCR thermocycler. The PCR machine 
was set for three holding steps the first being for 10 minutes at 25°c followed by 1 hour at 42°c 
and a final step for 5 minutes at 85°c. cDNA was quantified using the NanoDrop and then 
stored at-20°c. 
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2.7 Polymerase chain reaction (PCR) 
 
PCR is a method used to amplify specific DNA sequences that are selected by specific primers. 
PCR can be used to detect messenger RNA (mRNA) by amplifying a section of its cDNA. To do 
this, oligonucleotide primer sequences (Sigma, Poole, UK) were designed around the region of 
interest.  
 
Primer sequences were designed using the internet-based Primer3 program and were checked 
with the mRNA sequence of interest (Rozen and Skaletsky, 1998). In the case that multiple 
isoforms exist for the same gene, all isoforms were aligned together using the ClustalW 
alignment tool and primers were designed to overlap a region common to all the isoform 
sequences (Larkin et al., 2007). To check the specificity of the primers, both forward and 
reverse primer sequences were inputted into the NCBI Nucleotide BLAST search tool which 
searches the primer sequence against other genes (Altschul et al., 1990). This prevents the 
amplification of other genes that may have a similar sequence which would give a false 
positive result. 
 
The ReddyMix PCR Mastermix kit (Fisher Scientific, Leicestershire, UK) was used for each PCR 
reaction. For each reaction, 200 ng of cDNA was added to 0.2 ml flat cap PCR tube (Qiagen, 
Crawly, UK). 12.5 µl of ReddyMix was added followed by 1 µl 25 mM MgCl2, 2 µl of 1 µM 
primer (forward and reverse) and H2O up to a final volume of 20 µl. For genes that have lower 
expression, the cDNA and/or primer concentration was increased. For a negative control, a 
reaction mix was made with cDNA substituted with an equal volume of H2O. The PCR samples 
were then loaded onto the Tetrad PTC-225 Thermo Cycler (MJ Research, MA, USA) and the 
following program used: 
 
Initialisation:  95°c  15 minutes 
Denaturation:  95°c  20 seconds 
Annealing:  x°c  20 seconds Cycling 
Extension:  72°c  25 seconds 
Repeat cycling steps 35 times 
Final extension:  72°c  10 minutes 
 
(x) denotes the optimised primer annealing temperature ranging from 57°c to 64°c, primer 
sequences and annealing temperatures are listed in the Appendix (Table 8.2). The initialisation 
step is required to heat activate the DNA polymerase enzymes contained in the ReddyMix. 
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Denaturation causes melting of the double stranded DNA so that annealing of the primer 
sequences to the single stranded DNA can occur as new hydrogen bonds are formed. As the 
DNA polymerase enzyme binds to the template, cDNA is synthesised using dNTPs within the 
ReddyMix. Multiple cycles are required to ensure that the full length of DNA is synthesised and 
to amplify as much of the DNA as possible. A final extension stage then ensures that any 
remaining single stranded DNA is synthesised. The reaction products were then loaded onto 
the gel (placed in gel tank, submerged in 1x TAE) along with DNA Hyperladder II. The gel was 
run at 90 V until the size of PCR product was determinable compared to the DNA ladder. 
 
2.8 Quantitative polymerase chain reaction (qPCR) 
 
This qPCR method was used to determine the comparative expression of mRNA levels between 
the cell types. The kit used for qPCR was Rotor-Gene SYBR green PCR kit (Qiagen, West Sussex, 
UK). SYBR Green is a dye that binds to double stranded DNA therefore, as the PCR product is 
amplified it can be detected and quantified by its fluorescence signal.  
 
200 ng of cDNA was used per reaction with each sample analysed in triplicate. For each 
reaction, 12.5 µl of SYBR mix was added, 1 µl of 25 mM MgCl2, 2 µl of 1 µM primer template 
and RNase free water up to a total of 20 µl. cDNA was omitted from negative control samples. 
The qPCR reactions were loaded into the Rotor-Gene Q (Qiagen, West Sussex, UK) and the 
following program was used: 
 
Initialisation:  95°c  5 minutes 
Denaturation:  95°c  5 seconds 
Annealing:  x°c  5 seconds Cycling 
Extension:  60°c  10 seconds 
Repeat cycling steps 45 times followed by a melt stage. 
 
A post-qPCR melting stage was performed to determine if a single PCR product was being 
amplified in which case, a single peak would be visible and also to make sure that there were 
no false positives caused by primer dimer formation. During the melt stage, the Rotor-Gene Q 
machine has an option to determine the optimal fluorescence gain level and this was always 
selected. 
 
The relative mRNA expression values were calculated using the x=2-ΔΔ   formula where x 
represents the induction value and Ct represents the average threshold cycle of the triplicate 
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  m    . Δ     f        h  d ff    c     w     h     values of the gene of interest and the 
h u            f    c        A DH. ΔΔ               h  d ff    c     w     h  Δ   v  u  
of the cDNA sample compared to the control sample e.g. NEB1- h   H1 Δ   v  u      m     d 
and compared to NEB1- h  N Δ   v  u  .  
 
2.9 Small inhibitory RNA (siRNA) and plasmid DNA reverse transfection 
 
siRNA sequences were pre-designed and transiently transfected into cells to silence SMO. The 
siRNA sequence binds to the Argonaute protein which then degrades the specific mRNA. 
Reverse transfection is a more efficient method of transfection than normal transfection. A 
variety of different transfection reagents were tested on the keratinocyte cell lines using siGLO 
Cyclophilin B (Fisher Scientific, Leicestershire, UK) as a positive control. Cyclophilin B binds to 
the cell nucleus which fluoresces red that can be observed under a microscope and it can also 
be used to ensure knockdown efficiency by qPCR. 
 
Using various different transfection reagents, a siRNA concentration of 50 nM for 2 days was 
found to be most effective combined with Hiperfect (Qiagen, West Sussex, UK) transfection 
reagent. Hiperfect contains lipids that bind with the siRNA and allow its entry into the cell 
through the lipid bilayer. For DNA plasmid transfections, TransIT 2020 (Mirus Bio, WI, USA) was 
the most effective reagent which was optimised with EGFP-C2 at 1 µg. 
 
Hiperfect or TransIT 2020 was added to serum and antibiotic free DMEM media in 
polypropylene flow cytometry tubes and left to incubate for 5 minutes. 50 nM of siRNA was 
added to the mixture at a ratio of 1:3 of siRNA or DNA to the transfection reagent and 
incubated at room temperature for 15 minutes. Serum and antibiotic free media was 
supplemented to the mixture, added to the culture dish or plates and incubated at 37°c, 5% 
(v/v) CO2 for 30 minutes. During this time, NEB1 cells were trypsinised and counted. Cells were 
re-suspended in KGM media before being added to the siRNA or DNA treated culture dish or 
plates and incubated for 24 hours. The media was changed to KGM media after this period and 
harvested or fixed the next day. 
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2.10 Protein extraction and western blotting 
 
Cells were grown to 70% confluence before being harvested. Cells were washed once with PBS 
before 220 µl of pre-heated protein lysis buffer (Appendix Table 8.1) was added ensuring that 
the entire culture surface was covered. Cells were scraped off the surface then transferred to a 
1.5 ml tube before being heated at 95°c for 2 minutes. The lysate was then passed through a 
syringe and needle to reduce viscosity. 20 µl of the lysate was put into a 1.5 ml tube for 
quantification using the Bio-Rad DC Protein Assay kit (Bio-Rad, MA, USA). 2 µl of Solution S and 
98 µl of Solution A were added to the 1.5 ml tube and mixed. 800 µl of Solution B was added to 
each tube and mixed at which point, the mix would change colour. The protein binds to the 
alkaline copper tartrate solution (Solution A and S) and as the Folin containing Solution B is 
added, the protein bound to copper reduces Folin. This reduction reaction generates a blue 
colour solution with a minimum and maximum absorbance of 405 nm and 750 nm 
respectively. A high protein concentration creates stronger blue colour intensity. The reagents 
were added and samples transferred to cuvettes. Using a spectrophotometer, the protein 
absorbance (AU) was measured at a wavelength of 655 nm. A standard curve was generated 
using the AU measurements obtained from known concentrations of bovine serum albumen 
(BSA, Sigma, Poole, UK) from which the following equation was formed: 
 
 
      .    1
 . 1 
     .         c          f                 
 
After quantifying the protein, 50 µl of 5x protein loading dye (Fisher Scientific, Leicestershire, 
UK) was added to the remaining 200 µl of sample and stored at -20°c. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyse 
the protein expression levels of the cells. A resolving gel was made consisting of distilled water, 
30% (v/v) acrylamide gel, 1.5 M Tris (pH 8.8), 10% (w/v) SDS, 10% (w/v) ammonium 
persulphate (APS) and tetramethylethylenediamine (TEMED). The acrylamide gel forms cross 
links which creates pores by which the protein can be separated. The SDS negatively charges 
the protein so an electric current can be applied to separate the proteins. APS and TEMED are 
polymerisation agents that solidify the gel. A stacking gel was set on top of the resolving gel 
consisting of the same ingredients with 1 M Tris (pH 6.8) rather than 1.5 M Tris and with a 
higher concentration of acrylamide gel. A comb was set in the stacking gel so that protein 
samples could be loaded onto the gel. 
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Protein lysates were heated for 2 minutes at 95°c before 20 µg of protein was loaded into the 
gel. 10 µl of ColorPlus Prestained Protein Ladder (New England Biolabs, Hertfordshire, UK) was 
run alongside the samples. Gels were run in 1x running buffer (Appendix Table 8.1) for 
approximately 2 hours at 120 V. The electrical current creates a boundary that carries the 
protein through the stacking gel and into the resolving gel. The protein is condensed in a thin 
line before moving through the gel where the protein is separated by its molecular weight.   
 
Once the samples had run, the protein from the gel was transferred onto nitrocellulose paper 
(GE Healthcare, Buckinghamshire, UK) by electroblotting. SDS coats the sample protein to give 
it a negative charge and also breaks the tertiary structure but leaves the secondary structure 
intact. Gels were transferred using a Hoeffer transfer tank in pre-cooled 1x transfer buffer 
(Appendix Table 8.1) for 2 hours at 350 mA. The transfer cassette is orientated so that the 
protein moves towards the membrane at the positive anode. Methanol within the transfer 
buffer helps the transfer of smaller proteins to the membrane. Once transfer was complete, 
the membrane was washed in TBST or PBST buffer (Appendix Table 8.1) depending on the 
primary antibody to be probed with, before 1 hour of blocking at room temperature in 5% 
(w/v) milk powder dissolved in T/PBST. 
 
Membranes were then incubated for 16 hours at 4°c in the specific primary antibody diluted to 
1:1000 in T/PBST. The membranes were then washed three times in T/PBST for 5 minutes 
before 1½ hour incubation with a horseradish peroxidise (HRP) conjugated secondary antibody 
diluted to 1:1000 in T/PBST, at room temperature. Membranes were given three washes in 
T/PBST for 5 minutes. An ECL western blot detection system kit (GE Healthcare, 
Buckinghamshire, UK) was used on the blot which binds to the HRP to produce a 
chemiluminescent signal that was recorded onto ECL Hyperfilm (GE Healthcare, 
Buckinghamshire, UK) when exposed to the membrane in a darkroom. The exposure time of 
the film to the membrane varied depending on the level of protein present and the primary 
antibody used.              m m       w         d f   α-Tubulin as a protein loading 
control. 
 
Membranes were stripped of the primary antibodies (Appendix Table 8.3) in order to re-probe 
the same membrane for other proteins. A stripping buffer (Appendix Table 8.1) was added to 
the membrane and incubated at 55°c for 30 minutes. Membranes were then washed three 
times before being blocked again in 5% (w/v) milk and re-probed or stored in T/PBST at 4°c. 
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2.11 Immunocytochemistry 
 
Immunocytochemistry staining was used to determine the sub-cellular localisation of proteins. 
Cells were initially seeded in 12 well plates on top of 18 mm diameter glass cover slips (VWR 
International Ltd, Leicestershire, UK) at a density of 15,000 cells per well and allowed to grow 
for three days. The cells were washed twice with PBS before being fixed with 4% (w/v) 
paraformaldehyde for 15 minutes. Cells were then washed with PBS three times and 
permeablised in 0.1% (w/v) Triton X-100 (Sigma, Poole, UK) for 10 minutes. The cells were 
blocked in 3% (w/v) BSA (Fisher Scientific, Leicestershire, UK) for 30 minutes followed by the 
addition of the primary antibody (Appendix Table 8.3) diluted 1:1000 in 3% (w/v) BSA for 1 
hour.  
 
Following three PBS washes for 5 minutes each, a fluorescence dye labelled secondary 
antibody diluted to 1:800 in PBS was added and incubated for 1 hour while being protected by 
light. Alexa 488 and Alexa 568 secondary antibodies (Invitrogen, Paisley, UK) have green and 
red fluorescence spectra respectively. After three PBS washes, the nuclei of the cells were 
stained with 0.1 µg/ml of DAPI for 5 minutes before a final wash in PBS.  
 
Coverslips were mounted onto microscope slides using Vectashield fluorescence mounting 
medium (Vector Laboratories Ltd, Peterborough, UK) and stored at 4°c away from light. The 
slides were viewed and images taken on the Zeiss LSM 510 Meta Confocal Microscope. For the 
negative control, cells were stained with DAPI and the secondary antibodies, without any 
primary antibodies. All secondary antibodies were negative (Figure 2.2). 
 
Images taken by the confocal microscope were quantified using Image J software (Collins, 
2007). Images were edited to only show the fluorescence channel of the protein of interest 
and then converted to greyscale. Cells were selected and analysed based on the intensity of 
pixels taking into account the size of the cell. The relative density was then calculated which 
indicates the intensity of staining.  
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Figure 2.2: Negative controls for secondary immunofluorescence antibodies 
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2.12 Alamar blue viability/proliferation assay 
 
The Alamar blue assay (AbD Serotec, Kidlington, UK) was used to measure keratinocyte cell 
proliferation. The Alamar blue solution contains Resazurin that will produce the fluorescent 
red dye Resorufin under redox reaction conditions. The intensity level of the red fluorescence 
indicates the proliferation of the cells. Cells were seeded in a 6 well plate and left to settle for 
24 hours. The following day, 10% (v/v) of Alamar blue was added to the culture media. The old 
media was removed and the Alamar blue in media was added to the cells that were then 
incubated at 37°c for 6 hours. 100 µl of media was added to a white 96 well plate, each sample 
in triplicate. The control used was the Alamar blue with media. The fluorescence intensity was 
measured with the excitation wavelength set at 530-560 nm and an emission of 590 nm using 
a Wallac plate reader (Perkin Elmer, MA, USA). 
 
2.13 Gene expression microarray 
 
Gene expression microarray profiling was performed on NEB1-shCON and NEB1-shPTCH1 cells 
lines using Human Gene 1.1 ST Array Strip from Affymetrix (Affymetrix, CA, USA). The array 
chip contains 28,000 genes probed with multiple oligonucleotide sequences and in total, 
750,000 probes to determine the gene expression profile of each sample. Each sample was 
repeated in triplicate and the data normalised using the MetaCore pathway analysis software 
(GeneGo, CA, USA) performed by Dr Joanne Selway and Avijit Guha Roy from The University of 
Buckingham.  
 
Three Affymetrix chips were used for each sample and the raw data was processed using the 
multi array average (RMA) method. RMA utilises quantile normalisation that will fit all the 
chips used from the experiment into the same distribution and also gives them the same mean 
(Irizarry et al., 2003). This allows for normalisation and background correction of the data 
which will provide an expression value for each gene. From this, differentially expressed genes 
(DEGs) can be separated based on P-values and fold change.  
 
Probabilities of gene expression between the experimental and control group are generated 
u        c    ’s Signed Rank test where P-values are used to compare between different 
   u    f      .  u   y’  B w   h  m  h d     h   u  d                      which are then 
anti-logged to generate fold change values comparing the genes between samples (Gentleman 
et al., 2005). Genes with a P-value at or below 5% and a fold change greater than +/- 2 fold are 
considered as DEGs. 
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DEGs were analysed in MetaCore using its GeneGo database of cellular pathways and process 
networks. P-values represent the probability for a set of genes to appear on a network or 
process map to arise by chance. The smaller the P-value is, the less likely that the result has 
occurred by chance. The P-value also considers the number of genes from the experimental 
data versus the number of genes in the network map. The formula for calculating the P-value 
is: 
 
        
                
  
 
 
                        
         
              
 
 
N = total number of nodes in MetaCore database 
R    um     f  h     w   ’    j c   c        d        h           m c      y data list 
n = total number of nodes in each small network generated from the microarray data  
r = number of nodes with data in each small network generated from the microarray data  
 
Once the microarray DEGs were applied to the network and process maps, a Z-score was 
calculated for each sub-network. The Z-score ranks the sub-networks based on the number of 
DEG saturation on each map. A high Z-score shows that the network is highly saturated with 
DEGs from the microarray data. The formula for calculating the Z-score is: 
 
        
   
 
 
   
 
      
 
     
   
    
 
 
N = total number of nodes in MetaCore database 
R    um     f  h     w   ’    j c   c        d        h           m c      y d         
n = total number of nodes in each small network generated from the microarray data  
r = number of nodes with data in each small network generated from the microarray data 
 
2.14 DAVID functional annotation tool 
 
The database for annotation, visualisation and integrated discovery (DAVID) is a set of online 
bioinformatics tools that provides the means to highlight biological processes and functions 
from a given gene list (Huang et al., 2009). There are a number of annotation categories 
including protein-protein interactions, protein functional domains, disease associations, gene 
functional summaries and signalling pathways. 
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The functional annotation clustering tool was used in order to map the DEGs from the 
microarray analysis onto signalling pathway and process maps. This was to determine which 
pathways are affected by the suppression of PTCH1 and also which components of the 
pathways were differentially regulated. Also, the number of components that are highlighted 
on a map would help determine the extent by which certain pathways were affected. DAVID is 
able to map user defined gene lists onto well known KEGG (Kyoto encyclopaedia of genes and 
genomes) pathways to help interpret the data in a network context. 
 
2.15 Matrigel based organotypic culture 
 
The Matrigel organotypic culture provides a base for an artificial skin model. A dermis layer is 
created using Matrigel, collagen and fibroblasts. Keratinocytes are then seeded on top of the 
‘d  m  ’   y     d cu  u  d w  h          qu d      f c  wh     h  f       sts grow in culture 
media but not the keratinocytes. This to an extent mimics the skin in vitro. 
 
One day prior to the experiment, Matrigel (BD Pharmingen, NJ, USA) was taken from -20°c 
storage and allowed to defrost overnight at 4°c while on ice. On the day of the experiment, a 
mix was made up of 350 µl of Matrigel, 350 µl of Rat tail Collagen type 1 (Millipore, Watford, 
UK), 100 µl KGM media, 100 µl of FBS per gel. At this point, the mix is acidic therefore 1 M 
NaOH was added drop by drop until the solution changes from yellow to pink. 500,000 primary 
dermal fibroblasts re-suspended in 100 µl were added to the mix and all components were 
gently mixed in a 50 ml falcon tube avoiding any bubble formation. 1 ml of the mix was 
dispensed into the well of a 24 well plate and left in the incubator at 37°c, 5% (v/v) CO2 for 2 
hours. Once the gel had set, 1 ml of KGM media was added to the top of the gel and incubated 
overnight. 
 
The 1 ml of media was then removed from the gel and a 4.7 I.D x 8 mm cloning ring (Fisher 
Scientific, Leicestershire, UK) was pressed onto the gel within the well. This dislodges the gel 
from the walls of the well plate and provides an enclosed space to add 500,000 NEB1 cells re-
suspended in 500 µl of KGM media. This ensures that the NEB1 cells settle and grow on the 
surface of the gel. The gel was incubated overnight at 37°c, 5% (v/v) CO2.  
 
Stainless steel wire gauze that was sculpted to provide a raised platform was placed within a 6 
well plate. A single Cyclopore 0.4 µm polycarbonate membrane with a 13 mm diameter 
(Whatman, Kent, UK) was placed on top of the gauze. The ring was removed from the gel and 
placed directly on the membrane. 4.5 ml of KGM media was added to the well ensuring that 
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there were no bubbles underneath the gauze and that the media did not drown the gel. This 
allows the dermis part of the gel to receive media from the bottom while the NEB1 cells on the 
top do not. The organotypic model was incubated for 28 days or more with weekly media 
changes. At the end of the experiment, gels were either snap frozen of embedded in wax for 
histological sectioning. 
 
2.16 Statistical analyses 
 
All experiments were performed in triplicate. The standard deviation was calculated for 
experiments such as qPCR and Alamar blue proliferation assays. Standard deviation is a 
measure of the spread of data from the mean value. The following equation was used to 
measure the standard deviation: 
 
                     
       
     
 
x = score 
  = mean 
n = number of values 
Σ    um of values 
 
The   ud   ’   -test was used to determine if control and experimental sample data 
significantly differ from each other for example, if the increase or decrease of protein 
expression from ImageJ analysis was significant or not.  h    ud   ’   -test was calculated 
with the following equation: 
 
   
       
   
 
  
  
  
 
  
  
    = mean of the first data set 
    = mean of the second data set 
  
  = standard deviation of the first data set 
  
  = standard deviation of the second data set 
   = number of elements in the first data set 
   = number of elements in the second data set 
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Chapter 3  Introduction 
 
BCC genetics and the involvement of HH signalling have primarily been studied in PTCH+/-mice 
that are then UV irradiated to initiate tumourigenesis and the formation of BCC-like tumours 
(Donovan, 2009; Daya-Grosjean and Couve´-Privat, 2005; Mancuso et al., 2004). Similarly, 
manipulation of HH components such as GLI1 and GLI2 have demonstrated that tumours can 
develop while there are inconsistencies where one study has shown that the over-expression 
of SMO-M2 in the IFE leads to BCC formation while others show no tumour growth (Youssef et 
al., 2010; Grachtchouk et al., 2003). The HH pathway is known to interact with a number of 
major signalling pathways and UV irradiation may have non-specific effects. Mouse models do 
suggest that HH may play a role in BCC biology however it is unclear why different types of 
tumours develop when manipulating HH components.  
 
Regarding the HH signalling pathway, BCC is associated with the loss of function of PTCH1 
which leads to the downstream expression of GLI1 and GLI2 via SMO signalling. A study of NIH-
3T3 cells where mutant SMO is over-expressed revealed that HH signalling could not be 
repressed by Cyclopamine (Taipale et al., 2000). It is not known why a large number of BCC 
patients do not respond to SMO inhibitors and this brings into question how important HH 
signalling is in BCC biology (Van Hoff et al., 2009; Göppner et al., 2010). Furthermore, studies 
by Dr Neill’s group have shown that GLI1 is not highly expressed in a number of BCCs by 
immunohistochemistry (unpublished data). To understand more an in vitro model of BCC was 
developed by the suppression of PTCH1 using shRNA and the HH signalling pathway 
characterised. 
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3.1 Creation and characterisation of human keratinocyte cell lines with stable PTCH1 
suppression 
 
3.1.1 PTCH1 suppression in NEB1, N/Tert and HaCaT cell lines 
 
The human immortalised cell lines NEB1, N/Tert and HaCaT were chosen for this study as they 
are widely used in skin research and retain the ability to differentiate (Morley et al., 2003; 
Dickson et al., 2000; Boukamp et al., 1988). In addition, the levels of PTCH1 and the 
downstream HH signalling component GLI1 were analysed by qPCR to confirm that these cells 
were suitable for targeted PTCH1 suppression (Figure 3.1). PTCH1 was readily detected in all 
cells and compared to NEB1 cells, both N/Tert and HaCaT parental cell lines displayed higher 
levels of PTCH1 mRNA and lower levels of GLI1 mRNA.  
 
Parental NEB1, N/Tert and HaCaT cell lines were retrovirally transduced with a construct 
containing a non-targeting scrambled control (shCON) as well as two constructs targeting 
exons 3 (termed 29A) and 24 (termed 189A) of the PTCH1 gene respectively (Figure 3.2). After 
drug selection with Puromycin, clonal cell lines were derived by single cell seeding from the 
heterogeneous populations of NEB1-29A, NEB1-189A, N/Tert-29A and N/Tert-189A cells. 
HaCaT-29A and HaCaT-189A clonal lines were not generated due to time constraints.  
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Figure 3.1: qPCR analysis for PTCH1 and GLI1 fold induction in N/Tert and HaCaT, relative to NEB1 cells 
Error bars represent mean ± standard deviation. 
 
 
 
 
 
 
 
 
 
Figure 3.2: PTCH1 shRNA exon targets 
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A number of clonal cell lines were derived from 29A and 189A heterogeneous populations 
based on their compact, BCC-like morphology and the level of PTCH1 suppression was 
assessed by qPCR (Figure 3.3). Of the three keratinocytes cell lines, NEB1-189A-β1 cells 
showed the strongest suppression of PTCH1 which correlated with an increase of GLI1 and 
therefore, most of the studies were conducted on this particular clonal cell line. NEB1-189A-β1 
will now be referred to as NEB1-shPTCH1. Of the N/Tert clones, N/Tert-29A-β1 showed the 
lowest levels of PTCH1 and highest GLI1 induction. For consistency with NEB1-shPTCH1 (NEB1-
189A-β1) cells, N/tert-189A-β2 showed the strongest induction of GLI1 of the N/Tert-189A 
clones and will be referred to as N/Tert-shPTCH1 cells. The majority of the studies performed 
utilised 189A shPTCH1 clones but where 29A shPTCH1 clones were employed these will be 
clearly labelled. Interestingly, despite the suppression of PTCH1 there was no induction of GLI1 
in certain clones such as NEB1-29A-β2, NEB1-29A-β3 and N/tert-29A-β2. 
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Figure 3.3: qPCR for PTCH1 and GLI1 in shPTCH1 clonal cell lines 
PTCH1 and GLI1 mRNA expression levels in [A] NEB1-shPTCH1, [B] N/Tert-shPTCH1 clonal lines and 
heterogeneous populations of [C] HaCaT-shPTCH1 cells. Error bars represent mean ± standard deviation. 
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Morphologically, NEB1-shPTCH1 cells displayed a more compact cobblestone-like colony 
formation compared to NEB1-shCON cells and parental NEB1 cells. A similar more compact 
morphology was observed in N/Tert-shPTCH1 cells but as HaCaT cells are inherently compact, 
there was no visible difference between the control cell line and HaCaT-shPTCH1 cells (Figure 
3.4).  
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Figure 3.4: PTCH1 suppression induces a highly compact morphology in human keratinocytes 
Upon the suppression of PTCH1 in [A] NEB1, [B] N/Tert and [C] HaCaT cells, NEB1 and N/Tert cells 
display a compact cobblestone-like morphology. No such differences were observed in HaCaT cells as 
HaCaT-shCON cells grow as tight colonies.  
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To confirm that the increase of GLI1 is specifically due to reduced PTCH1 activity in NEB1-
shPTCH1 cells, a rescue experiment was performed by ectopically expressing the PTCH1B 
isoform and analysing GLI1 expression. As the PTCH1B vector only contains the coding 
sequence (i.e. START to STOP codons) its mRNA is not subject to degradation by the PTCH1 
shRNA as the hairpin targets a region that is downstream of the STOP codon in exon 24. 
Ectopic PTCH1B suppressed GLI1 to basal levels thus confirming that the increase of the latter 
is due to reduced PTCH1 function in NEB1-shPTCH1 cells (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: PTCH1B rescue experiment 
[A] The PTCH1B construct does not contain PTCH1 exon 24 which is targeted by the 189A shRNA vector. 
[B] qPCR for GLI1 in NEB1-shPTCH1 cells transfected with 1 µg PTCH1B, control cells were transfected 
with 1 µg PCI empty vector and 0.5 µg CFP as a normalisation control. Error bars represent mean ± 
standard deviation. 
 
 
 
 
0 
1 
2 
3 
4 
5 
6 
shCON + PCI shPTCH1 + PCI shPTCH1 + PTCH1B 
Fo
ld
 In
d
u
ct
io
n
 
PTCH1 GLI1 B 
A 
Exon 23 Exon 1 Exon 2 Exon 3 Exon 4 Exon 24 Exon 25 
Stop codon 
 
NEB1-shPTCH1 
shPTCH1 189A 
Exon 23 Exon 1 Exon 2 Exon 3 Exon 4 
PTCH1B 
  Chapter 3 
104 
 
Having established that GLI1 expression is increased in NEB1-shPTCH1 cells and that the 
increase is mediated through reduced PTCH1 function, GLI1 activity was measured using a GLI 
luciferase reporter assay. Unfortunately, a useful reading was unobtainable as the NEB1 cells 
were resistant to the lysis buffers provided in the Promega Dual Luciferase Reporter assay kit. 
Attempts to manually syringe, scrape, sonicate and freeze-thaw NEB1 cells were unsuccessful 
and did not provide enough protein for the assay. In addition, buffers known to lyse NEB1 cells 
were also ineffective as they impaired luciferase activity. Therefore, as opposed to measuring 
luciferase enzyme activity, luciferase mRNA expression was analysed by qPCR. NEB1 cells were 
transfected with 1 µg of 6xGLI-BS-Firefly reporter construct with 0.5 µg of GFP as a 
transfection control. qPCR targeting luciferase revealed a 3-fold increase in luciferase mRNA in 
NEB1-shPTCH1 cells compared to the control (Figure 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Analysis of GLI1 reporter activity 
[A] Diagram of 6xGLI-BS-Firefly reporter construct and [B] qPCR for Luciferase in NEB1-shPTCH1 cells 
transfected with 6xGLI-BS-Firefly reporter construct. Error bars represent mean ± standard deviation, 
student’s t-test shows a significant difference with 95% confidence (P<0.05). 
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3.2 Characterisation of NEB1-shPTCH1 cells 
 
3.2.1 Characterisation of Hedgehog signalling components in NEB1-shPTCH1 cells 
 
Having established that PTCH1 is strongly suppressed in NEB1-shPTCH1 cells, further 
characterisation at the protein level by immunocytochemistry confirmed a reduction of PTCH1 
protein which was quantified by Image J software (Figure 3.7). The commercial (Santa Cruz) 
PTCH1-C20 antibody is specific to the C-terminus of the protein and this gave a distinct signal 
in the nucleus of NEB1-shCON cells which was reduced in NEB1-shPTCH1 cells thus helping 
confirm antibody specificity. PTCH1 is generally considered to be a transmembrane protein 
however, a recent study showed that the protein is cleaved and that the C-terminus resides in 
the nucleus where it can regulate GLI1 (Kagawa et al., 2011). 
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Figure 3.7: Immunofluorescent analysis of PTCH1 protein expression 
[A] NEB1-shCON and NEB1-shPTCH1 cells stained for C-terminal PTCH1-C20. [B] Image J quantification 
for PTCH1 staining. Error bars represent mean ± standard deviation, student’s t-test shows a significant 
difference with 95% confidence (p<0.05). 
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Consistent with the results of qPCR analysis (Figure 3.3 A), GLI1 protein was also found to be 
increased in NEB1-shPTCH1 cells. Two different antibodies were used with GLI1-C18 detecting 
cytoplasmic and nuclear protein and GLI1-H300 detecting mainly nuclear protein (Figure 3.8). 
The reason for this is unclear but other studies in the laboratory have shown that both 
antibodies detect ectopic GLI1 by Western blot analysis of keratinocyte protein lysates. 
Interestingly, GLI2 which positively regulates GLI1 and is thought to be required for its elevated 
levels in BCC (Regl et al., 2002), showed a slight decrease in mRNA levels (Figure 3.9). 
Suppression of PTCH1 and increased GLI1 protein expression was also confirmed in N/Tert-
shPTCH1 cells (data not shown). 
 
Other components of the HH signalling pathway were also investigated in NEB1-shPTCH1 cells. 
SHH was found to be decreased at the protein and mRNA level and IHH at the mRNA level (n.b. 
no antibody was available for IHH immunocytochemistry). SMO mRNA was also increased two 
fold in NEB1-shPTCH1 cells (Figure 3.10). 
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Figure 3.8: Immunofluorescent analysis of GLI1 protein expression 
[A] NEB1-shPTCH1 cells stained for cytoplasmic GLI1-C18 and nuclear GLI1-H300. [B] Image J 
quantification for GLI1 staining. Error bars represent mean ± standard deviation, student’s t-test shows a 
significant difference with 95% confidence (P<0.05). 
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Figure 3.9: GLI2 mRNA expression in NEB1-shPTCH1 cells 
Error bars represent mean ± standard deviation. 
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Figure 3.10: Analysis of HH signalling components in NEB1-shPTCH1 cells 
[A] Immunofluorescent staining for SHH in NEB1 cells [B] quantified using Image J, student’s t-test 
showing a significant difference with 95% confidence (P<0.05). [C] qPCR for SHH, IHH and [D] SMO. Error 
bars represent mean ± standard deviation. 
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3.2.2 Non-canonical GLI1 signalling in NEB1-shPTCH1 cells 
 
To determine if the increase of GLI1 expression in NEB1-shPTCH1 cells is mediated through 
SMO (i.e. canonical HH signalling), NEB1-shPTCH1 cells were exposed to the SMO antagonist 
Cyclopamine-KAAD (Appendix Table 8.4). As shown by qPCR and IF, over a period of 24 hours 
GLI1 expression was strongly suppressed in NEB1-shCON cells whereas it was not significantly 
altered in NEB1-shPTCH1 cells (Figure 3.11).  
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Figure 3.11: GLI1 expression is not influenced by SMO pharmacological inhibition in NEB1-shPTCH1 cells 
[A] Immunofluorescent staining for GLI1-C18 and GLI1-H300 in NEB1 cells treated with 100 nM 
Cyclopamine-KAAD for up to 24 hours and [B] qPCR for GLI1. Error bars represent mean ± standard 
deviation. 
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NEB1 cells were treated with a second SMO inhibitor SANT1 which also had no effect upon 
GLI1 expression in NEB1-shPTCH1 cells (Figure 3.12). Indeed, GLI1 expression remained 
constant after prolonged exposure to Cyclopamine-KAAD or SANT1 (96 hours) (Figure 3.13 A 
and B). Finally, when cells were exposed to a higher concentration of Cyclopamine-KAAD (1 
µM), GLI1 expression was fully suppressed in NEB1-shCON cells but not in NEB1-shPTCH1 cells 
(Figure 3.13 C).  
 
To confirm that the results presented were not specific to the NEB1-shPTCH1 clone 189A-β1, 
other NEB1-shPTCH1 clones were treated with Cyclopamine-KAAD and analysed for GLI1 
expression. As for NEB1-shPTCH1 clone 189A-β1, the expression of GLI1 was not significantly 
suppressed by either drug in clone 189A-β5 (targeting the same exon, 24) or clone 29A-β1 
(targeting exon 3) (Figure 3.14).  
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Figure 3.12: Immunofluorescent staining for GLI1 (C18) in NEB1-shPTCH1 cells treated with the SMO 
inhibitor SANT1 at 100 nM 
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Figure 3.13: Image J analysis of GLI1-C18 staining in NEB1 cells treated with SMO inhibitors 
[A] Quantification of GLI1-C18 staining in NEB1 cells with prolonged exposure (96 hours) to 
Cyclopamine-KAAD at 100 nM and [B] SANT1 at 100 nM. [C] Image J analysis of NEB1 cells treated with 
Cyclopamine-KAAD at 1 µM. Error bars represent mean ± standard deviation. 
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Figure 3.14: GLI1 expression is maintained in other clonal shPTCH1 cells exposed to Cyclopamine-KAAD  
[A] Immunocytochemistry for GLI1-H300 and [B] qPCR in NEB1 cells treated with 100 nM Cyclopamine-
KAAD for 24 hours. Error bars represent mean ± standard deviation. 
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Subsequently, to validate the findings obtained with NEB1-shPTCH1 cells in another 
keratinocyte cell line, N/Tert-shPTCH1 cells were exposed to both SMO inhibitors. Again, GLI1 
expression was suppressed in the control cell line (N/Tert-shCON) but remained constant in 
N/Tert-shPTCH1 cells (Figure 3.15). 
 
In summary, all keratinocyte shPTCH1 cell lines that were treated with the SMO inhibitors 
retained a higher GLI1 expression level (compared to shCON cells) which suggests that PTCH1 
regulates GLI1 via a SMO-independent mechanism.  
 
NEB1 cells exposed to SMO inhibitors were analysed for GLI2 mRNA levels which were lower in 
NEB1-shPTCH1 cells compared to NEB1-shCON. GLI2 mRNA expression in both cell lines were 
suppressed by Cyclopamine-KAAD which suggests that GLI2 signalling occurs via canonical HH 
signalling (Figure 3.16). 
 
Taken together, these data suggest that there is a canonical SMO-GLI1/GLI2 signalling axis in 
shCON cells and a canonical SMO-GLI2 signalling axis in shPTCH1 cells, but they also indicate 
the presence of a non-canonical PTCH1-GLI1 signalling axis that is independent of SMO activity 
in shPTCH1 cells (Figure 3.17). 
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Figure 3.15: N/Tert-shPTCH1 cells treated with SMO inhibitors  
qPCR for GLI1 in N/Tert cells treated with 100 nM Cyclopamine-KAAD and SANT1 for 24 hours. Error bars 
represent mean ± standard deviation. 
 
 
 
 
 
 
 
 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
2 
shCON shCON + 
Cyc-KAAD 
shCON + 
SANT-1 
shPTCH1 shPTCH1 + 
Cyc-KAAD 
shPTCH1 + 
SANT-1 
Fo
ld
 In
d
u
ct
io
n
 
GLI1 
  Chapter 3 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: GLI2 mRNA expression in NEB1-shPTCH1 cells treated with SMO inhibitors  
Error bars represent mean ± standard deviation. 
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Figure 3.17: Schematic diagram depicting a novel non-canonical PTCH1-GLI signalling pathway in 
shPTCH1 cells (right panel) 
 
 
 
 
 
 
 
 
 
 
 
SUFU 
FU 
SUFU 
FU 
PTCH1 PTCH1 
GLI1 GLI1 
shRNA shRNA 
Cyc-KAAD/ 
SANT1 
Non-
canonical 
Canonical Signalling Non-canonical Signalling 
SMO SMO 
  Chapter 3 
122 
 
3.3 The role of SMO in NEB1-shPTCH1 cells 
 
3.3.1 Analysis of SMO siRNA treatment upon GLI1 expression in NEB1-shPTCH1 cells  
 
As noted above, SMO mRNA was increased in NEB1-shPTCH1 cells (Figure 3.10 D) and this 
correlates with the fact that SMO mRNA levels are known to be elevated in BCC (Xie et al., 
1998). SMO protein levels were shown to be increased in NEB1-shPTCH1 cells by 
immunofluorescent labelling (Figure 3.18). In addition, SMO was observed to be distinctly 
more nuclear with two commercial antibodies (Santa Cruz N19 and C17) although whether this 
reflects an increase of protein levels and/or increase of nuclear localisation is unclear. In 
addition, a third commercial antibody (Abcam ab72130) gave a stronger nuclear/peri-nuclear 
signal in NEB1-shPTCH1 cells. 
 
To determine if the increase of GLI1 expression is fully independent of SMO, siRNA targeting 
was employed to suppress SMO mRNA in NEB1-shPTCH1 cells. A decrease of SMO mRNA and 
protein levels was confirmed by qPCR and immunocytochemistry respectively (Figures 3.19 
and 3.20). With regards to GLI1, both mRNA and protein levels were suppressed upon SMO 
knockdown which indicates that, although GLI1 levels are unresponsive to SMO inhibitors in 
NEB1-shPTCH1 cells, they are not fully independent of SMO protein function (Figures 3.19). 
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Figure 3.18: SMO expression in NEB1 cells 
[A] Immunofluorescence staining with SMO (N19, C17) reveals increased nuclear localisation in NEB1-
shPTCH1 cells and [B] peri-nuclear staining with SMO-ab72130. 
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Figure 3.19: SMO and GLI1 mRNA expression in NEB1 cells treated with SMO siRNA 
Error bars represent mean ± standard deviation. 
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Figure 3.20: SMO and GLI1 protein expression in NEB1 cells treated with SMO siRNA 
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3.3.2 Analysis of EGFP-SMO-WT/M2 in NEB1 cells 
 
One reason for the lack of response to anti-SMO inhibitors in shPTCH1 cells may be that upon 
PTCH1 suppression, SMO translocates to the nucleus/peri-nucleus region where Cyclopamine-
KAAD and SANT1 are unable to inhibit SMO effectively. To investigate the subcellular 
localisation of SMO and its potential effect upon GLI1 expression, EGFP-SMO-WT (wild type) 
and EGFP-SMO-M2 (constitutively active mutant) fusion constructs were created for 
expression in NEB1-shCON and NEB1-shPTCH1 cells. I was unable to PCR amplify the predicted 
full length SMO coding sequence from NEB1 or N/Tert keratinocytes so the SMO-WT/M2 
coding sequences were sub-cloned from vectors obtained from the de Sauvage laboratory 
(Genentech, CA, USA). It was discovered that these constructs lack the N-terminal signal 
peptide (residues 1-31) that would be predicted to target the protein to its correct subcellular 
localisation; however, the plasmids were previously used to show that even without the N-
terminus SMO-M2 is oncogenic in soft agar assays and that it activates GLI1 in rat embryonic 
fibroblast REF52 cells (Xie et al., 1998). 
 
To confirm that the plasmids were functional, HEK293 cells were initially transfected with the 
EGFP-SMO-WT/M2 constructs and protein lysates were analysed by Western blot. A band of 
the correct size was present in both samples (Figure 3.21 B) and it was noted that the EGFP-
SMO-M2 band was considerably stronger than EGFP-SMO which may account for its enhanced 
tumourigenic potential. 
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Figure 3.21: EGFP-SMO-WT/M2 expression in HEK-293 cells 
(A) EGFP-SMO-WT and EGFP-SMO-M2 fusion proteins were generated by excising SMO from PRK-SMO 
and then ligating into pEGFP-C2, (B) validated by PCR for SMO and GFP. (C) Western blot for GFP in HEK-
293 cells transfected with EGFP-SMO-WT and EGFP-SMO-M2. (D) HEK-293 cells transfected with EGFP-
SMO-WT and EGFP-SMO-M2.  
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Subsequently, NEB1-shCON and NEB1-shPTCH1 cells were transfected the EGFP-SMO-WT/M2 
constructs: keratinocytes are difficult to transfect but using a reverse transfection method that 
I adapted from siRNA protocols, the transfection efficiency was increased to approximately 
20% of cells.  
 
Confocal microscopy revealed that EGFP-SMO-WT was predominantly cytoplasmic in both 
NEB1-shCON and NEB1-shPTCH1 cells: small areas of nuclear fluorescence were observed in 
NEB1-shPTCH1 cells (Figure 3.22) but these did not correlate with the uniform nuclear 
localisation of endogenous SMO observed by immunocytochemistry (Figure 3.18 A). Peri-
nuclear fluorescence was observed in NEB1-shCON and NEB1-shPTCH1 cells which correlated 
with the staining pattern using the anti-SMO Abcam antibody (Figure 3.18 B). The pattern of 
EGFP-SMO-M2 expression was similar to that of EGFP-SMO-WT in both NEB1-shCON and 
NEB1-shPTCH1 cells (Figure 3.23). 
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Figure 3.22: NEB1 cells transfected with EGFP-SMO-WT 
White arrows show nuclear localised EGFP-SMO in NEB1-shPTCH1 cells. 
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Figure 3.23: NEB1 cells transfected with EGFP-SMO-M2 
White arrows show nuclear localised EGFP-SMO-M2 in NEB1-shPTCH1 cells and red arrows highlight 
peri-nuclear expression. 
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3.3.3 EGFP-SMO-WT/M2 activates GLI1 in NEB1 cells 
 
Although a distinct increase of nuclear EGFP-SMO-WT/M2 was not observed in NEB1-shPTCH1 
cells, I sought to determine if either construct is capable of activating GLI1 expression and if 
this is increased upon PTCH1 suppression. A modest but reproducible increase of GLI1 was 
observed in both NEB1-shCON and NEB1-shPTCH1 cells with EGFP-SMO-WT and a more potent 
increase was observed with EGFP-SMO-M2 (Figure 3.24). Surprisingly, the fold-increase of GLI1 
was higher for EGFP-SMO-M2 in NEB1-shCON cells (~10 fold) compared to NEB1-shPTCH1 cells 
(~4 fold) despite comparable transfection efficiencies as determined by co-transfection with a 
CFP vector.  
 
In summary, these data demonstrate that EGFP-SMO (WT and M2) induces GLI1 expression 
but they do not support the notion that the increase of GLI1 observed in NEB1-shPTCH1 cells is 
mediated by an increase of nuclear SMO. 
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Figure 3.24: GLI1 mRNA expression in NEB1 cells transfected with EGFP-SMO-WT/M2 
Error bars represent mean ± standard deviation. 
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3.4 Functional studies of NEB1-shPTCH1 cells  
 
As well as investigating the HH signalling pathway, the in vitro BCC model was established to 
investigate specifically the effects of PTCH1 suppression upon certain aspects of keratinocyte 
biology including proliferation, invasion and anchorage-independent growth.  
 
With regards to proliferation rate, there was a slight but consistent decrease in NEB1-shPTCH1 
cells (29A and 189A) compared to the control (Figure 3.25). The Alamar blue proliferation 
assay measures redox reactions that occur in the mitochondria therefore, the assay better 
represents cell viability rather than proliferation. A more appropriate experiment would have 
been to measure the population doublings of the cells. 
 
Despite a lower proliferation rate as seen by the Alamar blue assay, NEB1-shPTCH1 cells were 
hyper-proliferative when seeded onto a Matrigel based organotypic culture system although 
there was no evidence of invasion into the artificial dermis characteristic of superficial BCC or 
compact colony formation characteristic of nodular BCC (Figure 3.26). The organotypic culture 
is an artificial model of the dermis mimicking the skin allowing for the culture of keratinocytes 
under these conditions. 
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Figure 3.25: Alamar blue proliferation assay of NEB1 cells 
Error bars represent mean ± standard deviation. 
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Figure 3.26: Organotypic skin model of NEB1 cells  
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3.5 Discussion  
 
This project has adopted a novel approach to investigating the role of PTCH1 in BCC biology by 
using RNAi to suppress the PTCH1 gene product in human keratinocytes. Modelling BCC by 
suppressing PTCH1 function is superior to ectopically expressing GLI1 because this is a better 
representation of the in vivo situation i.e. PTCH1 mutations have been found in numerous 
tumours whereas the increase of GLI1 in BCCs is less convincing. Indeed, one of the initial 
studies from our department showed that GLI1 was expressed at higher levels in the ORS of 
the hair follicle compared to the adjacent nodular tumour islands (Ghali et al., 1999). In 
addition, because of the feedback loop ectopic GLI1 leads to strong increase of endogenous 
PTCH1 levels with a subsequent increase of wild-type protein function as a cellular response to 
try and limit HH signalling.  
 
Clonal cell lines were derived from heterogenous populations and some of these cultured as 
more compact colonies than parental or control cells; this is a characteristic of nodular tumour 
islands and helped validate the clonal lines as a viable model of human BCC. In addition, the 
clonal lines proliferated slowly and BCCs are characterised by their slow growth. It has 
previously been shown that the retroviral transduction of N/Tert cells with an EGFP-GLI1 
fusion protein promotes tight colony formation (Neill et al., 2008). This suggests that the 
increase of GLI1 in shPTCH1 cells could cause this phenotypic change; however the level of 
GLI1 protein resulting from ectopic expression is considerably higher than that induced upon 
PTCH1 suppression and it is possible that additional factors regulate compact colony 
formation. This is supported by the fact that some clonal lines did not display an increase of 
GLI1 but were more compact than control shCON cells. Indeed, recent research in our 
laboratory (Dr Neill and Professor Philpott, unpublished data) has shown by 
immunohistochemistry that despite their similar histology, the expression of GLI1 varies 
considerably between nodular tumours from different patients which further supports the 
idea that GLI1-independent factors contribute to the compact phenotype as well as to tumour 
formation itself. However, the clonal cell lines NEB1-29A-β1 and NEB1-189A-β1 also displayed 
increased levels of GLI1. The induction of GLI1 via PTCH1 suppression was confirmed by the 
fact that the increase of endogenous GLI1 was suppressed upon ectopic expression of the 
PTCH1B isoform which is not targeted by the PTCH1 shRNA construct (Figure 3.5). 
 
Investigation of PTCH1 protein using an antibody that is specific for the C-terminal (PTCH1-
C20) in NEB1 cells revealed nuclear expression of PTCH1 in NEB1-shCON cells and a reduction 
in NEB1-shPTCH1 cells (Figure 3.7). This has been reported previously along with N-terminal 
  Chapter 3 
137 
 
PTCH1 expressed in the cytoplasm (Kagawa et al., 2011). PTCH1 is known to be a 
transmembrane protein that is localised to the cell membrane therefore its presence in the 
nucleus is surprising. It is unclear whether the full PTCH1 protein also resides in the nucleus or 
if this is a product of cleavage. This may be linked to SMO which was also found in the nucleus 
of NEB1-shPTCH1 cells (Figure 3.18). With PTCH1, SMO and GLI1 found in the nucleus, HH 
signalling may occur in the nucleus rather than at the cell membrane or in cilia. There is no 
mention in the literature of SMO being localised in the nucleus however, C-terminal PTCH1 has 
been shown to enter the nucleus and PTCH1 staining of Sertoli cells (cells that sustain the 
testis) revealed nuclear localisation (Kagawa et al., 2011; Kogerman et al., 2002). One study 
has also shown that PTCH1 is localised in the nucleus of sporadic nodular BCCs which suggests 
a role for PTCH1 signalling directly to SMO or GLI1 in the nucleus (Unden et al., 1997). 
 
This study has led to the discovery of a potentially novel mode of GLI1 signalling. 
Pharmacological inhibition of SMO in NEB1-shPTCH1 and N/Tert-shPTCH1 cells failed to reduce 
GLI1 expression compared to shCON cells where both GLI1 protein and mRNA levels were 
strongly reduced (Figures 3.11, 3.12 and 3.15). This shows that signalling of GLI1 in shCON cells 
is mediated through a canonical HH pathway whereby SMO activates GLI1. In NEB1-shPTCH1 
and N/Tert-shPTCH1 cells, inhibition of SMO did not suppress GLI1 expression which was also 
observed with different NEB1-shPTCH1 clones (Figures 3.14 and 3.15).  
 
The formation of BCC is thought to be dependent upon increased GLI1 expression and as such, 
novel compounds targeting SMO are being used in the clinic. The fact that GLI1 expression is 
not suppressed upon exposure to SMO pharmacological inhibitors in NEB1-shPTCH1 and 
N/Tert-shPTCH1 cells is interesting and it is worth noting that no studies have convincingly 
shown that GLI1 expression is actually reduced in BCCs using clinical compounds such as GDC-
0449. Various SMO inhibitors have been described including GDC-0449 however, many 
patients do not respond to these treatments and the levels of GLI1 have not been reported in 
non-responding tumours (Van Hoff et al., 2009). Indeed, having demonstrated that GLI1 is not 
suppressed by Cyclopamine-KAAD or SANT1 in shPTCH1 cells, the effects of anti-SMO 
inhibitors upon GLI1 expression in BCCs requires further evaluation.  
 
This mode of non-canonical GLI1 signalling may occur through other pathways such as TGF-β 
which has been shown to induce GLI1 and GLI2 expression in keratinocytes. It has also been 
reported that GLI2 is a direct transcriptional target of the SMAD pathway downstream of TGF-
β. TGF-β is able to induce GLI1 expression in a GLI2-dependent mode which could not be 
suppressed by Cyclopamine (Dennler et al., 2007). Also, pharmacological inhibition of TGF-β 
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has also been shown to suppress GLI2 expression in cancer cells that are resistant to 
Cyclopamine (Dennler et al., 2009). 
 
The finding that GLI1 expression is not reduced in NEB1-shPTCH1 cells upon treatment with 
SMO inhibitors suggests that GLI1 signalling is independent of SMO however siRNA inhibition 
of SMO reveals that GLI1 expression is in fact repressed (Figures 3.19 and 3.20). The mode of 
signalling may in fact be a novel form of canonical signalling whereby the suppression of 
PTCH1 allows SMO to activate GLI1 in a different way i.e. without cilia or directly at the 
nucleus. It is worth noting that GLI2 expression was not increased in NEB1-shPTCH1 cells 
compared to NEB1-shCON cells therefore, TGF-β expression in these cells requires 
characterisation.  
 
If TGF-β and downstream SMAD components are over-expressed in NEB1-shPTCH1, this still 
does not explain why GLI2 expression is not increased in these cells. The findings that GLI1 can 
be over-expressed in NEB1-shPTCH1 cells and not induce GLI2 expression suggests that GLI1 
and GLI2 can signal independently of each other. TGF-β activation has been shown to be 
required for SMO-mediated BCC development (Fan et al., 2010) however, the finding that TGF-
β inhibition suppresses GLI2 in Cyclopamine resistant cancer cells (Dennler et al., 2009) 
suggests that TGF-β may be driving the non-canonical HH pathway seen in NEB1-shPTCH1 cells.   
 
The idea that HH signalling can occur non-canonically has been explored and is not entirely a 
new concept. GLI1 was over expressed in NIH-3T3 cells and the increase of activity was 
confirmed with a GLI1 reporter construct. Treatment of the cells with Cyclopamine did not 
repress GLI1 reporter activity which only returned to basal levels when the cells were 
transfected with PTCH (3:1 ratio of PTCH:GLI1) (Rahnama et al., 2006). This shows that GLI1 is 
controlled by PTCH but signals independently of SMO. Also, if the HH pathway was linear i.e. 
PTCH1 signals through to GLI1 without the influence of any other pathway, a lower amount of 
PTCH would need to be transfected into NIH-3T3 cells to suppress GLI1. Since three times the 
amount of PTCH to GLI1 is required, GLI1 may be expressed thorough other non-conventional 
modes.  
 
As NEB1 cells display nuclear expression of PTCH1, SMO and GLI1 then potentially, if SMO 
signals to GLI1 in the nucleus this may explain why pharmacological SMO inhibitors did not 
reduce GLI1 levels in NEB1-shPTCH1 cells. SMO could potentially enter the nucleus to activate 
GLI1 in a mode where SMO can function despite the presence of a SMO inhibitor. Analysis of 
the SMO protein sequence reveals a bipartite N-terminal nuclear localisation sequence (NLS) 
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which provides evidence that SMO has the capacity to localise to the nucleus (Appendix Figure 
8.1).  
 
EGFP-SMO-WT/M2 clones were generated to determine if SMO is present in the nucleus 
however, the PRK-SMO sequence that was used to make the clone lacks the signal peptide 
which may affect the localisation of the protein. Transfection of NEB1-shCON cells with EGFP-
SMO-WT shows cytoplasmic expression of the protein while in NEB1-shPTCH1 cells there is 
some evidence of nuclear localisation as well as nuclear material positive for EGFP-SMO-WT 
(Figure 3.21). Expression of EGFP-SMO-M2 in NEB1-shPTCH1 cells also shows some nuclear 
localisation however, a peri-nuclear pattern is more evident (Figure 3.22).  
 
It is still unclear whether SMO localises and functions within the nucleus and this may be due 
to limited transfection efficiency and perhaps, EGFP-SMO-WT/M2 should be stably expressed 
in NEB1 cells to better determine the localisation. A problem with the reverse transfection 
method is that NEB1-shPTCH1 cells are not given the time to settle and form tight colonies. 
This may affect the expression of GLI1 and also the treatment of cells with the transfection 
reagent did alter the behaviour of the cells. Over expression of EGFP-SMO-WT/M2 in NEB1 
cells induced GLI1 mRNA and protein levels although there was a significantly greater 
induction caused by EGFP-SMO-M2 (Figure 3.24). Expression of EGFP-SMO-WT/M2 in HEK-293 
cells shows much stronger expression of EGFP-SMO-M2 suggesting that the mutant form of 
SMO is more stable than the wild type which may account for its tumourigenic potential 
(Figure 3.21). SMO-M2 mutations have been found in BCCs and expression of the more stable 
SMO-M2 could lead to constitutive activation of HH that gives rise to BCC development (Xie et 
al., 1998). To determine if nuclear SMO is the cause for GLI1 over expression in NEB1-shPTCH1 
cells, the NLS of EGFP-SMO-WT/M2 could be altered via site directed mutagenesis. NEB1 cells 
would then be analysed for the protein localisation of EGFP-SMO-WT/M2 as well as by qPCR 
for GLI1 to conclude whether or not GLI1 expression is reduced in NEB1 cells. Creating stable 
EGFP-SMO-WT/M2 expressing NEB1-shCON and NEB1-shPTCH1 cell lines would help 
determine where SMO-WT and SMO-M2 are localised in the cells and how the proteins behave 
when there are elevated levels of GLI1 i.e. in NEB1-shPTCH1.  
 
By comparing NEB1-shCON to NEB1-shPTCH1 cells, there is evidence that HH signalling may 
occur in the nucleus as opposed to the cell membrane or cilia. NEB1-shCON cells have nuclear 
PTCH1 and cytoplasmic SMO and GLI1. It is possible that PTCH1 may be suppressing HH 
signalling possibly by preventing SMO entering the nucleus although PTCH1 regulates SMO at 
the cell membrane to limit HH signalling. Although it has been reported that N-terminal PTCH1 
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is localised in the cytoplasm while C-terminal PTCH1 is present in the nucleus (Kagawa et al., 
2011) it is possible that full length PTCH1 is active at the cell membrane as well as the nuclear 
membrane. Immunocytochemistry for SMO-ab72130 reveals a peri-nuclear expression pattern 
in NEB1-shCON cells so PTCH1 may prevent SMO from entering the nucleus and activating 
GLI1. In contrast, NEB1-shPTCH1 cells have reduced nuclear PTCH1 allowing for SMO to 
migrate to and enter the nucleus and constitutively activate GLI1 which is also more nuclear. 
This would explain why there is greater SMO protein expression in and around the nucleus in 
NEB1-shPTCH1 compared to NEB1-shCON cells (Figure 3.18). It is not known how SMO 
inhibitors would act upon nuclear proteins i.e. is drug efficacy different if proteins are localised 
in certain parts of the cell. It should be stated that further experiments are required to be 
certain of the sub-cellular localisation of SMO by fractionation methods. 
 
BCC tumours that do not have mutated PTCH1, may still have increased HH signalling as a 
result of SMO activating mutations which negates the repressive function of PTCH1 on the 
pathway (Xie et al., 1998). However, a study has shown that SMO-M2 over expressing mice do 
not develop BCCs but instead, follicular Hamartomas emerge (Grachtchouk et al., 2003) 
although others have shown that BCCs develop on the ears and tail of mice transgenically 
expressing SMO-M2 (Wang et al., 2011). From the literature it is unclear whether SMO-M2 
mutation is sufficient for the development of BCC although there is a significant increase in 
GLI1 mRNA expression in transfected NEB1 cells. A study where NIH-3T3 cells were induced 
with SMO-WT and SMO-M2 to stimulate HH signalling reveals that the addition of Cyclopamine 
can suppress the pathway in cells induced with SMO-WT but not SMO-M2 (Taipale et al., 
2000). This raises questions to the nature of the SMO-M2 mutation for example, does the 
mutation prevent Cyclopamine from binding to the protein or not.  
 
Based on the findings that NEB1-shPTCH1 cells do not respond to SMO inhibitors, it may be 
possible that SMO-M2 operates non-canonically as opposed to SMO-WT. The involvement of 
cilia may also be a factor that has not yet been investigated. The HH pathway is mediated 
through cilia and upon SHH activation, SMO localises at the primary cilium (Corbit et al., 2005). 
In NEB1-shPTCH1 cells, SHH is not required as the HH pathway is constitutively active so SMO 
may be signalling independently of cilia however, this depends on whether SHH mediates 
canonical signalling through cilia in NEB1 cells. NEB1 cells should be analysed for cilia as there 
is the possibility that they are not present in the cells.  
 
With reduced PTCH1 in shPTCH1 cells, SMO and the other downstream targets are 
constitutively active however this does not explain why SMO inhibitors do not decrease GLI1 
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expression. It is likely that the SMO inhibitors do bind to SMO in NEB1-shPTCH1 cells however 
SMO could be acting in a different way to signal to GLI1 that is not affected by inhibitors. It is 
unknown exactly where the SMO antagonists bind regarding proteomics but this would help 
determine the active region of SMO in NEB1-shCON cells. This raises questions as to the 
effectiveness of SMO inhibitors to treat BCCs which may be determined by the method by 
which the tumour was initiated i.e. through PTCH1 mutations, SMO activation or UV associated 
DNA damage for example. 
 
Of the mouse models of BCC that exist mice that develop normally before PTCH1 is 
conditionally knocked down, display BCC formation (Adolphe et al., 2006). The mice and skin 
develop for 32 days before treatment with Retinoic acid which triggers the conditional knock 
down of PTCH1 in the mice. Histological sections are examined 4 weeks after the treatment. A 
criticism of this model is that BCCs occur in Gorlin’s patients after the loss of heterozygosity of 
PTCH1 (Gailani et al., 1996) therefore, even the presence of one functioning PTCH1 allele may 
prevent BCC formation. PTCH+/- mice have been shown to develop tumours that resemble BCCs 
upon UV irradiation (Donovan, 2009; Daya-Grosjean and Couve´-Privat, 2005). Another study 
has shown that PTCH+/- mice develop tumours that are similar to Trichoblastomas and UV 
irradiation of these mice increased the number of tumours and altered their appearance to be 
more similar to nodular BCCs (Mancuso et al., 2004). These studies suggest that BCCs do not 
form if at least one PTCH1 allele is functional and that a separate event such as a UV induced 
mutation is required to initiate tumour formation. 
 
Although the loss of PTCH1 in mice results in the formation of BCCs, other mouse studies 
where components of the HH pathway can lead to BCC formation while others do not. Further 
upstream of PTCH1, mice that have over expressed SHH ligand develop BCCs (Oro et al., 1997). 
At the end of the signalling cascade, mice over expressing GLI1 develop tumours resembling 
BCCs (Nilsson et al., 2000) compared to mice over expressing an activated mutant form of GLI2 
which developed multiple BCCs (Sheng et al., 2002; Grachtchouk et al., 2000). An interesting 
observation is that GLI2 mRNA is suppressed by SMO inhibitors in both NEB1-shCON and 
NEB1-shPTCH1 cells (Figure 3.9). This suggests that GLI2 is mediated through SMO in NEB1-
shPTCH1 cells unlike GLI1 so GLI2 may only signal canonically. GLI1 and GLI2 are part of a 
positive feedback loop (Regl et al., 2002) and it is unusual that in NEB1-shPTCH1 cells GLI2 is 
not induced in contrast to GLI1. An active mutant form of GLI2 has been shown to directly 
activate GLI1 while GLI1 can only activate GLI2 indirectly. It may be that GLI2 does not signal in 
the same non-canonical mode that GLI1 signals. It is difficult to draw conclusions over the 
involvement of GLI2 in BCC formation as mice were over expressing an active mutant of GLI2 
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and not the wild type protein which is much less transcriptionally active (Roessler et al., 2005; 
Sheng et al., 2002; Grachtchouk et al., 2000). Also, studies of mice over expressing SMO-M2 
show that follicular Hamartomas develop rather than BCCs even though this is a known 
mutation found in BCCs (Grachtchouk et al., 2003). The mouse studies show that the HH 
pathway alone may not be responsible for BCC formation as it would be expected that GLI1 
over expression would cause the illness. If the HH pathway were linear, the disruption of each 
component would result in the formation of the same tumour however this is not the case 
suggesting the HH pathway is not linear and that there is the possibility of non-canonical 
signalling where GLI1 and GLI2 can signal independently of other components such as SMO. 
 
Regarding NEB1-shPTCH1 cells as a model of BCC, shRNA does not fully suppress PTCH1 
meaning that there is a certain level of PTCH1 functionality. This may provide an explanation as 
to why Matrigel based organotypic culture of NEB1-shPTCH1 cells (Figure 3.26) did not result in 
BCC formation as there may need to be a certain level of PTCH1 suppression to initiate tumour 
formation despite the presence of a non-canonical mode of HH signalling in NEB1-shPTCH1 
cells. However, there was evidence of hyperproliferation of the epidermal layer and as NEB1-
shPTCH1 cells have heavily suppressed PTCH1, a separate event may need to occur before 
BCCs develop. This may be through UV irradiation as seen in mouse studies or via other 
pathways that are linked to HH signalling.  
 
However not all BCCs display a loss of PTCH expression and in fact, human nodular BCCs 
showed over expressed PTCH and SMO mRNA expression especially in areas where the tumour 
was advancing, superficial BCCs showed an absence of PTCH and SMO mRNA expression. It is 
possible that in these tumours, PTCH and SMO play a role in more aggressive BCCs (Tojo et al. 
1999). A study utilising PTCH+/- mice found that the wild type allele was being expressed as well 
as the mutated form which was shown to be capable of pathway inhibition (Uhmann et al., 
2005). Another study comparing PTCH+/- and PTCH-/- mouse embryonic fibroblasts showed that 
mutated PTCH is as stably expressed as the wild type PTCH and that both PTCH+/- and PTCH-/- 
mouse fibroblasts show similar induction of SMO and GLI2 but PTCH-/- cells have increased 
levels of GLI1 (Bailey et al., 2002). The study shows that a slight reduction of PTCH activity has 
the potential to initiate certain disease phenotypes. Another anomaly was reported in PTCH+/- 
mice where GLI1 expression was strongly expressed in medulloblastoma despite the presence 
of PTCH (Wetmore et al., 2000). These studies highlight that GLI1 can be over expressed even 
though PTCH1 is present which should supposedly suppress the HH pathway. Also, BCCs can 
form with active PTCH and GLI1 which suggests that GLI1 signalling may occur via other modes 
as PTCH should suppress GLI1. 
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The study has shown that GLI1 is expressed in NEB1-shPTCH1 cells via a non-canonical mode of 
signalling. Treatment of NEB1-shPTCH1 cells with SMO inhibitors failed to reduce GLI1 
expression suggesting that GLI1 signals independently of SMO however, GLI1 is repressed by 
SMO siRNA. This shows that NEB1-shPTCH1 cells are unresponsive to SMO inhibitors which 
have clinical implications for BCCs that may have arisen due to loss of function mutations to 
PTCH1. A potential reason for this is that SMO may enter the nucleus to directly influence GLI1 
expression or there is an unknown factor that is inducing GLI1 linked to loss of PTCH1 function 
(Figure 3.27). 
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Figure 3.27: Non-canonical HH signalling in NEB1-shPTCH1 cells 
[A] NEB1-shPTCH1 cells are unresponsive to SMO inhibitors however GLI1 is suppressed by SMO siRNA. 
[B] GLI1 may be induced by nuclear SMO or another undiscovered factor. 
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Chapter 4 Introduction 
 
Characterisation of NEB1-shPTCH1 cells as an in vitro model of BCC in chapter 3 revealed a 
potentially novel non-canonical mode of HH signalling. It was confirmed that the suppression 
of PTCH1 in NEB1-shPTCH1 cells leads to the over-expression of GLI1 as well as promoting a 
nodular BCC-like morphology of NEB1-shPTCH1 cells. NEB1-shPTCH1 cells were also shown to 
be unresponsive to pharmacological SMO inhibition as GLI1 levels were not reduced. However, 
GLI1 may not be fully independent of SMO as SMO siRNA did suppress GLI1 in NEB1-shPTCH1 
cells. This could be related to the finding that SMO is localised in the nucleus of NEB1-shPTCH1 
cells or via another signalling pathway. As such, gene expression microarray profiling of NEB1-
shPTCH1 cells was performed to determine which other pathways may be affected by the 
suppression of PTCH1 which may in turn be involved with BCC biology.  
 
The fact that NEB1-shPTCH1 cells were unresponsive to SMO inhibitors has clinical implications 
as studies have shown that many BCC patients did not respond to SMO antagonists such as 
GDC-0449 (Van Hoff et al., 2009). Performing a microarray analysis on NEB1-shPTCH1 cells 
treated with Cyclopamine-KAAD will therefore help determine which pathways are 
differentially regulated and potentially, pathways that may signal via a non-canonical HH 
mode. 
 
4.1 Gene expression profiling of NEB1-shPTCH1 cells 
 
As stated previously, one of the reasons for suppressing PTCH1 expression in human 
keratinocytes was to identify novel mechanisms that are regulated by this tumour suppressor 
protein and that may be important in BCC biology. Therefore, cDNA microarray profiling was 
employed to compare NEB1-shCON with NEB1-shPTCH1 keratinocytes. In addition, to help 
determine if any novel genes or pathways are mediated through canonical Hedgehog 
signalling, NEB1-shPTCH1 cells exposed to KAAD-Cyclopamine were included in the array: this 
also stems from the fact that GLI1 levels were insensitive to SMO pharmacological inhibition in 
NEB1-shPTCH1 cells, although this may have been because SMO has nuclear signalling 
capability which is insensitive to the anti-SMO compounds used in this study.   
 
Gene expression microarray profiling was performed on NEB1-shCON, NEB1-shPTCH1 and 
NEB1-shPTCH1 cells treated with 100 nM Cyclopamine-KAAD using the Human Gene 1.1 ST 
Array Strip from Affymetrix containing 28,000 genes. A threshold value of 2 fold change was 
set to identify differentially expressed genes (DEGs) between samples. When comparing NEB1-
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shPTCH1 to NEB1-shCON cells, the DEGs represented 6% of all transcripts whereas the DEGs 
represented 8% of all transcripts when comparing NEB1-shCON to NEB1-shPTCH1 + 
Cyclopamine-KAAD (Figure 4.1). A full list of DEGs can be found in the Appendix (Tables 8.5-
8.8). The efficacy of Cyclopamine-KAAD had been previously validated (Figures 3.11 B and 3.14 
B). 
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Figure 4.1: Pie chart showing number of DEGs identified when comparing NEB1-shPTCH1 vs NEB1-
shCON and NEB1-shPTCH1 + Cyclopamine-KAAD vs. NEB1-shCON as a percentage of all transcripts 
analysed 
 
 
 
 
 
 
 
 
 
1153, 6% 
1549, 8% 
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NEB1-shPTCH1 and NEB1-shPTCH1 + Cyclopamine-KAAD were compared to each other from 
which 478 DEGs were identified. Of these genes, 70% did not return to basal levels in the 
presence of Cyclopamine-KAAD (Figure 4.2). Comparison of the DEG expression values 
between NEB1-shPTCH1 and NEB1-shPTCH1 + Cyclopamine-KAAD samples did not show much 
difference in expression (Table 4.1). This raises the question as to which pathways or processes 
are affected by Cyclopamine-KAAD in NEB1-shPTCH1 cells or if non-canonical HH signalling can 
compensate for the inhibition of canonical HH signalling.   
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Figure 4.2: DEGs identified when comparing NEB1-shPTCH1 and NEB1-shPTCH1 + Cyclopamine-KAAD 
[A] Pie chart and [B] Venn diagram of DEGs unique to and independent of NEB1-shPTCH1 and NEB1-
shPTCH1 + Cyclopamine-KAAD. 
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Gene 
(Top 20) 
Expression vs. shCON Gene 
(Bottom 20) 
Expression vs. shCON  Gene 
expression shPTCH1 shPTCH1 + 
Cyc-KAAD 
shPTCH1 shPTCH1 + 
Cyc-KAAD 
MMP7 9.4698 4.9019 TCF7L1 -2.9485 -3.2716 6.56 - 8.21 
SCGB1A1 9.1472 6.0769 SPRR1A -3.0105 -3.4343 4.92 - 6.56 
CXCL10 8.2059 3.8459 WDR17 -3.0175 -2.4623 3.28 - 4.92 
PTGIS 7.0453 4.9474 ANKFN1 -3.0667 -2.8415 1.64 - 3.28 
ANKRD1 6.4681 1.4241 KRT15 -3.1023 -4.4795 0.00 - 1.64 
THY1 6.3496 7.2267 SERPINB13 -3.2266 -4.2575 -1.64 - 0.00 
NNMT 5.4516 5.1814 SH3BGRL -3.2415 -3.3636 -3.28 - -1.64 
SRPX 5.0397 4.8793 AGR2 -3.3173 -5.8835 -4.92 - -3.28 
ESX1 4.9818 4.9019 SPRR3 -3.3250 -4.7568 -6.56 - -4.92 
CXCL11 4.8906 2.5198 ZNF165 -3.4661 -5.3641 -8.21 - -6.56 
ADAM19 4.8456 5.1456 EPB41L4A -3.4661 -3.5472  
IL7R 4.8456 4.2281 SCD5 -3.4882 -3.2490 
GPRC5B 4.7349 4.1892 AMOT -3.6553 -3.4343 
FAM20C 4.5315 4.1315 SULT1E1 -3.7149 -5.2174 
SAA1 4.4076 3.5064 KRT4 -3.8106 -4.7240 
LAPTM5 4.2477 4.0652 MCOLN3 -3.8282 -3.6893 
MMP2 4.1315 3.8637 H2AFY2 -3.9267 -3.8548 
LIFR 3.9908 4.8232 PNLIPRP3 -4.3269 -6.0769 
CYP24A1 3.8548 3.8018 CNTN1 -4.3469 -4.4795 
CFB 3.8194 2.6329 MUC15 -4.3772 -3.7235 
ALDH2 3.7842 3.9908 KLHL13 -4.5525 -4.5842 
MCAM 3.7581 4.3369 LASS3 -5.8159 -5.7491 
APOBEC3G 3.6050 2.4284 ARHGEF9 -8.6538 -7.9815 
VIM 3.5718 3.4027 C9orf125 -8.7341 -8.0000 
SLCO2A1 3.5718 3.7494 FBN2 -10.1965 -10.0329 
 
 
Gene Expression vs. shCON  Gene 
expression shPTCH1 shPTCH1 + 
Cyc-KAAD 
CXCL11 4.8906 2.5198 6.56 - 8.21 
MMP2 4.1315 3.8637 4.92 - 6.56 
TGFB2 3.2868 3.3173 3.28 - 4.92 
SNAI1 2.4005 2.3241 1.64 - 3.28 
TNC 2.3565 2.0562 0.00 - 1.64 
MMP9 2.1987 2.3187 -1.64 - 0.00 
NES 1.9498 2.1189 -3.28 - -1.64 
LCN2 1.7411 -1.1019 -4.92 - -3.28 
FOSL1 1.6434 1.6974 -6.56 - -4.92 
CDKN1A 1.4573 1.3226 -8.21 - -6.56 
TP53 1.2628 1.2002 
 
IGFBP2 -2.6759 -2.9828 
 
Table 4.1: Comparison of DEGs when comparing NEB1-shPTCH1 and NEB1-shPTCH1 + Cyc-KAAD to 
NEB1-shCON expression 
[A] Table of top and bottom 20 genes that were differentially expressed. [B] Table of selected genes of 
interest related to BCC and cancer biology.   
A 
B 
  Chapter 4 
152 
 
A number of interesting targets were selected from the microarray and validated by qPCR 
using primer sequences as the microarray uses a number of probe sequences per gene, generic 
PCR probes were designed that take into account of all potential isoforms (Figure 4.3). The 
genes of interest are involved in BCC and tumour biology and will be discussed later such as 
MMP-9, CXCL11, SNAI1, THY1 and VIM (Discussion). Results from qPCR mimic the trend from 
the microarray data with the exception of KRT15 being slightly increased and MMP-9 in 
Cyclopamine-KAAD treated cells being significantly increased by qPCR. In general qPCR is more 
sensitive than the microarray.   
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Figure 4.3: qPCR validation of microarray target genes 
Comparison of CXCL11 and MMP-9 expression by [A] qPCR and [B] microarray analysis. [C] Comparison 
of other DEGs identified by microarray analysis with qPCR. Error bars represent mean ± standard 
deviation. 
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4.2 Functional grouping of differentially expressed genes 
 
A list of the DEGs (478) unique to PTCH1 were then analysed via the internet based DAVID 
bioinformatics resource (Huang et al., 2009). DAVID is a gene annotation tool that highlights 
biological processes and functions from list of DEGs. The software was used to overlay the list 
of DEGs onto known signalling pathways from the KEGG database. This gave an indication of 
whether there were interesting clusters of genes to investigate further as opposed to single 
genes that may be affected by the suppression of PTCH1. As such, a number of interesting 
signalling pathways were retrieved from the analysis including pathways in cancer, MAPK, TGF-
β and Toll-like receptor (TLR) pathways (Figures 4.4 to 4.7).  
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Figure 4.4: Pathways in cancer map of DEGs unique to PTCH1 from DAVID analysis  
    Upregulated and    downregulated DEGs and differentially expressed pathways. 
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Figure 4.5: MAPK signalling pathway map of DEGs unique to PTCH1 from DAVID analysis 
    Upregulated and    downregulated DEGs and differentially expressed pathways. 
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Figure 4.6: TGF-β signalling pathway map of DEGs unique to PTCH1 from DAVID analysis 
    Upregulated and    downregulated DEGs and differentially expressed pathways. 
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Figure 4.7: TLR signalling pathway map of DEGs unique to PTCH1 from DAVID analysis 
    Upregulated and    downregulated DEGs and differentially expressed pathways. 
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4.3 Novel pathways downstream of PTCH1 that may be linked to Basal cell carcinoma 
formation 
 
Using the data generated from the microarray, a more detailed analysis was performed using 
MetaCore software in order to identify networks in NEB1-shPTCH1 cells that may help 
understand how suppression of PTCH1 could promote BCC biology, these networks may be 
SMO dependent or SMO independent. Utilising the MetaCore software database, network 
maps were generated based on pathways that contain the DEGs (Figure 4.8 (legend), Figure 
4.9 and 4.10). The data set consisted of the 6% (1153) of DEGs and networks were generated 
based on gene associations that have been reported in scientific literature. DAVID analysis 
simply overlays the relevant genes onto a signalling pathway map whereas with MetaCore 
analysis, genes that are associated with other genes are clustered together. Network map 1 
(Figure 4.9) highlights two distinct clusters one of which consists of MAPK, ERK and JUN while 
the other cluster consists of caspases. Network map 2 (Figure 4.10) shows a number of 
interesting clusters such as NF-kB, IL-8, EGFR and Fatty acid binding protein (FABP). 
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Figure 4.8: MetaCore network map legend 
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Figure 4.9: Network map 1 of DEGs unique for NEB1-shPTCH1 compared to NEB1-shCON 
There are two main clusters of genes shown in this network map one of which contains a number of 
caspases which are involved in apoptosis. The second cluster contains MAPK and ERK as well as various 
transcription factors. 
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Figure 4.10: Network map 2 of DEGs unique for NEB1-shPTCH1 compared to NEB1-shCON 
This network map shows a number of fatty acid binding proteins (FABP). The other main focal point is 
NF-kB that has a number of genes clustered around which suggests that the suppression PTCH1 may 
have had a significant effect on the pathway. 
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Having compared NEB1-shPTCH1 cells to NEB1-shCON cells, NEB1-shPTCH1 + Cyclopamine-
KAAD cells were also compared to NEB1-shCON cells to determine which pathways or genes 
that are differentially regulated in NEB1-shPTCH1 return to basal levels i.e. pathways activated 
through the canonical HH pathway should return to basal levels upon the treatment 
Cyclopamine-KAAD.  
 
This data set consisted of the 8% (1549) of DEGs when comparing NEB1-shPTCH1 + 
Cyclopamine-KAAD cells to NEB1-shCON cells. MetaCore generated network map 3 (Figure 
4.11) shows ERK as well as MEK, FOS and JUN. The other major pathway that was exposed was 
the p53 pathway and components such as p21 and Cyclin D1. Network map 4 (Figure 4.12) 
highlights MMP-2, EGFR and structural cytoskeletal components such as actin, collagen IV and 
fibronectin. 
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Figure 4.11: Network map 3 of DEGs unique for NEB1-shPTCH1 + Cyc-KAAD compared to NEB1-shCON 
MEK genes are central to this network map as they are associated with various different pathways (JAK, 
STAT and ERK) and downstream transcription factors including FOS and JUN. Interestingly there are a 
number of cancer biology related genes that are more loosely clustered around MEK such as NF-kB, p53 
and p21. 
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Figure 4.12: Network map 4 of DEGs unique for NEB1-shPTCH1 + Cyc-KAAD compared to NEB1-shCON 
This network map consists of EGFR which could account for MEK/ERK expression as seen in Figure 4.11. 
Cytoskeletal components including actin, collagen IV, vinculin and fibronectin were clustered together 
which may account for the change in morphology of NEB1-shPTCH1 cells.  
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The DEGs unique to PTCH1 including unique genes which are affected by Cyclopamine-KAAD 
(478) were then analysed. MetaCore analysis was performed and network pathways were 
generated which also take into account the cellular localisation of the DEGs. This gives a better 
account of the pathways a receptor ligand may follow to activate a transcription factor for 
example. 
 
Network map 5 (Figure 4.13) shows a number of canonical pathway links between JNK, MEK, 
ERK, JUN, NF-kB and interleukin pathways. Network map 6 (Figure 4.14) highlights SMAD 
components while network map 7 (Figure 4.15) links EGF, FGF and VEGF with MEK, ERK, AKT 
pathways. 
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Figure 4.13: Network map 5 of DEGs unique to PTCH1 
The network map shows that NF-kB is associated with a number of ligands and receptors. Also, MEK, 
JNK and p38 were shown to signal to c-JUN.  
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Figure 4.14: Network map 6 of DEGs unique to PTCH1 
The network map highlights the signalling to SMAD2 and SMAD3 which may then interact with c-Myc. 
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Figure 4.15: Network map 7 of DEGs unique to PTCH1 
MEK and ERK signalling is the main feature of this network map and are shown to be associated with 
Androgen receptor, STAT3 and c-FOS transcription factors and stimulated by EGF, FGF and VEGF ligands 
and receptors. EGFR downstream targets ERK, MEK, PI3K and AKT appear on the map. 
  
 
 
 
 
 
  Chapter 4 
170 
 
4.4 Discussion 
 
Microarray analysis has revealed a number of interesting pathways and components that may 
help to better define BCC biology based on the assumption that suppression of PTCH1 plays a 
significant role in NEB1 cells. Surprisingly, the suppression of PTCH1 in NEB1 cells did not affect 
86% of the genes which is interesting as the HH pathway is a major signalling pathway (Figure 
4.1). 6% of genes were differentially regulated when comparing NEB1-shPTCH1 with NEB1-
shCON cells from which MetaCore network maps were generated.  
 
Microarray data analysis highlights the EGFR signalling pathway in a number of network maps 
as well as downstream targets such as JNK, MEK and ERK (Figures 4.5, 4.9, 4.10, 4.13 and 4.15). 
This is interesting as studies have shown that EGFR modulates GLI target genes in N/Tert cells 
through MEK/ERK pathways (Kasper et al., 2006). HH and EGFR synergy can induce oncogenic 
transformation via EGFR activation of RAS/RAF/MEK/ERK as well as JUN which was also shown 
in the array (Schnidar et al., 2009). Downstream of ERK, FOSL1 expression was increased in 
NEB1-shPTCH1 cells (Table 4.1). FOSL1 forms dimers with JUN pathway proteins to form the 
AP-1 transcription factor which has been implicated in carcinogenesis (Young and Colburn, 
2006). 
 
EGFR and MEK/ERK pathways have also been shown to induce GLI1 and GLI2 expression which 
may account for GLI1 not being suppressed by SMO inhibitors in NEB1-shPTCH1 cells. Although 
there is a link between EGFR and GLI1 expression, staining of BCCs reveals that pERK is absent 
in the majority of tumours (Neill et al., 2008). As such, the EGFR signalling pathway was 
investigated in further detail and will be discussed later (Chapter 5). Conversely, SHH 
expression is known to increase EGFR, JNK and Raf phosphorylation which leads to increased 
MMP-9 expression that is implicated in cell invasion and tumour aggression (Rebecca et al., 
2005; Tai et al., 2008). These studies suggest that HH and EGFR pathways may together 
contribute to tumour invasion through the activation of MMP-9 (Rebecca et al., 2005).  
 
With evidence that the downstream target ERK is differentially regulated in NEB1-shPTCH1 
cells, downstream targets such as CXCL11 were highlighted in the microarray and studies have 
shown that CXCL11 mRNA levels are increased in BCC tissue (Lo et al., 2010). Also, CXCL11 
expression increases during skin inflammation therefore there may be a link with stress 
response pathways and components like caspase (Flier et al., 2001).  
 
  Chapter 4 
171 
 
Another major signalling pathway to appear in the microarray was the NF-kB pathway (nuclear 
factor kappa-light-chain-enhancer of activated B cell) (Figures 4.10 and 4.13). NF-kB signalling 
is involved in inflammatory and innate immune responses and there is evidence that suggests 
that the pathway is important for tumour development. NF-kB itself is a transcription factor 
that controls immune factors, proliferation and prevent apoptosis (Karin et al., 2002). The 
inhibitor of kB kinase complex (IKK) is stimulated by a number of factors including interleukin-1 
(IL-1) or the CD40 ligand. IkB proteins that are bound to NF-kB heterodimers are 
phosphorylated leading to nuclear localisation and transcription of target genes (Karin et al., 
2002). Interleukins make up a large group of cytokines with IL-1β, IL-6, IL-8, IL-10, IL-12α and 
IL-12β highlighted by network analysis (Figure 4.14). IL-1, IL-6, IL-8 and IL-12 are reported to 
activate or signal through NF-kB whereas IL-10 is thought to inhibit signalling (Parik et al., 
2000; Libermann and Baltimore, 1990; Elliott et al., 2001; Weinstock et al., 2003; Wang et al., 
1995). 
 
The NF-kB pathway is shown to be involved in skin cancers however there is little known in 
relation to BCC biology (Sur et al., 2008). In melanoma, NF-kB is up-regulated to deregulate 
gene transcription and that active NF-kB is able to switch between pro and anti-apoptotic 
functions in these tumours (Ueda and Richmond, 2006). The NF-kB pathway is known to 
overlap with a number of different pathways and the IKK promoter contains a p53 binding site 
that inhibits transcription therefore the loss of p53 results in IKK up-regulation (Gu et al., 
2004). This suggests that the loss of or mutational inactivation of p53 leads to activation of the 
NF-kB pathway. Activation of EGFR has also been reported to stimulate NF-kB signalling and 
gene transcription. Inhibition of NF-kB reduces activity of certain EGF induced genes such as 
Cyclin D1 (Haussler et al., 2005). 
 
A study of pancreatic cancer reveals a positive correlation of NF-kB and SHH expression and 
that inhibition of NF-kB also does suppress SHH (Nakashima et al., 2006). SHH was shown to be 
induced by IL-1β and TNF-α acting upon NF-kB leading to the hypothesis that pancreatic cancer 
cell proliferation is accelerated by activation of both HH and NF-kB signalling. This was 
confirmed by others and further to this, the SHH promoter region was found to contain a NF-
kB binding site (Kasperczyk et al., 2009). Silencing of SHH prevented NF-kB stimulated 
proliferation also, NF-kB inhibition lead to decreased proliferation that could be rescued with 
the addition of SHH. NF-kB could contribute to GLI1 over expression in NEB1-shPTCH1 cells 
however SHH expression was decreased in the cells as the HH pathway is constitutively active. 
NF-kB may be responding to try and suppress the effects but this requires further study. 
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The p53 signalling pathway and downstream components such as p21 and Cyclin D1 were 
identified which have been strongly implicated in BCC formation although this is through UV 
irradiation (Figure 4.11). Regarding NEB1-shPTCH1 cells, these were not UV irradiated however 
the suppression of PTCH1 could be perceived as a form of cellular stress. This is because the 
HH pathway is constitutively active resulting in constant GLI1 expression therefore to prevent 
tumours from forming it is likely that the p53 or other pathways may become active. This may 
be an attempt to initiate apoptosis which could be examined in NEB1-shPTCH1 cells in future 
studies. Mouse models utilising PTCH+/- mice show that after UV irradiation, the mice develop 
nodular and infiltrative BCCs (Mancuso et al., 2004). As UV irradiation is a common initiator of 
BCC tumour formation, NEB1-shPTCH1 could be UV irradiated and then investigated further. 
This could be the event which is required for NEB1-shPTCH1 cells to develop tumours in 
organotypic culture for example. As there is no UV related damage in NEB1-shPTCH1 cells, it 
would be better to focus on EGFR signalling and downstream components as it is more 
relevant to our current BCC model although the p53 pathway is an important pathway to 
explore in the future. 
 
A number of caspases were identified and clustered together in a network pathway (Figure 
4.9). There are two main ways in which cells are targeted and disposed of, necrosis and 
apoptosis. Necrosis can be triggered when the targeted cell plasma membrane is ruptured so 
that an inflammatory response is generated (Brown, 2008). The second method is apoptosis. 
This is thought of as a cleaner form of cell death where DNA is fragmented forming apoptotic 
bodies that are phagocytosed by macrophages (Lauberet al., 2004). This results in cell death 
without an inflammatory response. In mammalian cells, apoptosis may occur via three modes 
which are the extrinsic, the intrinsic and the Granzyme B pathways (Ghavami et al., 2009). The 
extrinsic pathway is triggered by the ligation of cell death receptors (e.g. tumour necrosis 
factors, TNF) and involves the activation of caspase-8. The intrinsic pathway is initiated by 
cellular stress with subsequent activation of caspase-9 and this route involves the 
mitochondria as well as anti-apoptotic factors such as Bcl-2. Regarding BCCs, the intrinsic 
pathway is more relevant as UV exposure is a factor that is known to cause BCC formation. The 
role of UV-induced caspase-9 is known to be cell specific and shown to be active and play an 
important role in UV-induced apoptosis in human keratinocytes (Sitailo et al., 2002). Caspase-9 
is an initiator of apoptosis and it was shown that in HaCaT cells with two mutant p53 alleles, 
UV-induced apoptosis was inhibited. Therefore mutations of caspases have the potential to 
prevent apoptosis of potential tumour cells. Along with the p53 pathway, caspase expression 
could be characterised in NEB1-shPTCH1 cell for future experiments. 
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As the EGFR pathway is shown to be differentially regulated, it is possible that the PI3K/AKT 
pathway is active as caspases are negatively regulated to inhibit apoptosis (Cardone et al., 
1998; Brunet et al., 1999). AKT has also been shown to activate IKK (Li and Stark, 2002). Studies 
show that AKT is important for HH signalling as AKT positively regulates HH signalling implying 
that both pathways work in tandem and are required for embryonic development (Riobo et al., 
2006 A). In BCC biology there is conflicting data regarding pAKT levels and activity in tumours 
however this may depend on the tumour environment as factors such as the expression of 
caspases for example.  
 
Structural proteins were clustered together in a network map (Figure 4.12). Fibronectin binds 
cell surfaces and interact with other structural proteins including collagen, actin and heparin. 
Fibronectin is involved in processes including cell adhesion, migration, cell shape maintenance 
and wound healing. Histological studies of BCC reveal that fibronectin is strongly expressed in 
the stroma and concentrated around tumour islands. Fibronectin mRNA was localised in the 
stromal cells as well as in the central areas of the tumour islands (Peltonen et al., 1988). This 
suggests that the tumour cells regulate fibronectin expression in the stroma and may also 
explain why BCCs are rarely metastatic and locally destructive. Another study has compared 
actin expression between stromal tissue and tumour islands of BCC. Actin was expressed in the 
tumour islands in both aggressive and non-aggressive BCC however, strong expression was 
found in the stroma of the more aggressive BCCs (Adegboyega et al., 2010). Other studies have 
shown similar results where actin was present in the infiltrative component of 13/13 nodular 
BCCs as well as in 8/13 showing stromal staining. There was no actin present in the stroma on 
non-infiltrative nodular BCCs (Law et al., 2003). These studies suggest that actin expression 
may contribute in tumour invasiveness and aggression. Collagen IV consists of a number of 
collagen chain subunits that are bound together to give the fibres structural stability. 
Histological studies of Collagen IV show the protein to be expressed around the tumour islands 
and in the surrounding skin. Defects were found in the α1 subunit and the protein was absent 
in invasive tumours (Marasa et al., 2008; Quatresooz et al., 2003). 
 
NEB1-shPTCH1 cells display a tight colony formation which implies that in two-dimensional 
culture, these structural proteins may be expressed to maintain this morphology (Figure 3.4). 
Based on studies that show stromal fibronectin, actin and collagen IV, the expression of these 
may differ depending on tumour progression. There are a number of features that NEB1-
shPTCH1 cells possess suggesting that they may have tumourigenic potential but another 
factor to consider is that a tumour mass usually forms in order to establish the tumour before 
invasion. Once the tumour mass stabilises it is then viable to invade and spread at which point 
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the expression of fibronectin for example may change. To understand more about this, NEB1-
shPTCH1 cells could be cultured with fibroblasts and then the expression of fibronectin, actin 
and collagen IV analysed by immunocytochemistry. Although NEB1-shPTCH1 cells did not show 
tumourigenic potential in organotypic cultures, the cells may signal to the fibroblasts within 
the dermis component of the culture. If actin is expressed in NEB1-shPTCH1 cells and increased 
in fibroblasts this would suggest that NEB1-shPTCH1 cells have the potential to invade based 
on previous studies of BCC (Law et al., 2003). 
 
MMP-2 and MMP-9 are known to degrade collagen IV proteins which are associated with 
tumour invasion in a number of cancers. Malignant SCCs and melanoma tissue has been shown 
to express increased levels of MMP-2 mRNA (Orimoto et al., 2008). While MMP-2 protein 
expression was shown to be mostly absent in BCCs, MMP-9 protein was strongly expressed in 
aggressive tumours (Karahan et al., 2011). The significantly increased mRNA expression of 
MMP-2 (~8 fold) and MMP-9 (~16 fold)  in NEB1-shPTCH1 cells (Figure 4.3) would imply that 
the cells have the potential to migrate however, morphologically NEB1-shPTCH1 cells form 
tight colonies and are slow growing (Figure 3.4 and 3.26). A histological study of BCC reveals 
the absence of MMP-2 protein in all BCC subtypes whereas MMP-9 is strongly expressed with 
increased intensity in correlation to tumour aggressiveness (Karahan et al., 2011). A more 
interesting observation was the substantial increase of MMP-9 mRNA expression (~182 fold) 
upon NEB1-shPTCH1 cell treatment with Cyclopamine-KAAD (Figure 4.3 A). For future 
experiments, migration or scratch assays could be performed to investigate the effect of 
Cyclopamine-KAAD in NEB1-shPTCH1 cells. When cells were treated with SMO inhibitors, I did 
not observe any change in morphology however it would be interesting to determine if 
collagen IV expression is reduced and if this is the case, there could be other factors that are 
preventing the cells from migrating.  
 
Tenascin C (TNC) is an ECM glycoprotein identified from the microarray (Table 4.1) that has the 
capacity to bind with fibronectin. TNC is reported to have anti-adhesive properties related to 
binding with fibronectin preventing its functionality (Latijnhouwers et al., 2000). Fibroblasts 
extracted from healthy skin in Gorlin’s patients (PTCH+/-) were analysed for BCC components 
and TNC was one of the components that was over expressed (Valin et al., 2009). Furthermore, 
studies of TNC in skin tumours revealed TNC mRNA expression in BCC, SCC and melanoma 
tumour masses (Tuominen et al., 1997). A study of endometrial carcinoma (tumours that arise 
from the lining of the uterus) showed strong expression of TNC particularly in the most 
aggressive and invasive tumours (Doi et al., 1996). Strong levels of TNC were associated with 
reduced levels of oestrogen receptor and increased levels of TGF-β1 which supports the idea 
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that TNC is associated with tumour cell motility, invasion and further proliferation. 
Interestingly, TGF-β2 was shown to be increased in NEB1-shPTCH1 cells and other components 
of the pathway differentially expressed (Table 4.1 B and Figure 4.6).  
 
FABPs are responsible the shuttling of lipids, solubilising fatty acids and transporting them. 
Epidermal-FABP (E-FABP) is exclusive to keratinocytes and was shown in the microarray (Figure 
4.10). E-FABP expression is elevated in the keratinocytes of healing wounds (Kusakari et al., 
2006). E-FABP expression is thought to be expressed in relation to keratinocyte differentiation 
and it has been shown that E-FABP is negative in BCCs and SCCs (Masouye et al., 1996).  
 
DAVID gene annotation software was used to map the DEGs that were unique to PTCH1 onto 
network maps i.e. genes that are differentially expressed due to the suppression of PTCH1 and 
that did not return to basal levels upon Cyclopamine-KAAD treatment. This was to uncover 
potential genes and pathways that may induce GLI1 expression in NEB1-shPTCH1 cells 
accounting for the lack of response to SMO inhibitors. A number of the DEGs were highlighted 
in a map summarises pathways involved in cancer (Figure 4.4). A number of MAPK pathways 
were identified from the microarray which will be discussed in Chapter 5 (Figure 4.5).  
 
A major pathway to emerge from the data is the TGF-β signalling pathway (Figure 4.6) which 
has been linked to the HH pathway (Cretnik et al., 2009).  TGF-β has been reported to induce 
both GLI1 and GLI2 expression in keratinocytes and increased GLI expression was maintained 
in the presence of the SMO inhibitor Cyclopamine. This suggests that both GLI proteins can 
function independently of SMO (Dennler et al., 2007). TGF-β and SMAD pathway component 
mRNA is reported to be elevated in BCC (Gambichler et al., 2007). The TGF-β signalling 
pathway controls differentiation and proliferation among other functions and acts with the 
TGF-α cytokine to induce cell transformation as well as initiate apoptosis (Schuster and 
Krieglstein, 2002). SMAD and TAK1 are components of the TGF-β pathway and were 
highlighted in the microarray. It is possible that GLI1 over-expression in NEB1-shPTCH1 cells is 
mediated through the TGF-β pathway. It is also worth noting that TGF-β may be involved in 
regulating apoptosis as a number of caspases were differentially regulated.   
 
A number of TLRs were clustered together from the microarray (Figure 4.7). TLRs make up a 
family of receptors that are important for host defence from infection. There is also evidence 
that TLRs are important for tissue homeostasis maintenance and the regulation of 
inflammatory responses. Downstream of TLR, TRAF6 phosphorylates TAK1 which ultimately 
leads to NF-kB and MAPK pathways activation (Kawai and Akira, 2006). As well as TRAF6 and 
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TAK1, TLR2 and TLR4 were also shown in the pathway map. TLR expression is reported to be 
increased in tumours and polymorphisms of TLR2 and TLR4 have been associated with 
increased risk and tumour progression (El-Omar et al., 2008). TLR gene expression could be 
used to detect melanoma and antagonists of TLRs can inhibit melanoma cell migration (So and 
Ouchi, 2010). In BCCs Imiquimod creams are used as a treatment which acts via TLR-7 
activation. It is not clear exactly how the cream works however IL-1, IL-6, IL-12 and TNF-α 
cytokines are thought to play a role. This method has been shown to be successful for the 
treatment of superficial BCCs (Stockfleth et al., 2003). NEB1-shPTCH1 cells may cause the 
expression of TLRs in response to stress in similar fashion to the p53 pathway however the 
overlap of NF-kB signalling may be a factor which responds to HH signalling.  
 
Other interesting genes that emerged from the microarray include SNAI1, THY1, Vimentin 
(VIM) and KRT15 (Table 4.1 and Figure 4.3 B). SNAI1 is a target gene for HH signalling which 
promotes epithelial to mesenchymal transition (EMT) where cells lose the expression of genes 
such as E-cadherin thus allowing for cells to migrate or invade in the case of tumour cells 
(Katoh and Katoh, 2009). SNAI1 has also been reported to co-express with GLI1 in hair follicles 
and skin tumours. The over-expression of SNAI1 in RK3E rat kidney cell lines also induced GLI1. 
Conversely, the over expression of GLI1 in basal mouse keratinocytes induced SNAI1 
expression and cell proliferation in the IFE (Li et al., 2006). THY1 also known as CD90 is thought 
to affect intra-cellular signalling and modulate adhesion and migration. By comparing THY1 
positive to THY1 negative fibroblasts, it was discovered that THY1 regulates RHO GTPase which 
is important for cytoskeletal organisation and cellular adhesion. THY1 or CD90 is a cancer stem 
cell marker (Barker et al., 2004).  
 
VIM is a member of the intermediate filament family along with microtubules and actin. VIM is 
responsible for maintaining cell shape, integrity of the cytoplasm and stabilising cytoskeletal 
interactions. During normal conditions, cells express keratins and are generally stable but as 
VIM is expressed, this drives EMT (Gilles et al., 1996). VIM expression in prostate cancer and 
SCC has been shown to correlate with tumour invasiveness (Singh et al., 2003; Tomson et al., 
1996). In contrast, the decrease of keratins is thought to be associated with tumour 
progression such as KRT19 in SCC and KRT15 in psoriasis (Crowe et al., 1999; Waseem et al., 
1999). Suppression of VIM in SCC derived cells reduced proliferation, migration and invasion 
and also re-expressed KRT13, KRT14 and KRT15 (Paccione et al., 2008). These cells also showed 
significantly reduced tumourigenic potential as they were approximately 70% smaller than 
control SCC cells. Regarding BCC, tumours have been shown to originate from hair follicle stem 
cells that express KRT15 as seen in PTCH1+/- mice upon X-ray irradiation (Wang et al., 2011). 
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qPCR validation of the microarray for SNAI1, THY1 and VIM show that the expression of these 
DEGs are increased in NEB1-shPTCH1 cells (Figure 4.3 B). KRT15 expression is significantly 
reduced by qPCR whereas it is slightly increased from the microarray so this requires further 
validation. The stem cell marker nestin (NES) was also highlighted as a DEG and this is an 
intermediate filament protein (Table 4.1). NES is expressed in dividing cells of the central 
nervous system (CNS) among other tissues such as the bulge region of hair follicles (Hoffman, 
2007). NES is over-expressed in various tumours including prostate, breast and melanoma 
(Kleeberger et al., 2007; Li et al., 2007; Brychtova et al., 2007).  
 
Neutrophil gelatinase associated lipocalin (LCN2) is a soluble protein that carries small 
molecules to cells, specifically dimerising with MMP-9 (Kjeldsen et al., 1993). LCN2 that is 
detectable in serum is known to be increased on psoriatic patients and in general, an indicator 
of increased inflammation (Kamata et al., 2012). Normal skin expresses LCN2 and it is induced 
in skin disorders such as psoriasis and SCC while BCCs however were negative for LCN2 
expression (Mallbris et al., 2002). This suggests that LCN2 is over-expressed in NEB1-shPTCH1 
cells is the result of inflammation which correlates with the stress response pathways 
identified by microarray analysis. In endometrial cancer, increased LCN2 expression correlated 
with aggressiveness and a greater chance of reoccurrence (Mannelqvist et al., 2012). In a study 
of breast cancer LCN2 was reported to induce EMT as well as angiogenesis via VEGF signalling 
(Yang et al., 2012). LCN2 was also shown to regulate the HIF-1α transcription factor thorough 
ERK. Elevated LCN2 in NEB1-shPTCH1 cells may be signalling through ERK to increase certain 
downstream targets and this requires further exploration as LCN2 is a marker for 
aggressiveness in tumours.  
 
Insulin-like growth factor binding protein 2 (IGFBP2) is a regulator of the IGF pathway that is 
pro-survival and anti-apoptotic. IGFBP2 which was identified in the microarray with a -2.2759 
fold reduction in NEB1-shPTCH1 cells compared to NEB1-shCON cells (Table 4.1). Interestingly, 
a study of human and mouse BCC showed increased IGFBP2 expression after the loss of PTCH1 
expression (Villani et al., 2010). Furthermore, mice that over express SHH display increased 
expression of IGFBP2 in hair follicle cells (Harris et al., 2010). These studies suggest that IGFBP2 
expression is important in the hair follicle and that BCCs that arise from hair follicles may 
express IGFBP2 for that reason. NEB1-shPTCH1 cells are keratinocytes and if they have the 
capacity to develop into BCCs, this may not be associated with increased IGFBP2 expression. 
Another reason may be that IGFBP2 increases after the tumour initiation in NEB1-shPTCH1 
cells. These studies also suggest that perhaps it would be better to model BCC by suppressing 
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PTCH1 in ORS or cells from the bulge region. It would be interesting to compare the 
differences between hair follicle cells and keratinocytes. 
 
The behaviour of NEB1-shPTCH1 cells in two-dimensional culture suggests that genes such as 
SNAI1 and VIM expression would be reduced as the cells form tight colonies. These genes 
suggest that NEB1-shPTCH1 cells are capable of EMT and could be aggressive and invasive. If 
indeed KRT15 is reduced in NEB1-shPTCH1 cells, this would correlate with VIM expression. For 
this reason, NEB1-shPTCH1 cells should be further characterised in organotypic cultures as 
certain areas may have localised expression of the protein i.e. in areas of hyperproliferation for 
example.  
 
The data obtained from the microarray analysis provides a number of genes that are related to 
BCC biology and tumourigenesis as well as pathways that may account for non-canonical 
modes of GLI1 expression. A number of pathways represent ways by which NEB1-shPTCH1 
cells could overcome the effects of SMO inhibitors one of which is the ERK signalling pathway. 
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Chapter 5  Introduction 
 
Microarray analysis of NEB1-shPTCH1 cells revealed that a number of major signalling 
pathways are affected by the suppression of PTCH1. One significant pathway that was 
highlighted was the MEK/ERK pathway downstream of EGFR signalling. It has been shown that 
EGFR signalling modulates the expression of GLI1 in N/Tert keratinocytes and that a number of 
genes could be induced synergistically by GLI1 and EGF treatment. Furthermore, the GLI1 
target genes were modulated by EGFR signalling via MEK/ERK pathways (Kasper et al., 2006). 
Other studies have demonstrated that GLI1 and GLI2 expression is induced by EGFR mediated 
MEK/ERK signalling and that mouse BCCs treated with EGFR and GLI inhibitors reduced tumour 
growth (Schnidar et al., 2009).  
 
In contrast, the Neill group has previously shown that the over expression of GLI1 in N/Tert 
cells reduces EGFR expression and that ERK activity is also repressed. Furthermore, pERK 
protein was not expressed in 13/14 BCC tumours whereas it was expressed in the epidermis 
indicating that the loss of pERK may be important for tumour formation (Neill et al. 2008). 
These contradictions in the literature warrant further investigation to determine if MEK/ERK 
signalling is a viable therapeutic target for BCC treatment. As such, NEB1-shPTCH1 cells were 
analysed for the expression of EGFR signalling and downstream MEK/ERK components.  
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5.1 Analysis of EGFR pathway activity in shPTCH1 cells  
 
MetaCore analysis of the DNA microarray indicated that ERK signalling was more active in 
NEB1-shPTCH1 cells compared to the control (Figures 4.3, 4.5 and 4.13). Our research group 
has previously shown that ectopic GLI1 suppresses EGFR expression and ERK activity in N/Tert 
keratinocytes and that the active phosphorylated form of ERK (pERK) is predominantly absent 
in human BCC (Neill et al., 2008). In contrast, others have shown that EGFR signalling (via 
MEK/ERK/JUN) is strong in mouse BCC cell lines and that co-targeting EGFR and HH signalling 
has an additive effect in suppressing the growth of these cells (Schnidar et al., 2009). 
Therefore, the extent of EGFR/MEK/ERK signalling was investigated in NEB1-shPTCH1 cells. 
 
EGFR expression was shown to be reduced at the mRNA level and also by western blotting 
(Figure 5.1 A and B). Downstream of EGFR, pMEK and pERK protein levels were also reduced in 
NEB1-shPTCH1 cells compared to NEB1-shCON cells (Figure 5.1 C). To confirm if MEK/ERK 
signalling expression was reduced in NEB1-shPTCH1 cell, the expression of several target genes 
known to be activated by MEK/ERK signalling including FOS, JUN and MYC were investigated by 
qPCR in NEB1 and N/Tert cells (Figure 5.2 and 5.3). The expression of all these genes was 
increased in NEB1-shPTCH1 cells (189A) and this was additionally confirmed in NEB1-29A cells. 
Similar results were obtained from N/Tert-shPTCH1 cells although the fold inductions were not 
as high as those in NEB1-shPTCH1 cells.  
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Figure 5.1: EGFR pathway expression in NEB1 cells 
EGFR analysis by [A] qPCR and [B] western blotting.  
EGFR protein analysis of NEB1-shCON and NEB1-shPTCH1 cells by [A] Immunocytochemistry and [B] 
western blot in NEB1 cells. [C] Western blot for EGFR downstream targets pERK (E10), pMEK, MEK, ERK 
with α-Tubulin loading control.  
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Figure 5.2: qPCR for ERK target genes in NEB1 cells 
[A] FOS, JUN, MYC, [B] DUSP6, ELK, SRF, [C] EGR1 and CXCL11 mRNA expression in NEB1 cells. 
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Figure 5.3: qPCR for ERK target genes in N/Tert cells 
[A] FOS, JUN, MYC, [B] DUSP6, ELK, SRF, [C] EGR1 and CXCL11 mRNA expression in N/Tert cells. 
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At the mRNA level, there is evidence that the ERK signalling pathway is active however western 
blotting revealed that protein levels of MEK, pMEK and pERK were decreased in NEB1-shPTCH1 
cells compared to NEB1-shCON cells. This correlates with the finding that EGFR protein 
expression was reduced in NEB1-shPTCH1 cells however it does not explain why ERK target 
genes would be increased. Intriguingly, immunocytochemical analysis of pEGFR revealed an 
increase of nuclear localisation in NEB1-shPTCH1 cells (Figure 5.4 A). The reason for this is 
unclear but it could account for reduced MEK/ERK signalling due to weaker signals emanating 
from the outer cell membrane. Nuclear EGFR translocation is induced in cultured cells exposed 
to DNA damaging agents (including UVB irradiation) where it is linked with DNA repair and 
suppression of the apoptotic response (Xu et al., 2009).  
 
Further analysis by immunocytochemistry revealed that pERK was more localised in the 
nucleus in NEB1-shPTCH1 cells which could account for the increase of the pERK target genes 
(Figure 5.4 B). Also, immunocytochemical analysis of pMEK localisation was inconclusive 
although there was some evidence of nuclear pMEK in NEB1-shPTCH1 cells that was not 
observed in NEB1-shCON cells (Figure 5.4 C). 
 
Nuclear EGFR has signalling capability and has been shown to activate expression of the target 
genes COX2, iNOS and STAT3 (Wang et al., 2010). However, no increase of any known nuclear 
EGFR target gene was observed in NEB1-shPTCH1 cells and this was not pursued further 
(Figure 5.5). 
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Figure 5.4: pEGFR, pERK and pMEK protein expression in NEB1 cells 
Immunofluorescence staining of [A] pEGFR (Y1173 and Y845), [B] pERK (20G11) and [C] pMEK in NEB1-
shCON and NEB1-shPTCH1 cells. 
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Figure 5.5: qPCR for EGFR target genes in NEB1 cells 
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5.2 EGFR signalling and control of GLI expression in shPTCH1 cells 
 
Several studies have shown that GLI1 transcriptional activity is increased by MEK/ERK 
signalling and it has also been shown that GLI1 expression is actually induced by MEK/ERK 
signalling (Schnidar et al., 2009). To determine if MEK/ERK signalling regulates the increase of 
GLI1 in NEB1-shPTCH1 cells, cultures were exposed to the MEK inhibitor U0126 as well as the 
EGFR inhibitor AG1478. The expression of GLI1 returned to basal levels in the presence of both 
U0126 and AG1478 indicating that the increase of GLI1 is mediated by EGFR/MEK/ERK 
signalling (Figure 5.6). Intriguingly, inhibition of EGFR, led to an increase of GLI2 mRNA levels 
which raises concerns about the use of anti-EGFR compounds for the treatment of BCC and 
possibly other tumours. 
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Figure 5.6: NEB1 cells treated with EGFR and MEK inhibitors 
NEB1 cells were treated with AG1478 (1µM) or U0126 (10µM) for 24 hours. Error bars represent mean ± 
standard deviation. 
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5.3 Discussion 
 
The EGFR signalling pathway and its downstream targets are altered in NEB1-shPTCH1 cells 
due to the suppression of PTCH1. The Neill group has previously shown that EGFR signalling 
influences GLI1 target genes in human keratinocytes and that strong GLI1 activity negatively 
regulates EGFR/ERK signalling (Neill et al., 2008). The previous study involved over expressing 
GLI1 in N/Tert keratinocytes using an EGFP-GLI1 fusion protein whereas this study utilised 
NEB1-shPTCH1 cells with a modest increase of GLI1 levels however there was a reduction in 
EGFR mRNA expression in NEB1-shPTCH1 cells compared to NEB1-shCON cells (Figure 5.1). 
Interestingly, analysis of pEGFR (Y1173 and Y845) showed increased nuclear expression in 
NEB1-shPTCH1 cells compared to NEB1-shCON cells (Figure 5.5 A). Phosphorylation of Y845 
has been implicated in maintaining activation of EGFR (Hubbard et al., 1994) while Y1173 
phosphorylation has been linked to ERK activation (Hsu et al., 2011). Despite a decrease in 
EGFR protein and mRNA expression in NEB1-shPTCH1 cells, downstream ERK and its target 
genes are more active. 
 
Western blot analysis of EGFR downstream targets pERK and pMEK showed that there was 
reduced expression in NEB1-shPTCH1 cells compared to NEB1-shCON cells (Figure 5.4). Similar 
to pEGFR expression, there was increased nuclear staining for pERK and pMEK in NEB1-
shPTCH1 cells compared to NEB1-shCON cells (Figure 5.5 B and C). Again, this suggests that 
pERK and pMEK are more active in NEB1-shPTCH1 due to nuclear protein localisation. 
However, without a MEK/ERK reporter construct, it would be difficult to determine if ERK is 
more active in the cells. NEB1 cells were difficult to lyse as discussed earlier when attempting 
to perform a Luciferase assay therefore ERK target genes were analysed (Figures 5.2 and 5.3). 
 
Based on the data obtained from the microarray that suggests EGFR signalling is differentially 
regulated, ERK target genes were analysed by qPCR in both NEB1 and N/Tert cells. 
Downstream targets of ERK were increased in NEB1-shPTCH1 cells compared to NEB1-shCON 
cells (Figure 5.2) and also a similar trend was seen in N/Tert cells although not in all ERK targets 
(Figure 5.3). As ERK is phosphorylated and translocates to the nucleus, it acts upon FOS, JUN, 
MYC and ELK transcription factors (Kerkhoff and Rapp, 1998). FOS and SRF are known to bind 
to each other to regulate DNA binding activity (Prywes et al., 1988). Also, activated ERK has 
been shown to induce phosphorylation of ELK (Cruzalequi et al., 1999). EGR1 expression in PC3 
prostate cell lines has been shown to be mediated through the EGF induced ERK signalling 
pathway (Gregg and Fraizer, 2011). CXCL11 is part of the CXC chemokine family and binds to 
the CXC Receptor 3 (CXCR3) that is involved in T-cell recruitment and skin immune response 
  Chapter 5 
191 
 
(Lo et al., 2010). A study has shown that inhibition of the ERK pathway results in the 
suppression of CXCL11 (Hosokawa et al., 2010). This along with the nuclear expression of 
pEGFR that may lead to increased expression of pERK and pMEK supports the idea that ERK 
signalling is more active in NEB1-shPTCH1 cells compared to NEB1-shCON cells.  
 
One potential explanation for increased nuclear pERK is the suppression of DUSP6. DUSP6 
dephosphorylates pERK to inhibit pathway activity therefore, a decrease in DUSP6 mRNA 
expression correlates to the fact that there is increased nuclear pERK in NEB1-shPTCH1 cells 
but this is contradicted by lower levels of pERK protein shown by western blotting. Indeed, 
DUSP6-/- mice display increased levels of ERK signalling and a feature of this is reduced 
apoptosis (Maillet et al., 2008). Another reason for the changes in EGFR signalling could be a 
stress response due to the suppression of PTCH1 that results in GLI1 activation. Nuclear EGFR 
translocation is known to be induced in human keratinocytes exposed to UV irradiation and 
functionally, nuclear EGFR is associated with transcription, proliferation and DNA repair (Wang 
et al., 2010). Suppression of PTCH1 in NEB1-shPTCH1 cells could induce a similar stress 
response whereby there is an increase in nuclear pEGFR expression.  
 
As mentioned earlier, the EGFR and HH signalling pathways are likely to be linked and that the 
over expression of GLI1 leads to differential expression of EGFR components in keratinocyte 
cell lines. The tight colony formation observed in NEB1-shPTCH1 cells was also observed when 
GLI1 was over expressed in N/Tert keratinocyes (Neill et al., 2008). In contrast, studies have 
shown that the EGFR and HH pathways are synergistically linked as demonstrated in N/Tert 
keratinocytes where 19 genes were found to be induced synergistically by GLI1 and EGF 
treatment also; GLI1 target genes were shown to be modulated by EGFR signalling through 
MEK/ERK pathways (Kasper et al., 2006). This is further supported by the study of mouse BCC 
cell lines ASZ001 and BSZ2 (Ptch−/−) as well as CSZ1 (p53−/−). These cell lines express higher 
levels of EGFR mRNA compared to keratinocytes. By inhibiting both EGFR with gefitinib and GLI 
signalling with GANT61 there is a reduction of BCC growth which suggests that both are a good 
target for BCC therapy (Schnidar et al., 2009). Conversely, this suggests that the dysregulation 
of both pathways may give rise to BCC formation or development. 
 
The study also demonstrated that EGFR/MEK/ERK pathways increase GLI1 and GLI2 expression 
(Schnidar et al., 2009) In agreement with this, the expression of GLI1 was reduced in NEB1-
shCON and NEB1-shPTCH1 cells that were treated with the EGFR inhibitor AG1478 and both 
GLI1 and GLI2 were suppressed with the MEK inhibitor U0126 (Figure 5.6). However, inhibition 
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of EGFR, led to an increase of GLI2 mRNA levels which suggests that EGFR and HH signalling do 
not act in  synergy with regards to control of GLI2 in human keratinocytes. 
 
This data also shows that the inhibition of MEK/ERK effectively suppresses both GLI1 
(canonical as well as non-canonical GLI1 that is not suppressed by SMO inhibitors) and GLI2 in 
NEB1-shPTCH1 cells which could be a good therapeutic target. In NIH-3T3 cell, MEK and ERK 
were able to stimulate GLI reporter activity and when MEK/ERK combined with either GLI1 or 
GLI2, there was a much greater induction of GLI reporter activity (Riobo et al., 2006 B). Based 
on this and the data generated that shows activation of ERK signalling, GLI1 induction in NEB1-
shPTCH1 cells may be mediated through ERK rather than the canonical HH pathway. The 
question then arises as to whether the loss of PTCH1 leads to MEK/ERK mediated GLI 
expression in a signalling mode that may not require SMO. This would explain why NEB1-
shPTCH1 cells do not respond to SMO inhibitors to a certain extent but not why SMO siRNA 
represses GLI1. One study has shown that SMO-/- breast cells that are treated with SHH ligand 
can activate ERK also, SHH was able to activate ERK in the presence of Cyclopamine (Chang et 
al., 2010). This implies that SHH can activate ERK independently of SMO and this may be 
mimicked in NEB1-shPTCH1 cells whereby reduced PTCH1 leads to increased GLI1 levels 
through increased ERK activity independently of SMO. 
 
Treatment of NEB1 cells with EGFR inhibitor increased GLI2 expression despite GLI1 expression 
being reduced (Figure 5.6). This is interesting as GLI1 and GLI2 are part of a feedback loop 
therefore if GLI1 is suppressed then GLI2 should also be suppressed (Regl et al., 2002). The 
induction of GLI2 may occur to compensate for the suppression of GLI1. Also, the data 
suggests that GLI1 and GLI2 can be expressed independently of each other i.e. GLI2 expression 
does not depend on GLI1 expression. To use such inhibitors for therapy may therefore induce 
GLI2 which in turn could facilitate BCC growth. A study where the targeting of both the EGFR 
and HH pathways reduced mouse BCC growth (Schnidar et al., 2009) could therefore be 
interpreted as the EGFR inhibitor reducing GLI1 and the HH inhibitor repressing GLI2. If the 
MEK/ERK cascade is disrupted by the EGFR inhibitor, it is likely that both GLI1 and GLI2 are 
reduced. 
 
Despite demonstrating that the ERK pathway is more active in NEB1 and N/Tert cells due to 
the suppression of PTCH1, this does not correlate in BCC tissue. Immunohistological studies of 
pERK and pAKT in BCC tissue show that neither protein is active in BCC (Neill et al., 2008; 
Hafner et al., 2012). Dr. Dimalee Herath (Neill Group) has done extensive analysis of EGFR 
signalling in BCCs and confirmed that pERK is not expressed in non-aggressive human BCCs. 
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Interestingly, Dr. Herath has also shown that human BCCs express pMEK so why it does not 
phosphorylate its principal target ERK (the un-phosphorylated protein is expressed in the 
tumours) is surprising and under further investigation. Moreover, Dr. Herath has also shown 
that pERK is not expressed in mouse BCCs whereas pMEK is abundant (unpublished data). 
 
The expression of pEGFR, pERK and pMEK was examined in 15 non-invasive and 14 invasive 
human BCCs. All phospho-proteins were expressed in normal and tumour associated epidermis 
(nuclear/cytoplasmic) but whereas pEGFR and pMEK were also present in all tumours (albeit at 
varying levels and with no apparent correlation), pERK was consistently absent in non-invasive 
BCCs; pERK staining was slightly higher in invasive tumour islands but the main feature of these 
samples was that pERK was often localised to the stroma. pERK (but not pMEK) was 
dramatically absent compared to the epidermis. Conversely, pERK (but not pMEK) was 
expressed in the stromal cells of a more aggressive BCC-like variant which correlates with the 
presence of stromal pERK in invasive human BCC (unpublished data).  
 
As pEGFR was localised in the nucleus in nodular BCCs and in NEB1-shPTCH1 cells, it is possible 
that this could account for the global reduction of pERK due to reduced EGFR activity at the 
cell membrane. Analysis of the EGFR signalling in human tumours reveals that the canonical 
pathway is not fully active in BCC and that further work is required to determine if and how 
components of the pathway warrant therapeutic attention. Indeed, whether or not loss of ERK 
activity is important for tumour formation also requires further investigation including how 
this affects GLI transcriptional activity. 
 
Also, a major risk factor for BCC is UV radiation therefore NEB1 cells would have to be UV 
irradiated and analysed for changes to HH and EGFR components as a number of studies that 
employ PTCH+/- mice irradiate the mice in order to initiate BCC formation. This would provide a 
better understanding of whether a secondary event is required in NEB1-shPTCH1 cells to 
initiate BCC formation as these cells showed no sign of invasion in organotypic culture (Figure 
3.26). Currently, ERK signalling is active in NEB1-shPTCH1 cells and the induction of 
downstream targets such as CXCL11 indicate that the cells have the potential to develop BCCs 
although how CXCL11 can be over expressed in BCCs in the absence of pERK is a mystery. It is 
possible that a secondary event such as a mutation may be required that represses ERK which 
could then lead to BCC formation.  
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Chapter 6 Discussion and conclusion 
 
6.1 Overview 
 
This study has employed RNAi technology to suppress PTCH1 expression in immortalised 
human keratinocytes with the aim of identifying novel genes and mechanisms that may 
contribute to BCC biology. Current thinking predicts that the loss of PTCH1 function leads to 
activation of the canonical HH signalling pathway which is critically dependent upon the G 
protein-coupled receptor SMOOTHENED. However, although anti-SMO inhibitors can 
effectively suppress the formation of BCC-like tumours in pre-clinical mouse models and they 
have also demonstrated good results in clinical trials, many tumours only partially or do not 
respond to these drugs. One explanation for the lack of patient response to anti-SMO 
compounds is that although PTCH1 mutations are the most common genetic aberration in 
BCC, such mutations have not been identified in all BCCs and therefore the formation of these 
tumours may be PTCH1-independent (and by association independent of SMO and canonical 
HH signalling). However, in tumours that arise from mutational inactivation of PTCH1, an 
alternative explanation for the lack of response to anti-SMO compounds is that there are SMO-
independent signalling mechanisms that contribute to tumour formation and progression. 
Therefore, to help identify these potential mechanisms, this study employed RNAi technology 
to suppress PTCH1 in immortalised human keratinocytes combined with gene expression 
profiling. In addition, this novel approach was also used to investigate the effect of PTCH1 
suppression upon canonical HH signalling and control of the GLI transcription factors. 
 
The validity of suppressing PTCH1 to create an in vitro model of BCC was first supported by the 
observation that in two-dimensional culture some clonal NEB1-shPTCH1 cell lines cultured as 
more compact colonies compared to parental or control cells, a morphology similar to that of 
nodular BCC. A similar phenotype was observed in N/Tert-shPTCH1 cells but no such difference 
was found in HaCaT-shPTCH1 cells. Microarray analysis of NEB1-shPTCH1 cells did reveal a 
number of interesting genes related to cell morphology, migration and invasion. The over 
expression of GLI1 in N/Tert cells results in tight colony formation with actin and E-cadherin 
expressed at the cell membrane to ensure that the cells bind closely with each other (Neill et 
al., 2008). It is difficult to determine which form of BCC NEB1-shPTCH1 cells are modelling but 
the morphology of the cells would suggest that they are more like nodular BCC in two-
dimensional culture and superficial in organotypic culture.  
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The study of structural protein expression should be examined on a larger scale i.e. the BCC 
tumours and surrounding stromal tissue. As a result, NEB1-shPTCH1 cells should be cultured 
with fibroblasts and examined in the context of NEB1-shPTCH1 cells signalling to the 
surrounding fibroblasts. MMP-2 and MMP-9 are associated with tumour invasion and degrade 
collagen IV that keeps cells attached to each other. MMP-2 was shown to be absent in BCCs 
while MMP-9 was strongly expressed in aggressive BCCs as determined by 
immunohistochemistry (Karahan et al., 2011). In areas where the tumour may become invasive 
i.e. the periphery of the tumour mass, it is more likely that MMP-9 will be expressed here so 
that the cells can migrate more easily into the surrounding tissue. Once the cells have migrated 
and new tumour masses are formed, the expression of MMP-9 may become reduced. If MMP-
9 is more active in NEB1-shPTCH1 cells, the stromal cells (co-cultured fibroblasts) may exhibit a 
reduction of collagen IV. Other structural components revealed through microarray analysis 
could also be analysed in this capacity, for example, fibronectin and actin that have been 
shown to be found in BCC tumour islands and stromal cells (Peltonen et al., 1988; Adegboyega 
et al., 2010). It is possible that in two-dimensional culture NEB1-shPTCH1 cells express certain 
structural proteins to maintain phenotype as it is characteristic of tumours to firstly establish 
itself as a cellular mass. The addition of fibroblasts as the stromal component in a co-culture 
system may alter the expression of these structural proteins.  
 
Mouse models of BCC have demonstrated that the manipulation of the HH signalling pathway 
does not always result in BCC tumour formation therefore NEB1-shPTCH1 cells were generated 
as an alternative model using human keratinocytes. Similar to PTCH+/- mouse models where 
BCCs are induced after UV irradiation, NEB1-shPTCH1 cells should be UV irradiated. It is worth 
noting that many studies that utilise PTCH+/- mice did not always develop actual BCCs after UV 
treatment but tumours that only resemble BCCs (Donovan, 2009; Daya-Grosjean and Couve´-
Privat, 2005; Mancuso et al., 2004). Based on this, NEB1-shPTCH1 cells should be UV irradiated 
and then analysed further by making Matrigel based organotypic cultures. This would allow us 
to compare the differences between the cells post UV irradiation.  
 
NEB1-shPTCH1 and NEB1-shCON cells that were compared by microarray analysis identified 
the p53 signalling pathway as being differentially regulated. UV irradiation of NEB1-shPTCH1 
cells may lead to the formation of BCCs as studies have shown that tumours arise from UV 
induced p53 loss of function mutations (Mancuso et al., 2004; D'Errico et al., 1997; Denef et 
al., 2000; Zhang et al., 2001). A study of PTCH+/- p53-/- mice showed increased BCC 
carcinogenesis however this may be attributed to the over expression of SMO because there 
was no BCC formation in the ears or tail where SMO was absent (Wang et al., 2011). This 
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implies that there is a specific set of mutations that are required for the formation of BCC that 
may follow the suppression of PTCH1 with a p53 loss of function mutation for example. 
Indeed, this provides evidence for how BCCs develop however as mentioned earlier, UV 
irradiation of PTCH+/- mice does not necessarily lead to BCC formation. The specific effects of 
UV irradiation with regards to other signalling pathways needs to be better defined as well as 
the involvement with HH signalling as PTCH+/- p53-/- mice developed BCCs where SMO was 
expressed (Wang et al., 2011). This could be achieved by treating NEB1-shPTCH1 cells with p53 
inhibitors and analysing the HH pathway components for changes however, UV irradiation 
should also be performed as this would take into account the other stress responses and the 
adaptations that the cells may undertake if there is any permanent damage. 
 
As opposed to PTCH+/- mouse models that have to be UV irradiated before tumours develop, 
an inducible PTCH1 knockout mouse system has shown that BCC-like tumours develop in mice 
(Adolphe et al., 2006). The knockout of PTCH1 occurs in the basal cell population which may be 
the critical factor that causes these tumours to form. Based on these subtle differences in 
mouse models, there are variations in the tumours that develop. This is something to consider 
regarding NEB1-shPTCH1 cells as a model of BCC as I have mentioned earlier - tumours may 
develop after UV irradiation but it would be difficult to protect the cells from non-specific 
effects. Another approach to this could be to suppress PTCH1 in other cell types such as those 
specific to hair follicles. It has been proposed that BCCs arise from ORS cells (Crowson, 2006; 
Owens and Watt, 2003) therefore it may be better to isolate ORS cells then suppress PTCH1 in 
these cells. It can be argued that ORS cells and basal cell keratinocytes are similar because ORS 
cells are a continuation of the IFE and stem cells may be an important factor. The basal layer is 
consistent of approximately 10% of stem cells that gives rise to TA cells that differentiate to 
either the IFE, sebaceous gland or hair follicle (Li and Neaves, 2006; Watt et al., 2006). ORS 
cells surround the bulge region that contains a niche for epithelial stem cells (Cotsarelis et al., 
1990). Compared to basal layer stem cells, bulge region stem cells differentiate into eight types 
of cell including the IFE, ORS, hair fibre and GE (Liu et al., 2003). Also, it is understood that the 
main source of stem cells that give rise to keratinocytes are from the hair follicle as opposed to 
the basal layer therefore, bulge region stem cells or DP could be isolated and PTCH1 
suppressed in these cells (Cotsarelis et al., 1990). As NEB1-shPTCH1 may not develop into BCCs 
solely from the suppression of PTCH1, further mutations may be required and stem cells that 
reside in the DP or bulge region for long periods may accumulate a number of mutations or 
changes over time that may be required for BCCs to develop. Furthermore, bulge region stem 
cells are pre-programmed to be more invasive through the dermis than keratinocytes which 
  Chapter 6 
198 
 
potentially makes the cells more tumourigeneic if stem cells were to be used as a model 
(Perez-Losanda and Balmain, 2003). 
 
Based on mouse studies where different components of the HH pathway are manipulated, 
different forms of tumour develop which demonstrates that there may be a set of specific 
requirements for actual BCCs to develop. GLI1 over expressing mice were able to develop BCC-
like tumours (Nilsson et al., 2000) while the expression of an activated mutant form of GLI2 
resulted in multiple BCC formation (Sheng et al., 2002; Grachtchouk et al., 2000). Controlled 
targeted expression of GLI2 in hair follicle stem cells and the IFE showed that nodular BCCs 
arise from hair follicle stem cells while superficial BCCs arise from IFE (Grachtchouk et al., 
2011). It would therefore be interesting to compare how the loss of PTCH1 expression affects 
hair follicle stem cells as opposed to keratinocytes and if BCCs arise from different cell types.  
 
SUFU+/- mice have been shown to develop Gorlin-type characteristics and fibroblasts derived 
from SUFU-/- mice showed increased levels of GLI1 mediated HH signalling (Svard et al., 2006). 
Further upstream of SUFU, SMO activating mutations have been reported in BCCs however, 
mice that carry the SMO-M2 mutation develop hamartomas (Xie et al., 1998; Grachtchouk et 
al., 2003). One explanation for hamartomas developing instead of BCCs was that the induction 
of HH signalling was not strong enough as demonstrated in a GLI2 over expressing mouse 
model where HH signalling induction was much greater in comparison, thus leading to BCC 
formation (Grachtchouk et al., 2003). Another study has shown that SMO-M2 mice develop 
BCCs but here it was shown that the tumours originate from undifferentiated basal layer stem 
cells (Youssef et al., 2010). The stem cell capacity of the cells may be the crucial factor that 
determines whether tumours form or not in BCCs that do not arise from UV irradiation 
therefore a population of stem cells from the hair follicle may be a better model to suppress 
PTCH1. 
 
6.2 Non-canonical Hedgehog signalling in BCC 
 
As shown in Chapter 3, NEB1-shPTCH1 cells are unresponsive to pharmacological SMO 
inhibitors although GLI1 may be mediated through SMO as demonstrated by SMO siRNA which 
was able to partially suppress GLI1. One hypothesis for this is that SMO translocates to the 
nucleus where it regulates GLI1 which was based upon the discovery that SMO is localised in 
the nucleus of NEB1-shPTCH1 cells. With the transfection of EGFP-SMO-WT fusion protein into 
NEB1-shPTCH1 cells, there was some evidence of nuclear SMO localisation although this was 
not convincing. The transfection of EGFP-SMO-WT/M2 in NEB1 cells also induced GLI1 mRNA 
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expression. To better understand about this non-canonical mode of HH signalling, NEB1-shCON 
cells could be transfected with EGFP-SMO-WT/M2 which would induce GLI1 expression then 
the cells treated with Cyclopamine-KAAD to see if HH signalling could be suppressed. If SMO-
WT/M2 induced HH signalling can be repressed by Cyclopamine-KAAD, it would imply that 
GLI1 expression is mediated through SMO signalling. It is possible that Cyclopamine-KAAD 
binds to SMO-M2 but the protein is able to activate the signalling cascade via another mode. 
 
Also, the cells could be treated with SHH upon transfection of EGFP-SMO-WT and EGFP-SMO-
M2 to establish whether SMO localisation is altered upon stimulation of the pathway. 
Although PTCH1 is strongly suppressed in NEB1-shPTCH1 cells, there is still some expression of 
PTCH1 therefore it would be interesting to see if SHH can stimulate the pathway. If this is the 
case, the cells could be treated with SMO inhibitors to determine if any increase of GLI1 could 
be suppressed. Also, if cilia are not present in NEB1 cells we could determine other locations 
where HH signalling occurs i.e. nucleus mediated signalling. 
 
An important observation from performing the microarray on NEB1-shPTCH1 cells was that a 
large number of DEGs are insensitive to the presence of the SMO inhibitor Cyclopamine-KAAD. 
As for GLI1, whether or not their expression is truly SMO-independent would require qPCR 
analysis in cells transfected with SMO siRNA. A comparison of NEB1-shPTCH1 cells treated with 
Cyclopamine-KAAD and NEB1-shPTCH1 cells treated with SMO siRNA would clarify which 
signalling pathways are SMO dependent as well as those that are affected if the cells are 
resistant to SMO inhibitors. In addition, analysis of these DEGs could be performed in NEB1 
and N/Tert keratinocytes over expressing EGFP-SMO-WT and EGFP-SMO-M2 to help determine 
if they are SMO-dependent or SMO-independent. 
 
One of the interesting and unexpected observations from my project was that the expression 
of MMP-9 mRNA is strongly increased in the presence of anti-SMO inhibitors. The expression 
of MMP-9 protein was not investigated but if it is increased then it would be interesting to 
determine if MMP-9 is elevated in tumours exposed to anti-SMO inhibitors. As discussed 
above, MMP-9 is associated with tumour cell invasion and although there is no evidence that 
tumours spread in patients receiving anti-SMO inhibitors, it is a clinically undesirable aspect 
which warrants further investigation. However, the analysis of MMP-9 expression in tumours 
may be used as a marker of drug exposure in patients taking anti-SMO inhibitors even if their 
tumours do not respond favourably to these drugs.  
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In order to determine the correct treatment for BCC, it would be a better strategy to find the 
causative factor before administering treatment. An example of this was demonstrated in a 
study where an active mutant of SMO induced hamartoma development in mice via 
constitutively active HH signalling however, the addition of the Wnt antagonist Dkk1 resulted 
in the inhibition of hamartoma development (Yang et al., 2008). This suggests that inhibition of 
Wnt may serve as a viable therapeutic target for tumours initiated via mutant SMO expression. 
 
Before therapies can be selected, a better understanding of the impact of PTCH1 suppression 
on other major signalling pathways such as the TGF-β pathway is required. Using NEB1-
shPTCH1 cells, the expression levels of TGF-β would be established to confirm if there is an 
increase. If this is the case, a TGF-β inhibitor could be used to treat NEB1-shPTCH1 cells to see 
whether GLI1 levels are reduced. Reciprocally, NEB1-shCON and NEB1-shPTCH1 cells could 
then be treated with TGF-β to determine if GLI1 is induced as demonstrated in one study 
(Dennler et al., 2007). Microarray analysis revealed that the TGF-β pathway and SMAD genes 
were over expressed in NEB1-shPTCH1 cells and studies have also demonstrated that TGF-β 
and SMAD pathway components are over expressed in BCC (Gambichler et al., 2007). 
Furthermore, it would also be interesting to determine if TGF-β signalling could be suppressed 
by SMO inhibitors and if there are differences between NEB1-shCON and NEB1-shPTCH1 cells 
for example, could TGF-β signalling account for increased ERK signalling and how does the 
induction or suppression of the pathway affect ERK target genes. Both pharmacological SMO 
inhibitors as well as SMO siRNA could be used to try and suppress TGF-β expression so this 
may help determine if TGF-β is causing increased GLI1 expression despite SMO being inhibited.  
 
6.3 Novel genes and pathways that may be important in BCC aetiology 
 
The other major signalling pathway identified by gene expression profiling (Chapter 4) was 
MEK/ERK signalling which is possibly activated through EGFR signalling. EGFR at the mRNA and 
protein level was reduced in NEB1-shPTCH1 cells compared to NEB1-shCON cells however 
there was increased nuclear localisation of pEGFR. The results observed with NEB1-shPTCH1 
cells support the previous findings of the Neill group whereby increased GLI1 activity in N/Tert 
cells negatively regulated EGFR expression and downstream signalling (Neill et al., 2008). 
However, Neill et al. (2008) did not investigate the expression of ERK target genes. Indeed, 
despite a global decrease of pERK expression in NEB1-shPTCH1 cells, they display an increase 
of nuclear pERK and an increase of target genes associated with ERK signalling. To investigate 
this further, a reporter construct for ERK could be transfected into NEB1-shPTCH1 cells to 
assess ERK activity providing that this is optimised and made viable for NEB1 cells. Also, if 
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NEB1-shPTCH1 cells are rescued with the PTCH1B isoform, it would help determine if the 
suppression of PTCH1 is involved in reducing EGFR expression and/or increased ERK target 
expression. Similarly, the transfection of NEB1-shCON cells with PTCH1B may increase EGFR 
expression and it would be interesting to determine how this would affect pERK subcellular 
localisation, total expression levels and activity. 
 
Another factor to consider would be whether ERK mediated GLI1 expression signals via SMO or 
not. A study utilising SMO-/- breast cells treated with SHH ligand has been shown to activate 
ERK as well as in the presence of Cyclopamine (Chang et al., 2010). As demonstrated in this 
study, SHH was able to activate ERK independently of SMO and this may explain how GLI1 
signals in NEB1-shPTCH1 cells. To confirm this, NEB1-shPTCH1 cells could be treated with SMO 
inhibitors and the expression of ERK target genes analysed. However, it should be mentioned 
that SMO suppression by siRNA did reduce GLI1 levels. Therefore GLI1 expression may be 
mediated via SMO in NEB1-shPTCH1 cells but the activation of ERK signalling (through the 
suppression of PTCH1) also activates GLI1. Indeed, pharmacological inhibition of EGFR 
(AG1478) and MEK (U0126) led to a decrease of GLI1 in both NEB1-shCON and NEB1-shPTCH1 
cells. ERK target genes could therefore be analysed in NEB1-shCON cells treated with 
Cyclopamine-KAAD to confirm if ERK signalling is still active or not. 
 
Interestingly, the expression of GLI2 was increased upon exposure to the EGFR inhibitor 
AG1478 whereas both GLI1 and GLI2 were suppressed by the MEK inhibitor U0126 in both 
NEB1-shCON and NEB1-shPTCH1 cells; this suggests that EGFR regulates GLI2 independently of 
MEK/ERK and it would be interesting to determine if there is a corresponding increase of GLI 
reporter activity in keratinocytes exposed to AG1478. Mouse studies have demonstrated that 
the induction of GLI2 can lead to the formation of BCCs (Sheng et al., 2002; Grachtchouk et al., 
2000) therefore, if BCCs are treated with EGFR inhibitors this may in fact facilitate BCC 
development. It would be a better strategy to use MEK inhibitors to treat BCCs that may arise 
as the result of GLI1 or GLI2 over expression. MEK may control or signal to GLI specifically in 
the nucleus and not the cytoplasm which would explain the increased nuclear localisation of 
pERK and pMEK in NEB1-shPTCH1 cells.  
 
Despite these observations in cultured keratinocytes, immunohistological staining of BCCs by 
Dr. Herath (Neill/Philpott Group) revealed that pERK is predominantly absent from tumours. 
Moreover this lack of pERK protein expression in BCC tissue has been reported in other studies 
(Neill et al., 2008; Hafner et al., 2012). Dr. Herath observed that pERK was present in the 
epidermis but lost in the tumour therefore it is possible that the loss of ERK expression may be 
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an important factor in BCC initiation. As such, NEB1-shPTCH1 cells could be grown in 
organotypic culture and then via an inducible knockout system, ERK could be suppressed. This 
would help determine whether loss of ERK expression as a second event after the suppression 
of PTCH1 could initiate BCC formation in the organotypic culture model. Another anomaly 
discovered by Dr. Herath was the positive expression of pMEK in the panel of BCCs so why its 
direct downstream target ERK is not phosphorylated is unexpected. Dr. Herath has also 
demonstrated that BCC-like tumours derived from X-ray irradiated PTCH1+/- mice do not 
express pERK whereas they do express pMEK and this is under investigation.  
 
The Neill/Philpott group has shown that GLI1 expression in a panel of BCCs is highly variable 
with some tumours displaying strong GLI1 expression while GLI1 is absent in others 
(unpublished data). With pERK predominantly absent from BCCs and some tumours lacking 
GLI1, it is possible that GLI1 expression is mediated by pMEK independently of pERK. The panel 
of BCCs analysed by Dr. Herath should therefore also be analysed for GLI1. NEB1 cells could 
also be treated with GLI1 siRNA to determine how MEK/ERK expression is affected in 
particular, if pERK remains in the nucleus of NEB1-shPTCH1 cells. 
 
An explanation for increased nuclear pERK in NEB1-shPTCH1 cells may be that DUSP6 
expression was reduced which would prevent the dephosphorylation of pERK. As such, the 
panel of BCCs analysed by Dr. Herath could be stained for DUSP6 to determine if there is a 
correlation between pERK and DUSP6 protein expression as well as the protein localisation i.e. 
DUSP6 could be present in tumours but absent in the epidermis. This theory may apply if 
DUSP6 protein were to be localised in the nucleus of tumour cells. 
  
It is also possible that EGFR signalling is altered in NEB1-shPTCH1 cells as a stress response as 
nuclear EGFR expression has been observed in human keratinocytes after UV irradiation (Wang 
et al., 2010). Furthermore, mouse BCC cell lines ASZ001 and BSZ2 (Ptch−/−) as well as CSZ1 
(p53−/−) express higher levels of EGFR mRNA compared to normal keratinocytes (Schnidar et 
al., 2009).  To address this, both NEB1-shCON and NEB1-shPTCH1 cells could be UV irradiated 
and EGFR components examined. In this case also the protein localisation of pEGFR and pERK 
could be examined as well as total protein levels. The differential expression of caspases in 
NEB1-shPTCH1 cells also suggests that the cells are responding to a form of cellular stress. This 
may be to initiate apoptosis however other anti-apoptotic factors may have an effect similar to 
a study where HaCaT cells with two mutant p53 alleles showed that UV-induced apoptosis was 
inhibited (Sitailo et al., 2002). Changes to the p53 signalling components caused by the 
suppression of PTCH1 in NEB1-shPTCH1 cells may contribute to differential expression of 
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caspases as shown by microarray profiling. This would need to be analysed further as to 
determine specifically which caspases are induced in NEB1-shPTCH1 cells. 
 
Immune responses may also play a part in BCC formation as highlighted by the over expression 
of CXCL11 in NEB1-shPTCH1 cells which is involved in T-cell recruitment and is a skin immune 
response (Lo et al., 2010). CXCL11 has been shown to be an ERK target gene and has also been 
reported to be expressed at higher levels in BCCs (Hosokawa et al., 2010; Lo et al., 2010). The 
expression of CXCL10 and CXCL11 were also shown to be mediated through ERK (Hosokawa et 
al., 2010). The over expression of a number of caspases in NEB1-shPTCH1 cells may contribute 
to the induction of CXCL11 during skin inflammation (Flier et al., 2001). 
 
Other inflammatory response pathways that appear in the microarray include NF-kB signalling. 
While there is little known regarding NF-kB signalling in BCC, the pathway is up regulated in 
melanoma (Ueda and Richmond, 2006). The stimulation of NF-kB signalling may be involved in 
preventing apoptosis which is a feature of tumours (Karin et al., 2002). A number of 
interleukins were also up regulated in NEB1-shPTCH1 cells which provide more evidence of an 
immune response to the suppression of PTCH1 in NEB1-shPTCH1 cells. Each of the interleukins 
should be further analysed by qPCR to determine specifically which cytokines are most active 
i.e. are the interleukins signal activators or repressors. The NF-kB pathway has also been 
reported to interact with p53, EGFR and HH signalling pathways (Gu et al., 2004; Haussler et 
al., 2005; Nakashima et al., 2006). As such, NEB1-shCON and NEB1-shPTCH1 cells could be 
treated with inhibitors of p53, EGFR, NF-kB and the HH pathway to determine how 
components of each of these pathways may interact with each other and similarly, each of the 
pathways could be stimulated as well. Depending on the findings, inhibitors could also be 
combined with the purpose of finding ways to suppress GLI1 in NEB1-shPTCH1 cells for 
example. From a therapeutic perspective once the cause of the tumour is identified then a 
suitable inhibitor combination could be administered. Further characterisation of the tumour 
may be of benefit for example, to know if ERK signalling is active in which case a MEK/ERK 
inhibitor may not be useful.   
 
Toll-like receptors (TLRs) that are involved in tissue homeostasis maintenance and regulating 
inflammatory responses were shown to the differentially expressed in NEB1-shPTCH1 cells. 
Downstream of TLR activation, MAPK and NF-kB pathways were active in NEB1-shPTCH cells 
and this link between these pathways has been described in the literature (Kawai and Akira, 
2006). The therapeutic potential of the pathway has been identified in studies where TLR 
associated Imiquimod cream has been used to successfully treat superficial BCCs (Stockfleth et 
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al., 2003). It is possible that NEB1-shPTCH1 cells exhibit increased TLR mediated signalling as a 
stress response which could subsequently affect the p53, MAPK and NF-kB pathways. It is not 
known which pathway could be the main initiator of this multi-pathway cascade if this is 
indeed occurring but with the use of inhibitors with NEB1-shPTCH1 cells, this could be 
determined. By identifying the main pathway that is altered by suppressing PTCH1, inhibition 
of this pathway may then reduce the expression of a number of inter-connected signalling 
pathways which could be a very specific mode of targeted therapy. A good example of this 
would be the use of MEK/ERK inhibitor to suppress GLI1 and GLI2 in NEB1-shPTCH1 cells 
although a profile of the tumour would need to be generated first. 
 
Microarray analysis also revealed the induction of SNAI1 (HH target gene) and VIM in NEB1-
shPTCH1 cells compared to NEB1-shCON cells. SNAI1 and VIM are both indicators of EMT and 
the over expression of these genes implies that NEB1-shPTCH1 cells have tumourigenic 
potential (Katoh and Katoh, 2009; Tomson et al., 1996). However, the tight cobblestone 
morphology of NEB1-shPTCH1 cells suggests that the cells may not migrate which further 
justifies the co-culture of these cells with fibroblasts. It is possible that NEB1-shPTCH1 cells 
may become invasive in the presence of fibroblasts so the staining of NEB1-shPTCH1 colonies 
with VIM or E-cadherin may reveal a specific staining pattern i.e. if NEB1-shPTCH1 cells have 
the potential to invade then E-cadherin expression may be less pronounced in the cells 
surrounding the colony (Katoh and Katoh, 2009). It is possible that a certain level of expression 
for VIM for example has to be exceeded before EMT initiates and this may occur upon UV 
irradiation of NEB1-shPTCH1 cells. VIM expression has been shown to correlate with tumour 
invasiveness therefore, once BCC formation is initiated then perhaps VIM expression is further 
induced depending on the classification of tumour (Singh et al., 2003; Tomson et al., 1996). 
The inhibition of VIM in SCC derived cells reduced proliferation, migration and invasion which 
may have implications for treating infiltrative BCCs however this does not address how non-
infiltrative BCCs develop (Paccione et al., 2008). Furthermore, it is not yet established which 
type of BCCs NEB1-shPTCH1 cells most closely resemble and this requires further investigation. 
 
LCN2 which is an indicator of increased inflammation (Kamata et al., 2012) was also shown to 
be induced in NEB1-shPTCH1 cells. LCN2 has been shown to be over expressed in SCCs but 
negative in BCCs (Mallbris et al., 2002). It may be that the loss of LCN2 expression in NEB1-
shPTCH1 cells could be an indicator of BCC formation. LCN2 may also be involved in the 
process leading up to tumour initiation as studies have demonstrated that increased LCN2 
expression correlated with aggressiveness as well as inducing EMT and angiogenesis in human 
breast cancer (Mannelqvist et al., 2012; Yang et al., 2012). As such, LCN2 should be analysed in 
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NEB1-shPTCH1 cells under normal conditions and then under stress i.e. after UV irradiation as 
well as in co-culture with fibroblasts. With increased UV mediated stress, there may be an 
induction of EMT markers like SNAI1 and VIM as mentioned earlier. There may be a certain 
mutation that is required or a change that occurs which would suppress LCN2 expression in 
BCCs once tumours have formed. A specific threshold may need to be exceeded at which point 
LCN2 expression is not required, similar to what may occur with ERK signalling. Another 
anomaly is the decreased expression of IGFBP2 in NEB1-shPTCH1 cells as studies have shown 
that the loss of PTCH1 expression in human and mouse BCCs leads to increased IGFBP2 levels 
(Villani et al., 2010). Furthermore, mice over expressing SHH displayed increased IGFBP2 in hair 
follicle cells (Harris et al., 2010). It is possible that IGFBP2 plays an important role in hair follicle 
biology possibly in the stem cell component or in cells that have the potential to develop into 
BCCs. Similarly, expression of IGFBP2 may be induced after tumour formation.  
 
6.4 Conclusion 
 
This study has identified a number of caveats with regards to how the loss of PTCH1 function 
and by association canonical Hedgehog signalling is thought to promote BCC formation. In 
particular, the data presented reveal that: 
 
1) PTCH1 (or at least the C-terminal half) is expressed in the nucleus of human keratinocytes 
whereas it is generally considered to be a 12-span transmembrane receptor protein (this 
supports the results of a recent study which showed that the C-terminal half of PTCH1 is 
nuclear and controls GLI1 expression in C3H10T1/2 cells (Kagawa et al. 2011). 
 
2) PTCH1 suppression leads to an increase of nuclear/perinuclear SMO (although SMO is 
considered a transmembrane receptor, the presence of a strong N-terminal bipartite nuclear 
localisation signal indicates that nuclear signalling is possible and is currently under 
investigation in the Neill group). 
 
3) The effects of PTCH1 suppression upon the transcriptome - including the increase of GLI1 
levels - are largely insensitive to the presence SMO pharmacological inhibitors. 
 
Following on from point 3, the chemokines CXCL10 and CXCL11 were increased in shPTCH1 
keratinocytes; these genes were recently shown to be increased in human BCC with functional 
activity that supports tumourigenesis (Lo et al., 2010) but they did not return to basal levels in 
the presence of SMO inhibitors. This in vitro model also identified a number of BCC and 
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tumour related characteristics i.e. nodular BCC-like morphology and expression of LCN2, 
SNAI1, and VIM as well as major signalling pathways such as NF-kB, TGF-β and MEK/ERK 
pathways that can be attributed to active HH signalling. These studies help support the validity 
of shPTCH1 keratinocytes as a model of BCC and show that this model may be used to identify 
novel SMO-independent genes and signalling mechanisms involved in the aetiology of this 
common tumour form.  
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Chapter 8 Appendix 
 
8.1 Standard buffers and reagents 
 
Buffer Protocol 
PBST PBS containing 0.5 % (v/v) Tween 
Protein lysis buffer 5 ml 1 mM Tris-HCl 
20 ml 10 % (v/v) APS 
200 µl 0.5 M sodium orthovanadate 
Made up to 100 ml with distilled water, adjusted to pH 8.4 
Running buffer 30 g Tris 
188 g glycine 
10 g SDS 
Made up to 100 ml with distilled water 
Diluted 1:10 (v/v) with distilled water 
Stripping buffer 3.75 g Tris 
10 g SDS 
3.57 ml β-mercaptoethanol 
Made up to 50 ml with distilled water, adjusted to pH 6.8 
TAE 48.4 g Tris 
11.4 ml 17.4 M glacial acetic acid 
3.7 g EDTA 
Made up to 1 L with distilled water 
Diluted 1:10 (v/v) with distilled water 
TBST 12.1 g Tris 
40 g sodium chloride 
Made up to 50 ml with distilled water, adjusted to pH 7.6 
50 ml of buffer diluted with 450 ml of distilled water 
2.5 ml (0.5 %) Tween 
Transfer buffer 30 g Tris 
144 g glycine 
Made up to 1 L with distilled water 
100 ml of buffer added to 200 ml of methanol and made up to 1 L with distilled water 
   
Table 8.1: Table of standard buffers and reagents 
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8.2 PCR primer sequences 
 
Gene Forward primer Reverse primer Annealing 
temperature 
(°C) 
Product size 
(base pairs) 
CFP CCTGAAGTTCATCTGCACCA GGTGATATAGACGTTGTGGCTGA 60 331 
COX2 TGAAACCCACTCCAAACACA GAGAAGGCTTCCCAGCTTTT 60 187 
CXCL11 GTGCTACAGTTGTTCAAGGC CTAGGTTTTTCAGATGCTCT 60 291 
DUSP6 CCGCAGGAGCTATACGAGTC TTGAGCTTCTTGAGCAGCAG 60 248 
EGFR TCAAATTGTGCCGAACAAGA ATCTGACATTGGGGTTCCAG 57 180 
EGR1 CCGCAGAGTCTTTTCCTGAC TGGGTTGGTCATGCTCACTA 60 200 
ELK GAAGCCATTCCTTTGTCTGC CCCTATTGAAAAGCCCCATT 60 183 
FOS GGAATTAACCTGGTGCTGGA TCAGACCACCTCAACAATGC 60 240 
GAPDH GTGAACCATGAGAAGTATGACA CATGAGTCCTTCCACGATACC 60 123 
GFP TATATCATGGCCGACAAGCA GAACTCCAGCAGGACCATGT 64 219 
GLI1 GAAGACCTCTCCAGCTTGGA GGCTGACAGTATAGGCAGAG 60 243 
GLI2 TGGCCGCTTCAGATGACAGATGTTG CGTTAGCCGAATGTCAGCCGTGAAG 58 200 
IHH CACCCCCAATTACAATCCAG CGGTCTGATGTGGTGATGTC 59 231 
iNOS CTCTATGTTTGCGGGGATGT TTCTTCGCCTCGTAAGGAAA 57 179 
JUN ACAGAGCATGACCCTGAACC CCACCATGCCTGCCCCGTTG 60 326 
KRT15 CATGACCACCACATTTCTGC TCCTCCTGACCCTGAAGAGA 58 175 
Luciferase AGTGCTCATCATCGGGAATC CATCCAACATTTTCGTGTCG 58 202 
MMP-2 AGGGCACATCCTATGACAGC ATTTGTTGCCCAGGAAAGTG 60 186 
MMP-9 TTGACAGCGACAAGAAGTGG TCACGTCGTCCTTATGCAAG 60 174 
MYC CCTGCGTGACCAGATCCCGGAGT CTCCTCTGCTTGGACGGACA 60 103 
PTCH1 ACTCGCCAGAAGATTGGAGA TCCAATTTCCACTGCCTGTT 58 173 
SHH GCTCGGTGAAAGCAGAGAAC CCAGGAAAGTGAGGAAGTCG 59 180 
SNAI1 TTTACCTTCCAGCAGCCCTA CCCACTGTCCTCATCTGACA 60 207 
SMO GGCTGCTGAGTGAGAAG CTGGTTGAAGAAGTCGTAGAAG 58 565 
SRF ACGACCTTCAGCAAGAGGAA AAGCCAGTGGCACTCATTCT 60 248 
STAT3 TGTGCGTATGGGAACACCTA AGAAGGTCGTCTCCCCCTTA 60 170 
THY1 CCCAGTGAAGATGCAGGTTT GACAGCCTGAGAGGGTCTTG 60 185 
VIM CCCTCACCTGTGAAGTGGAT CAACCAGAGGGAGTGAATCC 60 330 
 
Table 8.2: Table of PCR primer sequences 
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8.3 Primary antibodies 
 
Primary antibody Company Type Size(kDa) 
α-Tubulin Santa Cruz Rabbit polyclonal 55 
EGFR Santa Cruz Goat polyclonal 170 
ERK Cell Signaling Rabbit polyclonal 42, 44 
GFP ab290 Abcam Rabbit polyclonal 27 
GLI1 C18 Santa Cruz Goat polyclonal 150 
GLI1 H300 Santa Cruz Rabbit polyclonal 150 
MEK Cell Signaling Rabbit monoclonal 45 
pEGFR Y845 Santa Cruz Rabbit polyclonal 170 
pEGFR Y1173 Santa Cruz Goat polyclonal 170 
pERK E10 Cell Signaling Mouse monoclonal 42, 44 
pERK 20G11 Cell Signaling Rabbit monoclonal 42, 44 
pMEK Cell Signaling Rabbit polyclonal 45 
PTCH C20 Santa Cruz Goat polyclonal 140 
SHH Santa Cruz Goat polyclonal 27 
SMO ab72130 Abcam Rabbit polyclonal 86 
SMO C17 Santa Cruz Goat polyclonal 85 
SMO N19 Santa Cruz Goat polyclonal 85 
 
 
Table 8.3: Table of primary antibodies 
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8.4 Pharmacological inhibitors 
 
Inhibitor Target Company Details 
AG1478 
(658552) 
EGFR Merck Cell permeable, reversible, competitive inhibitor 
Cyclopamine-KAAD 
(239804) 
SMO Merck Cell permeable, competitive inhibitor 
SANT1 
(559303) 
SMO Merck Cell permeable, competitive inhibitor 
U0126 
(662005) 
MEK Merck Cell permeable, non-competitive inhibitor 
 
Table 8.4: Table of pharmacological inhibitors 
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8.5 SMO nuclear localisation signal 
 
 
 
 
 
 
 
 
 
   1  MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARR    50 
  51  SAAVTGPPPPLSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQE   100 
 101  EAHGKLVLWSGLRNAPRCWAVIQPLLCAVYMPKCENDRVELPSRTLCQAT   150 
 151  RGPCAIVERERGWPDFLRCTPDRFPEGCTNEVQNIKFNSSGQCEVPLVRT   200 
 201  DNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAVTGLCTLFTLA   250 
 251  TFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGT   300 
 301  MRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTY   350 
 351  QPLSGKTSYFHLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYR   400 
 401  AGFVLAPIGLVLIVGGYFLIRGVMTLFSIKSNHPGLLSEKAASKINETML   450 
 451  RLGIFGFLAFGFVLITFSCHFYDFFNQAEWERSFRDYVLCQANVTIGLPT   500 
 501  KQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKATLLIWRRTWC   550 
 551  RLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPV   600 
 601  AGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEE   650 
 651  QANLWLVEAEISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPST   700 
 701  IPRLPQLPRQKCLVAAGAWGAGDSCRQGAWTLVSNPFCPEPSPPQDPFLP   750 
 751  SAPAPVAWAHGRRQGLGPIHSRTNLMDTELMDADSDF                787 
 
Positively and negatively influencing subsequences are coloured according to the following scale: 
Negative ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Positive 
 
 
Figure 8.1: SMO nuclear localisation signal 
The nuclear localisation signal was identified in SMO using the NucPred software (Brameier et al., 2007).  
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8.6 Affymetrix array data 
 
Fold 
change Symbol Description 
9.4698 MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 
9.1472 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 
8.2059 CXCL10 chemokine (C-X-C motif) ligand 10 
7.0453 PTGIS prostaglandin I2 (prostacyclin) synthase 
6.4681 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 
6.3496 THY1 Thy-1 cell surface antigen 
5.4516 NNMT nicotinamide N-methyltransferase 
5.0397 SRPX sushi-repeat-containing protein, X-linked 
4.9818 ESX1 ESX homeobox 1 
4.8906 CXCL11 chemokine (C-X-C motif) ligand 11 
4.8456 ADAM19 ADAM metallopeptidase domain 19 
4.8456 IL7R interleukin 7 receptor 
4.7349 GPRC5B G protein-coupled receptor, family C, group 5, member B 
4.5315 FAM20C family with sequence similarity 20, member C 
4.4076 SAA1 serum amyloid A1 
4.2477 LAPTM5 lysosomal protein transmembrane 5 
4.1315 MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 
3.9908 LIFR leukemia inhibitory factor receptor alpha 
3.8548 CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 
3.8194 CFB complement factor B 
3.7842 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 
3.7581 MCAM melanoma cell adhesion molecule 
3.6050 APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
3.5718 VIM vimentin 
3.5718 SLCO2A1 solute carrier organic anion transporter family, member 2A1 
3.4661 FAP fibroblast activation protein, alpha 
3.4502 TRIM31 tripartite motif-containing 31 
3.3792 APOD apolipoprotein D 
3.3714 PMEPA1 prostate transmembrane protein, androgen induced 1 
3.3636 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
3.3636 SIRPA signal-regulatory protein alpha 
3.3173 INHBA inhibin, beta A 
3.2868 TGFB2 transforming growth factor, beta 2 
3.2716 IFITM1 interferon induced transmembrane protein 1 (9-27) 
3.2565 HLA-B major histocompatibility complex, class I, B 
3.0314 ATP8A2 ATPase, aminophospholipid transporter, class I, type 8A, member 2 
3.0175 SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12 
2.9417 LOXL2 lysyl oxidase-like 2 
2.9012 RNASE7 ribonuclease, RNase A family, 7 
2.8613 LPXN leupaxin 
2.8613 C15orf48 chromosome 15 open reading frame 48 
2.8415 TRIM22 tripartite motif-containing 22 
2.8219 IL32 interleukin 32 
2.7830 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 
2.7574 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
2.7447 PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
2.7258 ZNF114 zinc finger protein 114 
2.7195 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 
2.6945 SPATA18 spermatogenesis associated 18 homolog (rat) 
2.6945 GULP1 GULP, engulfment adaptor PTB domain containing 1 
Table 8.5: Table of top 50 DEGs with a 2-fold cut off when comparing NEB1-shPTCH1 cells to NEB1-
shCON cells 
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Fold 
change Symbol Description 
-2.2191 ASNS asparagine synthetase (glutamine-hydrolyzing) 
-2.2243 ACADSB acyl-CoA dehydrogenase, short/branched chain 
-2.2346 SLC19A3 solute carrier family 19, member 3 
-2.2605 GJB6 gap junction protein, beta 6, 30kDa 
-2.3295 HMGN5 high-mobility group nucleosome binding domain 5 
-2.3839 ANKRD22 ankyrin repeat domain 22 
-2.4061 RPS6KA6 ribosomal protein S6 kinase, 90kDa, polypeptide 6 
-2.4116 SCNN1B sodium channel, nonvoltage-gated 1, beta 
-2.4340 MTSS1 metastasis suppressor 1 
-2.4566 BMP7 bone morphogenetic protein 7 
-2.4852 WASF3 WAS protein family, member 3 
-2.5024 SCNN1G sodium channel, nonvoltage-gated 1, gamma 
-2.5082 LRRC6 leucine rich repeat containing 6 
-2.5374 UPK3B uroplakin 3B 
-2.5491 MANEA mannosidase, endo-alpha 
-2.5907 SPRR1B small proline-rich protein 1B 
-2.6268 FAM63B family with sequence similarity 63, member B 
-2.6635 POF1B premature ovarian failure, 1B 
-2.6759 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
-2.7069 CAPNS2 calpain, small subunit 2 
-2.7447 TGM1 transglutaminase 1 
-2.7638 SEC11C SEC11 homolog C (S. cerevisiae) 
-2.8024 C1orf21 chromosome 1 open reading frame 21 
-2.9079 PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) 
-2.9485 CXCR7 chemokine (C-X-C motif) receptor 7 
-2.9485 TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) 
-3.0105 SPRR1A small proline-rich protein 1A 
-3.0175 WDR17 WD repeat domain 17 
-3.0667 ANKFN1 ankyrin-repeat and fibronectin type III domain containing 1 
-3.1023 KRT15 keratin 15 
-3.2266 SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 
-3.2415 SH3BGRL SH3 domain binding glutamic acid-rich protein like 
-3.3173 AGR2 anterior gradient homolog 2 (Xenopus laevis) 
-3.3250 SPRR3 small proline-rich protein 3 
-3.4661 ZNF165 zinc finger protein 165 
-3.4661 EPB41L4A erythrocyte membrane protein band 4.1 like 4A 
-3.4822 SCD5 stearoyl-CoA desaturase 5 
-3.6553 AMOT angiomotin 
-3.7149 SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 
-3.8106 KRT4 keratin 4 
-3.8282 MCOLN3 mucolipin 3 
-3.9267 H2AFY2 H2A histone family, member Y2 
-4.3269 PNLIPRP3 pancreatic lipase-related protein 3 
-4.3469 CNTN1 contactin 1 
-4.3772 MUC15 mucin 15, cell surface associated 
-4.5525 KLHL13 kelch-like 13 (Drosophila) 
-5.8159 LASS3 LAG1 homolog, ceramide synthase 3 
-8.6538 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 
-8.7341 C9orf125 chromosome 9 open reading frame 125 
-10.1965 FBN2 fibrillin 2 
Table 8.6: Table of bottom 50 DEGs with a 2-fold cut off when comparing NEB1-shPTCH1 cells to NEB1-
shCON cells 
 
  Chapter 8 
258 
 
 
Fold 
change Symbol Description 
7.2267 THY1 Thy-1 cell surface antigen 
6.3938 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 
6.0769 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 
5.1814 NNMT nicotinamide N-methyltransferase 
5.1456 ADAM19 ADAM metallopeptidase domain 19 
4.9474 PTGIS prostaglandin I2 (prostacyclin) synthase 
4.9019 ESX1 ESX homeobox 1 
4.9019 MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 
4.8793 SRPX sushi-repeat-containing protein, X-linked 
4.8232 LIFR leukemia inhibitory factor receptor alpha 
4.3369 MCAM melanoma cell adhesion molecule 
4.2281 IL7R interleukin 7 receptor 
4.1892 GPRC5B G protein-coupled receptor, family C, group 5, member B 
4.1315 FAM20C family with sequence similarity 20, member C 
4.0652 LAPTM5 lysosomal protein transmembrane 5 
3.9908 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 
3.8637 MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 
3.8459 CXCL10 chemokine (C-X-C motif) ligand 10 
3.8018 CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 
3.7668 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 
3.7494 SLCO2A1 solute carrier organic anion transporter family, member 2A1 
3.7321 PMEPA1 prostate transmembrane protein, androgen induced 1 
3.5145 FAP fibroblast activation protein, alpha 
3.5064 SAA1 serum amyloid A1 
3.4027 VIM vimentin 
3.3173 TGFB2 transforming growth factor, beta 2 
3.3173 INHBA inhibin, beta A 
3.3173 PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
3.2191 LOXL2 lysyl oxidase-like 2 
2.9690 HLA-B major histocompatibility complex, class I, B 
2.9622 CYGB cytoglobin 
2.9282 SIRPA signal-regulatory protein alpha 
2.8812 ATP8A2 ATPase, aminophospholipid transporter, class I, type 8A, member 2 
2.8024 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 
2.7959 CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 
2.7574 MMD monocyte to macrophage differentiation-associated 
2.7447 PLAT plasminogen activator, tissue 
2.7321 QPRT quinolinate phosphoribosyltransferase 
2.7321 ZNF114 zinc finger protein 114 
2.7069 GRAMD1B GRAM domain containing 1B 
2.7007 DGAT2 diacylglycerol O-acyltransferase 2 
2.6945 DOCK10 dedicator of cytokinesis 10 
2.6635 GLIPR1 GLI pathogenesis-related 1 
2.6451 SLC41A2 solute carrier family 41, member 2 
2.6329 CFB complement factor B 
2.5967 APOD apolipoprotein D 
2.5550 LPXN leupaxin 
2.5198 CXCL11 chemokine (C-X-C motif) ligand 11 
2.4909 SPATA18 spermatogenesis associated 18 homolog (rat) 
Table 8.7: Table of top 50 DEGs with a 2-fold cut off when comparing NEB1-shPTCH1 + Cyc-KAAD cells to 
NEB1-shCON cells 
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Fold 
change Symbol Description 
-2.5491 UPK3B uroplakin 3B 
-2.5787 PARP16 poly (ADP-ribose) polymerase family, member 16 
-2.6268 ERO1LB ERO1-like beta (S. cerevisiae) 
-2.6759 BLNK B-cell linker 
-2.7702 SPRR1B small proline-rich protein 1B 
-2.7766 ANKRD22 ankyrin repeat domain 22 
-2.8415 ANKFN1 ankyrin-repeat and fibronectin type III domain containing 1 
-2.8812 SEL1L sel-1 suppressor of lin-12-like (C. elegans) 
-2.8945 SEC11C SEC11 homolog C (S. cerevisiae) 
-2.9079 TMEM50B transmembrane protein 50B 
-2.9147 SCNN1B sodium channel, nonvoltage-gated 1, beta 
-2.9622 GPR1 G protein-coupled receptor 1 
-2.9759 PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) 
-2.9828 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 
-3.0175 ASNS asparagine synthetase (glutamine-hydrolyzing) 
-3.1023 SDF2L1 stromal cell-derived factor 2-like 1 
-3.1602 STARD5 StAR-related lipid transfer (START) domain containing 5 
-3.1675 CAPNS2 calpain, small subunit 2 
-3.1675 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 
-3.2490 SCD5 stearoyl-CoA desaturase 5 
-3.2716 TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) 
-3.3636 SH3BGRL SH3 domain binding glutamic acid-rich protein like 
-3.3636 TGM1 transglutaminase 1 
-3.4343 AMOT angiomotin 
-3.4343 SPRR1A small proline-rich protein 1A 
-3.4422 FICD FIC domain containing 
-3.4502 CXCR7 chemokine (C-X-C motif) receptor 7 
-3.5472 EPB41L4A erythrocyte membrane protein band 4.1 like 4A 
-3.6893 MCOLN3 mucolipin 3 
-3.7149 HERPUD1 homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain 1 
-3.7235 MUC15 mucin 15, cell surface associated 
-3.8548 H2AFY2 H2A histone family, member Y2 
-4.1030 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 
-4.2575 SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 
-4.4795 CNTN1 contactin 1 
-4.4795 KRT15 keratin 15 
-4.5842 KLHL13 kelch-like 13 (Drosophila) 
-4.7240 KRT4 keratin 4 
-4.7568 SPRR3 small proline-rich protein 3 
-5.2174 SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 
-5.3641 ZNF165 zinc finger protein 165 
-5.7491 LASS3 LAG1 homolog, ceramide synthase 3 
-5.8835 AGR2 anterior gradient homolog 2 (Xenopus laevis) 
-6.0769 PNLIPRP3 pancreatic lipase-related protein 3 
-6.6807 DDIT3 DNA-damage-inducible transcript 3 
-7.9815 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 
-8.0000 C9orf125 chromosome 9 open reading frame 125 
-10.0329 FBN2 fibrillin 2 
Table 8.8: Table of bottom 50 DEGs with a 2-fold cut off when comparing NEB1-shPTCH1 + Cyc-KAAD 
cells to NEB1-shCON cells 
 
